[go: up one dir, main page]

WO1992018132A1 - Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor - Google Patents

Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor Download PDF

Info

Publication number
WO1992018132A1
WO1992018132A1 PCT/US1992/002749 US9202749W WO9218132A1 WO 1992018132 A1 WO1992018132 A1 WO 1992018132A1 US 9202749 W US9202749 W US 9202749W WO 9218132 A1 WO9218132 A1 WO 9218132A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
methyl
acid
amino
group
Prior art date
Application number
PCT/US1992/002749
Other languages
French (fr)
Inventor
Glen J. Gormley
Elizabeth Stoner
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of WO1992018132A1 publication Critical patent/WO1992018132A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Definitions

  • This invention relates to a new method of treatment for patients, i.e. men having benign
  • BPH prostatic hyperplasia
  • Benign prostatic hyperplasia affects a substantial number of males over the age of 50 and usually requires surgery in advanced stages for relief.
  • testosterone (T) is secreted by the testes and adrenal glands but can undergo a 5 ⁇ -reductase mediated conversion to
  • DHT dihydrotestosterone
  • DHT is preferentially bound by the nucleus of prostatic cells thus indicating that DHT, rather than T, is the primary androgen required by the prostate for its growth and function. This led to the hypothesis that, by inhibiting 5 ⁇ -reductase, the formation of DHT could be curtailed and hopefully prostate regression obtained.
  • Finasteride, 17B(N-t-butyl)carbamoyl-4-aza- 5 ⁇ -androst-1-en-3-one was developed as a compound which was found to inhibit 5 ⁇ -reductase and exhibit positive effects against benign prostatic hyperplasia. Finasteride is a 4-azasteroid and a competitive inhibitor of the enzyme.
  • Typical 4-aza steroid 5 ⁇ -reductase inhibitors known in the art include those developed by Merck. (See U.S. Pat. 4,377,584 to Rasmusson, et al.; U.S. Pat. 4,220,735 to Rasmusson, et al.; U.S. Pat. 4,845,104 to Carlin, et al.; U.S. Pat. 4,760,071 to
  • Rasmusson, et al. which discloses finasteride, being 17ß-(N-t-butyl)carbamoyl-4-aza-5 ⁇ -androst-1-en-3-one, known by its trademark as PROSCAR®; U.S. Pat. 4,732,897 to Cainelli, et al.; U.S. Pat. 4,859,681 to Rasmusson, et al.; EPO Publn. 0 155 076; EPO Publn. 0 004 949; and EPO Publn. 0 314 189.
  • estrogens i.g. estradiol
  • estradiol may be formed in the testes and prostate by the action of the enzyme, aromatase.
  • estrogens participate biochemically, but they are implicated and associated with prostate enlargement, i.e. benign prostatic hyperplasia.
  • a method of treating patients with benign prostatic hyperplasia who are in need of such treatment comprising the step of administering in combination to such patients therapeutically effective amounts of a 5 ⁇ -reductase inhibitor, e.g. a 17ß-substituted non-azasteroid, 17ß-acyl-3-carboxyandrost-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)- amide or cinnamoylamide derivative, aromatic 1,2- diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and an aromatase inhibitor.
  • a 5 ⁇ -reductase inhibitor e.g. a 17ß-substituted non-azasteroid, 17ß-acyl-3-carboxyandrost-3,5-diene, benzoylaminoph
  • the present invention provides an effective method of treating BPH in patients in need of symptomatic relief by administering therapeutically effective amounts
  • the aromatase inhibitor in association with a 5 ⁇ -reductase inhibitor or pharmaceutical composition thereof.
  • the active compounds may be administered together or in any order, as discussed hereinafter.
  • patients in need of such treating is meant male patients with functioning gonads who are being treated with a 5 ⁇ -reductase inhibitor in a therapeutic program designed to combat benign prostatic hyperplasia (BPH) and are discovered to be in need of symptomatic relief.
  • BPH benign prostatic hyperplasia
  • Aromatase is an enzyme complex incorporating a NADPH-cytochrome c-reductase and a cytochrome P450 component which mediates the conversion of androgens to estrogens, Bellino, J. Steroid Biochem. 17:261-270 (1982).
  • the reaction is believed to involve three hydroxylation steps, two at the C-19 position (Meyer, Biochem. Biophys. Acta 17: 441-442 [1955]; Marato et al., Biochem. Biophys. Res. Comm. 6: 334-338 [1961]) and one at C-2 (Hahn and Fishman, J. Biol. Chem. 259: 1689-1694 [1984]; Brodie et al., J. Am.
  • aromatase inhibitor as defined herein is any steroidal or non-steroidal compound which prevents the conversion of androgens to estrogens.
  • the compounds include substrate analogues of
  • Non-steroidal compounds that block aromatase activity are also included within the scope of the invention. These non-steroidal compounds include compounds or analogues that can bind to the enzymatic active site of aromatase and inhibit enzymatic activity. Nonsteroidal or steroidal compounds will also include compounds or analogues that bind to the enzyme at a site away from the enzymatic site and cause a structural change in the enzyme which results in a loss of enzymatic activity.
  • Aromatase inhibitors further include non-steroidal compounds that interfere with cytochrome P450 mediated hydroxylations such as those described by Brodie, et al., J. Steroid Biochem. 27: 899-903 (1987). The following compounds are known
  • non-steroidal aromatase inhibitors as disclosed by the associated reference.
  • the reference will also directly contain a method for making the compound or will direct one who wishes to use the compound to a method for producing the compound.
  • the aromatase inhibitors of the instant invention known in the art include, but are not limited to, the following compounds:
  • the invention is also intended to include any biologically active equivalents of an aromatase inhibitor as described above.
  • Preferred is where the 4-aza steroid has the formula:
  • R 1 and R 3 are independently hydrogen, methyl or ethyl
  • R 2 is a hydrocarbon radical selected from straight or branched chain substituted or unsubstituted alkyl, cycloalkyl, or aralkyl of from 1-12 carbons or monocyclic aryl optionally containing 1 or more lower alkyl substituents of from 1-2 carbon atoms and/or 1 or more halogen substituents,
  • R' is hydrogen or methyl
  • R' hydrogen or ß-methyl
  • R''' is hydrogen, ⁇ -methyl or ß-methyl
  • R 1 is hydrogen, methyl or ethyl
  • R 2 is branched chain alkyl cycloalkyl, aralkyl of from 4-12 carbons, phenyl, optionally substituted by methyl, chloro or fluoro, substituted or unsubstituted 1-, 2-adamantyl, 1-,
  • Representative compounds of the present invention include the following:
  • N-substituent, and wherein a double bond can be optionally present as indicated by the dotted line in position 1.
  • alkyl, cycloalkyl, aralkyl, monocyclic aryl, 1-, 2-adamantyl or 1-, 2-norbornanyl moieties can be substituted with one or more substi- tuents of the following: C 1 -C 4 linear/branched alkyl, including methyl, ethyl, isopropyl, n-butyl; nitro; oxo; C 7 -C 9 aralkyl, including benzyl; (CH 2 ) n COOR where n is 0-2 and R is H or C 1 -C 4 linear/branched alkyl including methyl, ethyl; CH 2 OH; OH; OR where R is C 1 -C 4 linear/branched alkyl including methyl, ethyl; halo, including fluoro, bromo, iodo; COOH;
  • amino group of the adamantyl or norbornanyl moiety can also be substituted as R 1 with methyl and ethyl, as well as hydrogen.
  • compositions or esters where a basic or acidic group is present on the substituted alkyl, cycloalkyl, aralkyl, adamantyl or norbornanyl moiety.
  • an acidic substituent i.e. -COOH, there can be formed the
  • a basic group i.e. amino
  • acidic salts i.e. hydrochloride, hydrobromide, acetate, pamoate, and the like
  • a basic group i.e. amino
  • acidic salts i.e. hydrochloride, hydrobromide, acetate, pamoate, and the like
  • esters can be employed, e.g. acetate, maleate, pivaloyloxymethyl , and the like, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.
  • 1-aminocarboxyl-1-AD 2-cyano-2-AD; 3,5-dimethyl- 7-ethyl-1-AD; 4-hydroxy-1-AD; 1-hydroxy-2-AD;
  • R 2 as substituted norbornanyl moieties are (where NB is norbornanyl):
  • novel compounds of formula I of the present invention can be prepared by a method
  • 17ß-(carbomethoxy)-4-aza-5- ⁇ -androstan-3-ones which includes the stages of optionally 1) dehydrogenating said starting material to produce the corresponding compound containing a double-bond in the 1,2-position of the A-ring, 2) converting the 17-carbomethoxy substituent into an N-substituted alkyl, cycloalkyl, aralkyl, monocylic acyl, or adamantylcarbamoyl substituent and, if desired, 3) alkylating the A-ring nitrogen to introduce a N-methyl or N-ethyl
  • the products of our invention are formed by optionally: (1) heating a 17ß-alkoxycarbonyl-4-aza-5 ⁇ -androstan-3-ones, com pound III, (prepared in the literature as described in the reference US Patent 4,377,584) with a dehydrogenating agent such as benzeneseleninic anhydride in a refluxing inert solvent, e.g. chlorobenzene, to form a 17ß-alkoxycarbonyl-4-aza-5 ⁇ -androst-1-ene-3-one IV (alternately, the dichlorodicyanobenzoquinone process of Dolling, et al., JACS 1988, Vol. 110, pp.
  • a dehydrogenating agent such as benzeneseleninic anhydride
  • a refluxing inert solvent e.g. chlorobenzene
  • the formed 5 ⁇ -androst- 1-en-3-one compound from Step 1 can be reacted with, e.g. sodium hydride under anhydrous conditions in a neutral solvent such as dimethylformamide; (3) contacting the resulting reaction mixture with an alkyl (methyl or ethyl) iodide to form the corresponding 17-ß-alkoxy-adamantyl-carbamoyl-4-alkyl-4-aza-5 ⁇ - androst-1-en-3-one V; (4) subsequently hydrolyzing said 17ß-alkoxycarbonyl-4-alkyl-4-aza-5 ⁇ -androst- 1-en-3-one with a strong base, such as aqueous
  • 17ß-(2-pyridylthiocarbonyl)-4-alkyl-4-aza-5 ⁇ -androst-1-en-3-one VII can be isolated by chromatography on e.g. silica gel; and (6) said pyridylthio ester can be thenreacted with 1-adamantyl-, 2-adamantylamine or norbornanylamine in an inert solvent e.g. tetrahydrofuran, to form the desired product 17ß-N-adamantyl- carbamoyl-4-alkyl-4-aza-5 ⁇ -androst-1-en-3-one VIII which can be isolated by chromatography e.g. on silica gel.
  • the previous reaction is carried out in the absence of first forming the double bond at position 1, the corresponding 17B-(N-adamantyl-carbamoyl)-4-alkyl-4-aza-5 ⁇ -androstan-3-one (or
  • N-norbornanyl carbamoyl compound is prepared.
  • the corresponding N-unsubstituted-17ß(N-adamantyl-carbamoyl)-4-aza-5 ⁇ -androst-1-en-3-one XIV is readily prepared from the 17ß (alkoxycarbonyl)-4-aza-5 ⁇ -androstone-3-one IV by repeating the above series of reaction steps but omitting the alkylation Step 2 herein above, i.e. treatment of the 4-aza-5- ⁇ -androst-1-en-3-one with e.g. sodium amide followed by methyl or ethyl iodide via intermediates XII and XIII.
  • the 16-methyl derivative wherein R''' is methyl are prepared from known 16-methyl-17-acyl-4-methyl-4-aza-5 ⁇ -androstan-3-ones, e.g.
  • X is 2-pyridylthio or 1-benzotriazoloxy.
  • R 2 is 1- or 2-adamantyl or norbornanyl.
  • a preferred 4-azasteroid is a 17ß-acyl-4-aza- 5 ⁇ -androst-1-ene-3-one compound of the formula:
  • R is selected from hydrogen, methyl and ethyl;
  • R 2 is (a) a monovalent radical selected from
  • oxygen-containing radicals is present; (2) -SH, -SC 1 -C 4 alkyl, -SOC 1 -C 4 alkyl,
  • N(R3) 2 which can be protected, where R 3 is independently H or C 1 -C 4 alkyl, where the monoaryl ring can also be further substituted with C 1 -C 4 alkyl;
  • heterocyclic radical selected from 2- or 4-pyridyl, 2-pyrrolyl, 2-furyl or thiophenyl;
  • R', R'' and R'' are each selected from hydrogen and methyl, and pharmaceutically acceptable salts thereof.
  • a preferred embodiment of the compounds of our invention process is: the compound of above Structure IA,
  • R is hydrogen or methyl
  • R 2 is branched chain alkyl, or cycloalkyl of from 4-10 carbons, and R'' and R''' are hydrogen.
  • Another embodiment of the invention is the compounds of above Structure I where R 2 is phenyl, or phenyl substituted by substituents described above, including where
  • R 2 is phenyl, 2-, 3-, or 4-tolyl, xylyl,
  • Representative compounds of the invention are:
  • the compounds of formula IA of the present invention are prepared by a method starting with the known steroid ester of the formula:
  • 17ß-(carbomethoxy)-4-aza-5 ⁇ -androstan-3-one which includes the stages of (1) dehydrogenating said starting material to produce the corresponding compound containing a double bond in the 1,2-position of the A-ring, (2) converting the 17-carbomethoxy substituent into a 17ß-acyl substituent and, if desired (3) alkylating the A-ring nitrogen to introduce 4-methyl or 4-ethyl substituents into the A-ring.
  • the 4-aza nitrogen be unsubstituted.
  • the dehydrogenation step can be carried out, e.g. according to the procedure of Dolling, et al. involving dichlorodicyanobenzoquinone, JACS (1988) Vol. 110, pp. 3318-3319.
  • Stage (2) may consist of one or more chemical steps and if desired may take place before stage (1) or following stage (1) or stage (3).
  • the products of our invention are formed by (1) heating a 17ß-alkoxycarbonyl-4-aza-5 ⁇ - androstan-3-one compound III with a dehydrogenating agent such as benzeneseleninic anhydride in refluxing chlorobenzene to form a 17ß-alkoxycarbonyl-4-aza-5 ⁇ -androst-1-en-3-one (IV), (2) the formed 5 ⁇ -androst- 1-en-3-one compound from step (1) is reacted with sodium hydride and under anhydrous conditions in a neutral solvent such as dimethylformamide, (2) contacting the resulting reaction mixture with an alkyl (methyl or ethyl) iodide to form the corresponding 17ß-alkoxycarbonyl-4-alkyl-4-aza-5 ⁇ -androst-1-en-3-one (V), (3) subsequently hydrolyzing said 17ß-alkoxycarbonyl-4-alkyl-4-aza-5 ⁇ -androst-1-en-3-one with a
  • the corresponding 17ß-acyl-4-aza-5 ⁇ -androst-1-en-3-one XV is readily prepared from the 17ß(alkoxycarbonyl)-4-aza-5 ⁇ -androsten-3-one (IV) by repeating the above series of reaction steps but omitting step 2 hereinabove, i.e., treatment of the 4-aza-5 ⁇ -androst-1-en-3-one with sodium amide followed by methyl or ethyl iodide.
  • reaction with a Grignard reagent R 2 MgX gives the ketone, 17ß-R 2 CO-, corresponding to the R 2 moiety associated with the Grignard reagent.
  • the 16-methyl derivative wherein R''' is methyl are prepared from known 16-methyl-17-acyl-4-methyl-4-aza-5 ⁇ -androstan-3-ones, e.g.
  • R 2 is p-hydroxybiphenyl
  • this can be derived by starting with an appropriate bromobiphenylylphenol, e.g. p-bromobiphenylphenol, protecting the phenolic -OH with a conventional blocking group, e.g.
  • trioganosilyl i.e. t-butyldimethylsilyl
  • silyl group by the use of, e.g. refluxing aqueous tetrabutylammonium fluoride.
  • protected hydroxy is meant the alcoholic or carboxylic -OH groups which can be protected by conventional means
  • C 1 -C 4 alkyl is meant linear or branched alkyl, including methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and t-butyl.
  • thiophenyl substituted R 2 e.g. p-methylthiophenyl magnesium chloride
  • the corresponding 17ß- (substituted thio-benzoyl)-4-alkyl-4-aza-5 ⁇ -androst- 1-en-3-one is prepared wherein phenyl is R 2 .
  • R 2 MgX for all the species included within the scope of this invention, are available or can readily be made by one skilled in the art.
  • R 2 is C 1 -C 4 alkyl thiophenyl
  • R 2 can be formed from the appropriate C 1 -C 4 alkyl thiobromobenzene, e.g. p-methylthiobromobenzene
  • the formed C 1 -C 4 alkyl thiobenzene can be used to further prepare C 1 -C 4 alkyl sulfoxides by oxidation with e.g. m-chloroperbenzoic acid.
  • the resulting sulfoxide can be further oxidized by the use of the m-chloroperbenzoic acid reaction to proceed for a longer period of time to form the C 1 -C 4 alkyl sulfone.
  • the sulfoxide can be used in the Pummerer rearrangement to form the corresponding thiol.
  • R 2 is formed from the appropriate bromobenzene, e.g. p-N,N-dimethylaminosulfobromobenzene which is used directly in the Grignard reaction to form the final product.
  • the thioalkyl groups on the phenyl ring i.e. -(CH 2 ) m SH, where m is 1-4, are readily formed via a four step procedure from an alkoxy alkyl phenyl bromide, Br-C 6 H 4 -(CH 2 ) m OCH 3 .
  • Direct addition of the Grignard reagent prepared from above-bromoalkyl phenyl derivative to the thiopyridyl ester results in the keto derivative, i.e. 17ß(4-methoxyalkyl- benzoyl)-4-aza-5 ⁇ -androst-1-ene-3-one.
  • VTII 17ß-(p-dimethylaminophenyl-carbonyl)-4- alkyl-4-aza-5a-androst-1-en-3-one
  • R 2 is hydroxyphenyl
  • this can be derived by starting with an appropriate bromophenol, e.g. p-bromophenol, protecting the phenolic -OH with a conventional blocking group, e.g. trioganosilyl, i.e. t-butyldimethylsilyl, carrying out the Grignard reaction and then deblocking the silyl group by the use of, e.g. refluxing aqueous tetrabutylammonium fluoride.
  • a conventional blocking group e.g. trioganosilyl, i.e. t-butyldimethylsilyl
  • R 2 being hydroxyethylphenyl
  • the same blocking procedure can be analogously conducted starting with the appropriate hydroxyalkyl
  • bromophenol e.g. p-hydroxymethylbromobenzene, or p-hydroxyethylbromobenzene.
  • R 2 is carboxyphenyl
  • R 2 is -O-C 1 -C 4 alkyl
  • the appropriate bromo-O-C 1 -C 4 alkyl benzene e.g. p-methoxybromo-benzene, is utilized for the Grignard reaction.
  • protected hydroxy is meant the alcoholic or carboxylic -OH groups which can be protected by conventional means
  • ketone reduction products of IA in combination with an aromatase inhibitor for treatment of BPH being secondary alcohols of the formula:
  • R is selected from hydrogen, methyl and
  • R 2 is (a) a monovalent radical selected from
  • a polycyclic aromatic radical which can be substituted with one or more of: -OH, protected -OH, -OC 1 -C 4 alkyl, C 1 -C 4 alkyl, halo or nitro;
  • oxygen-containing radicals is present
  • R 3 is independently H or C 1 -C 4 alkyl, where the monoaryl ring can also be further substituted with C 1 -C 4 alkyl; and (4) heterocyclic radical selected from 2- or 4-pyridyl, 2-pyrrolyl, 2-furyl or thiophenyl;
  • R', R'' and R''' are hydrogen or methyl, wherein the dotted line represents a double bond which can be present, and pharmaceutically
  • R 2 phenyl contains a carbonyl function, it can be selectively blocked and then regenerated after the borohydride reduction by conventional methods.
  • the borohydride reduction can be carried out in, e.g. water or aqueous methanol, at a temperature of room temperature to 50oC and the product then isolated and purified by conventional means.
  • the compounds are also active as 5-alpha reductase inhibitors in the treatment of patterned alopecia.
  • the compounds of the present invention prepared in accordance with the method described above, are, as already described, potent agents in combination with an aromatase inhibitor for the treatment of BPH.
  • the aromatase inhibitor, and the 5 ⁇ -reductase inhibitor are administered in combination separately or as one single combined pharmaceutical composition via parenteral or oral means.
  • the aromatase inhibitor and the 5 ⁇ -reductase inhibitor are administered orally as separate compositions.
  • the amount of each component administered is determined by the attending clinicians taking into consideration the etiology and severity of the disease, the patient's condition and age, the potency of each component and other factors.
  • the aromatase inhibitor compositions are generally administered in a dosage range of about ⁇ o to 400 mg/kg (body weight) per day with 50 to 250 mg per day in a single dose being preferred.
  • 17 ⁇ -substituted steroidal 5a-reductase inhibitors which are non-4-aza steroids are known in the art and include those developed by SmithKline Beckmann as disclosed in U.S. Pat. 4,882,319 to Holt, et al.; U.S. Pat. 4,910,226 to Holt, et al; EPO
  • the A ring has up to 2 double bonds
  • the B, C, and D rings have optimal double bonds where indicated by the broken lines, provided that the A, B, and C rings do not have adjacent double bonds and the D ring does not have a C 16 -C 17 double bond when R3 represents two substituents or a divalent substituent;
  • Z is (CH 2 )n and n is 0 or 2, provided that Z is (CH)n when adjacent to a double bond;
  • X is H, Cl, F, Br, I, CF 3 , or C 1-6 alkyl
  • Y is H, CF 3 , F, Cl, or CH 3 , provided that Y is H when there is no C 5 -C 6 double bond;
  • R 1 is H or C 1-8 alkyl
  • R 2 is absent or present as H or CH 3 , provided R 2 is absent when the carbon to which it is attached is unsaturated; and R 3 is
  • NR 5 R 6 where R 5 and R 6 are each independently selected from hydrogen, C 1-8 alkyl,
  • OR 7 where R 7 is hydrogen, alkali metal, C 1-8 alkyl, benzyl, or (b) -Alk-OR 8 , where Alk is C 1-12 alkylidene, and R 8 is
  • the B ring has a C 5 -C 6 double bond, R 1 is CH 3 , and R 3 is keto,
  • the A-nor ring has a C 3 -C 4 double bond and R 3 is acetoxy or acetyl;
  • R 1 is CH 3 and R 3 is acetoxy or acetyl
  • the A-nor ring has a C 3 -C 4 double bond and R 1 is methyl; or (v) the B ring has a C 3 -C 4 double bond and R 3 is ß-hydroxy.
  • N-t-butyl-androst-3,5-diene-17 ⁇ -carboxamide-3-carboxylic acid N,N-diisopropyl-androst-3,5-diene-17 ⁇ -carboxamide-3- carboxylic acid,
  • R 1 is (a) C 1 -C 6 linear or branched alkyl
  • C 3 -C 12 cycloalkyl which can be substituted with C 1 -C 4 alkoxy or C 1 -C 4 linear/branched alkyl;
  • C 6 -C 12 aryl, or C 7 -C 13 aralkyl which can be substituted with one or more of: -OH, -OC 1 -C 4 alkyl, C 1 -C 4 alkyl, -(CH 2 ) m OH, -(CH 2 ) n COOH, including protected -OH, where m is 1-4, n is 1-3;
  • C 3 -C 12 cycloalkyl which can be substituted with C 1 -C 4 alkoxy or C 1 -C 4 linear/branched alkyl; C 5 -C 12 aryl, or C 7 -C 13 aralkyl which can be substituted with one or more of: -OH, -OC 1 -C 4 alkyl, C 1 -C 4 alkyl, -(CH 2 ) m OH, -(CH 2 ) n COOH, including protected -OH, where m is 1-4, n is 1-3, and R 2 is selected from COOH, SO3H, PO(OH) 2 , PH(O)OH.
  • R 1 is t-butyl, cyclokalkyl, phenyl, p-hydroxyphenyl, 1-adamantyl, 2-adamantyl, NH-t-butyl, NH-isobutyl, NH-cyclohexyl, NH-phenyl, NH-p-hydroxy-phenyl, NH-1-adaxmantyl, NH-2-adamantyl, and R 2 is COOH,
  • Representative compounds include:
  • non-steroidal 5a-reductase inhibitors as developed by ONO Pharmaceutical Co., LTD., Osaka, Japan and as described in US patents 4,780,469; 4,847,275;
  • the benzoylaminophenoxy butanoic acid derivatives are of the formula:
  • R' is hydrogen or alkyl of from 1 to 4 carbon atom(s);
  • A is oxygen atom, sulfur atom or sulfinyl (SO) group; both R 1 's are methyl or chlorine, or the two R 1 's and the carbon atoms of the benzene ring to which the two R 1 's are linked together are
  • R 2 represents a group of formula
  • B is oxygen, sulfur or a group of formula: NR 11 wherein R 11 is hydrogen or alkyl of from 1 to 4 carbon atom(s),
  • R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are, independently, hydrogen, alkyl of from 1 to 4 carbon atom(s), halogen, trifluoromethyl or cyclobutylmethyl,
  • n 0 or 1
  • n is an integer of from 1 to 5
  • R 9 is a hydrogen, alkyl of from 1 to 5 carbon atom(s) or a group of formula:
  • R 12 , R 13 , R 14 , and R 15 are, independently, hydrogen, alkyl of from 1 to 4 carbon atom(s), halogen, trif luoromethyl or cyclobutylmethyl, and 1 is an integer of from 1 to 4, and
  • R 10 is a group of formula:
  • a 5 ⁇ -reductase inhibitor in this invention is a cinnamoylamide of the
  • R 2 and R 3 each independently represents a hydrogen or methyl group with the proviso that
  • R 1 represents hydrogen and (R 1 )n represents a member selected from the group consisting of 3-group, 4-pentyl group, 4-neopentyl group, 4-(2-ethylbutyl) group and
  • Representative compounds include:
  • A represents a single bond or a group of methylene, ethylene, trimethylene, tetramethylene, vinylene, propenylene, butenylene, butadienylene or ethynylene group optionally being substituted by one, two or three of straight or branched alkyl group(s) of from 1 to 10 carbon atom(s) and/or phenyl group(s);
  • B represents a heterocyclic ring of from 4 to 8 members containing one, two or three hetero atom(s) selected from the group consisting of oxygen, nitrogen and sulphur atom(s), wherein the said ring may
  • T represents an oxygen atom or a sulphur atom
  • R 1 represents a group of general formula:
  • R 3 represents a hydrogen atom, a halogen atom, a hydroxy group, a nitro group, a group of general formula: ⁇ COOR 7 , wherein R 7 represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s), or a straight or branched alkyl, alkoxy or alkylthio group of from 1 to 6 carbon atom(s);
  • R 4 represents a group of general formula:
  • U represents an oxygen atom or a sulphur atom
  • R 8 represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s)
  • n and m represent an integer of from 1 to 10, respectively
  • p and q represent zero or an integer of from 1 to 10, respectively, or non-toxic salts thereof.
  • Representative compounds include:
  • aromatic 1,2-di(thio)ethers of the formula:
  • A is an 1,2-disubstituted aromatic ring; preferably a benzene ring; wherein
  • X is independently O, S, SO, or SO 2 ;
  • R is H
  • R' and R" are independently
  • the compounds of the instant invention are inhibitors of the human testosterone-5 ⁇ -reductase enzyme.
  • X in the general formula above is O or S, preferably where one X is 0, and particularly where both Xs are 0, e.g., resulting in the catechol
  • C 1 -C 4 alkyl includes linear or branched species, e.g. methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, t-butyl.
  • C 1 -C 4 alkoxy includes linear or branched
  • Halo includes fluoro, chloro, bromo or iodo.
  • Substituted phenyl includes phenyl substituted by one or more of C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or halo, and the like, as defined above, representative examples include o, m-, p-methoxy phenyl; 2,4-dimethoxyphenyl; 2-chloro-4-ethoxyphenyl; 3,5-dimethoxyphenyl; 2,4-dichlorophenyl; 2-bromo-4-methylphenyl, o-fluorophenyl, and the like.
  • Haloalkyl includes C 1 -C 4 alkyl, defined above, substitued with one or more "halo" as
  • C 1 -C 4 alkylthio includes C 1 -C 4 alkyl, defined above, substituted with at least one
  • divalent thio (-S-) grouping including; methylthio, ethylthio, isopropylthio, n-butylthio, and the like.
  • C 1 -C 4 alkylsulfinyl includes C 1 -C 4 alkyl, defined above, substituted with at least one -SO-grouping including; methylsulfinyl, ethylsulfinyl; isopropylsulfinyl, and the like.
  • C 1 -C 4 alkylsulfonyl includes C 1 -C 4 alkyl, defined above, substituted with at least one sulfonyl group, -SO 2 -, including; methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, and the like.
  • C 1 -C 4 mono or dialkyl amino includes amino, substituted with one or more C 1 -C 4 alkyl groups as defined hereinabove, including: methylamino,
  • the R group or groups on the benzene ring can be present initially in the process, such as in starting material I in Flow Chart A, e.g. phenyl, methyl, methoxy, cyano, trifluoromethyl,
  • reaction e.g. chloro, as by chlorination, nitro by nitration, or created from a starting or added
  • salts and esters thereof are meant, salts and esters of the acid groups in the final molecule which can be used as part of the human drug delivery system and include the salts: sodium, potassium, calcium, ammonium, substituted ammonium, quaternary ammonium, and esters: ethyl ester, aceturate, besylate, edetate, phenpropionate, acetate, pamoate, and esters which serve as "prodrug” formulations which will hydrolyze in the body at physiological pH's to regenerate the acid, including pivaloylates, e.g. pivoxetil and pivoxil, and Kanebo esters, and the like.
  • pivaloylates e.g. pivoxetil and pivoxil
  • Kanebo esters and the like.
  • y where y is 1-6, preferably 3, can contain at least one R' substituent as defined above, and can be, e.g., -CH 2 -; -CH 2 -CH 2 -; -CH 2 -CH 2 -CH 2 -, ; -; -; -; ; ;
  • -CH 2 -CH CH-(CH 2 ) 2 -; and the like.
  • z is 6-20, preferably 10-16, can contain at least one R" substituent as defined above, and can be; e.g., -(CH 2 ) 6 -, -(CH 2 ) 20 -, ;
  • R' and R" can also be -NHCOCH 3 , which can be hydrolyzed to amino by conventional acid or base hydrolysis in the final molecule; R' and R" can also be oxo, obtained by, for example, HBr addition to an alkene followed by conversion to an alcohol and subsequent oxidation to the ketone.
  • R' or R" is H and particularly preferred is where both and
  • one X is O and R, R' , R" , y and z are defined above ; and particularly preferred are the compounds ,
  • X is O or S and n is 10-16.
  • the compounds of the instant invention can be made by the procedure outlined in the following Flowchart A-1.
  • Compound I is the starting substrate in the invention process and is a 1,2-substit ⁇ ted benzene ring.
  • X can be independently 0 or S and "PG" represents a hydroxy or thio protecting group which is inactive during Step (A) but can be subsequently removed by, e.g. palladium on carbon catalyst in ethanol under a pressurized H 2 atmosphere.
  • PG Representative examples of “PG” include:
  • Step (A) benzyl, p-methoxybenzyl, p-halobenzyl; including p-chlorobenzyl, p-fluorobenzyl, and the like.
  • Other protective groups which are known will be obvious to one skilled in the art to carry out the function of Step (A).
  • L is a leaving group, e.g., halogen, including bromo, chloro, or sulfonate, and the like
  • R a is a C 1 -C 4 linear or branched alkyl portion of the ester, including methyl, ethyl, isopropyl, t-butyl, sec-butyl, and the like
  • R 1 and Y are or defined above, include, but are not limited to:
  • Step (A) the condensation of I and II to produce III takes place in an non-hydroxylated polar organic solvent, e.g., acetone, ethyl acetate, methylethylketone, dioxan, THF, diethyIketone, and the like,
  • a proton acceptor is also present, e.g. potassium carbonate, sodium bicarbonate, pyridine, triethylamine, and the like.
  • the reaction is carried out under an inert atomosphere, e.g. dry nitrogen, and heated at reflux or allowed to sit for an extended period of time at room temperature. Workup is conventional.
  • Step (B) the protecting group, "PG", is catalytically removed at ambient temperature under a pressurized, hydrogen atmosphere in an organic solvent to produce IV, being a phenol or thiophenol.
  • Operable catalysts include 5% Pd/C, and the like.
  • the organic solvent should be inert under the reaction conditions and includes ethyl acetate, ethanol, methanol, dioxane, and the like.
  • Step (C) involves reacting IV with V to produce VI, the diester.
  • the reaction conditions are similar to those described in Step (A) utilizing an inert organic solvent for the reactants and a proton acceptor.
  • V useful in the invention are:
  • Step (D) the diester can be deesterified by aqueous basic hydrolysis, e.g. NaOH in MeOH/H 2 O to yield the diacid VII upon acidification.
  • Flow Sheet B-1 illustrates the specific synthesis of 7.
  • a solution of 3 in e.g., ethyl acetate is catalytically hydrogenated at room temperature under e.g. 40 psig of H 2 in the presence of a 5% Pd/C catalyst to yield ethyl 4-(2-hydroxyphenoxy) butyrate 4 in Step (B).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is a new treatment for men with benign prostatic hyperplasia (BPH), involving combination therapy of a 5α-reductase inhibitor, e.g. a 17β-substituted non-azasteroid, 17β-acyl-3-carboxy-androst-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)amide or cinnamoylamide derivative, aromatic 1,2-diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylamino-phenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, e.g. finsteride, in combination with an aromatase inhibitor, i.e., fadrazole, being 4-(5,6,7,8-tetra-hydroimidazo-[1,5-α]pyridin-5-yl)benzonitrile. The combination provides therapy at the molecular level for the underlying cause of the disease as well as providing symptomatic relief. Pharmaceutical compositions useful for treatment are also disclosed.

Description

TITLE OF THE INVENTION
PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a Continuation- in-Part of U.S. Application Serial No. 07/746,388, (Case
18364IA) filed August 16, 1991, which in turn is a
continuation-in-part application of U.S.S.N.
07/686,720, (Case 18364) filed on April 17, 1991.
BACKGROUND OF THE INVENTION
1. Field of the Invention This invention relates to a new method of treatment for patients, i.e. men having benign
prostatic hyperplasia (BPH), involving combination
therapy of administering therapeutically effective
amountB of a 5α-reductase inhibitor in combination
with an aromatase inhibitor. 2. Background of the Invention
Benign prostatic hyperplasia (BPH) affects a substantial number of males over the age of 50 and usually requires surgery in advanced stages for relief.
It is known that testosterone (T) is secreted by the testes and adrenal glands but can undergo a 5α-reductase mediated conversion to
dihydrotestosterone (DHT) in peripheral sites
including the liver, skin, and prostate. DHT is preferentially bound by the nucleus of prostatic cells thus indicating that DHT, rather than T, is the primary androgen required by the prostate for its growth and function. This led to the hypothesis that, by inhibiting 5α-reductase, the formation of DHT could be curtailed and hopefully prostate regression obtained. Finasteride, 17B(N-t-butyl)carbamoyl-4-aza- 5α-androst-1-en-3-one, was developed as a compound which was found to inhibit 5α-reductase and exhibit positive effects against benign prostatic hyperplasia. Finasteride is a 4-azasteroid and a competitive inhibitor of the enzyme. It shows no affinity for the androgen receptor and so would not be expected to interfere with the binding and action of T in those tissues, such as muscle, which respond to T, and thus should not result in feminizing characteristics. Typical 4-aza steroid 5α-reductase inhibitors known in the art include those developed by Merck. (See U.S. Pat. 4,377,584 to Rasmusson, et al.; U.S. Pat. 4,220,735 to Rasmusson, et al.; U.S. Pat. 4,845,104 to Carlin, et al.; U.S. Pat. 4,760,071 to
Rasmusson, et al., which discloses finasteride, being 17ß-(N-t-butyl)carbamoyl-4-aza-5α-androst-1-en-3-one, known by its trademark as PROSCAR®; U.S. Pat. 4,732,897 to Cainelli, et al.; U.S. Pat. 4,859,681 to Rasmusson, et al.; EPO Publn. 0 155 076; EPO Publn. 0 004 949; and EPO Publn. 0 314 189.
It is also known that small amounts of estrogens, i.g. estradiol, may be formed in the testes and prostate by the action of the enzyme, aromatase. It is not clear exactly how these
formed estrogens participate biochemically, but they are implicated and associated with prostate enlargement, i.e. benign prostatic hyperplasia.
USP 4,598,072 to Schering AG describes the combination of an aromatase inhibitor and an anti-androgen for treatment of benign prostatic hyperplasia. However, specific 5-alpha reductase inhibitors are not suggested or mentioned as
suitable anti-androgen agents.
What is desired in the art is a combination therapy both to treat the underlying DHT-dependent cause of BPH and to treat the estrogen-dependent associated cause of the disease as well. SUMMARY OF THE INVENTION
By this invention there is provided a method of treating patients with benign prostatic hyperplasia who are in need of such treatment comprising the step of administering in combination to such patients therapeutically effective amounts of a 5α-reductase inhibitor, e.g. a 17ß-substituted non-azasteroid, 17ß-acyl-3-carboxyandrost-3,5-diene, benzoylaminophenoxybutanoic acid derivative, fused benz(thio)- amide or cinnamoylamide derivative, aromatic 1,2- diethers or thioethers, aromatic ortho acylaminophenoxy alkanoic acids, ortho thioalkylacylaminophenoxy alkanoic acids, pharmaceutically acceptable salts and esters thereof, and an aromatase inhibitor.
The combined effect of a 5α-reductase inhibitor in inhibiting DHT production in the prostate and the aromatase inhibitor, i.e. fadrazole, will result in a greater effect on suppressing the growth and symptomatic relief of enlarged prostate than either agent by itself.
BRIEF DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS
In one preferred aspect, the present invention provides an effective method of treating BPH in patients in need of symptomatic relief by administering therapeutically effective amounts
of the aromatase inhibitor in association with a 5α-reductase inhibitor or pharmaceutical composition thereof. The active compounds may be administered together or in any order, as discussed hereinafter. By the term "patients in need of such treating" is meant male patients with functioning gonads who are being treated with a 5α-reductase inhibitor in a therapeutic program designed to combat benign prostatic hyperplasia (BPH) and are discovered to be in need of symptomatic relief.
The use of therapeutically effective amounts of the 5α-reductase inhibitor and the aromatase inhibitor in accordance with this invention effectively treats the adverse symptoms of BPH including nocturia, hesitancy, decreased urinary flow, and the like.
Aromatase is an enzyme complex incorporating a NADPH-cytochrome c-reductase and a cytochrome P450 component which mediates the conversion of androgens to estrogens, Bellino, J. Steroid Biochem. 17:261-270 (1982). The reaction is believed to involve three hydroxylation steps, two at the C-19 position (Meyer, Biochem. Biophys. Acta 17: 441-442 [1955]; Marato et al., Biochem. Biophys. Res. Comm. 6: 334-338 [1961]) and one at C-2 (Hahn and Fishman, J. Biol. Chem. 259: 1689-1694 [1984]; Brodie et al., J. Am. Chem. Soc. 91; 1241-1242 [1969]) which result in the conversion of the A ring of the androgen molecule to an aromatic ring. Since aromatization is a unique reation in the biosynthesis of steroids, specific inhibitors should not cause deprivation of other essential steroids. The inhibition or blocking of the conversion of androgens (testosterone, androstenedione) to estrogens (estradiol, estrone) results in an accumulation of androgens (testosterone, androstenedione) which may be responsible for participating in or mediating benign prostatic hyperplasia.
An aromatase inhibitor as defined herein is any steroidal or non-steroidal compound which prevents the conversion of androgens to estrogens. The compounds include substrate analogues of
androstenedione, testosterone or other steroidal substances involved in the aromatase pathway,
Henderson, J. Steroid Biochem. 27: 905-914 (1987). Non-steroidal compounds that block aromatase activity are also included within the scope of the invention. These non-steroidal compounds include compounds or analogues that can bind to the enzymatic active site of aromatase and inhibit enzymatic activity. Nonsteroidal or steroidal compounds will also include compounds or analogues that bind to the enzyme at a site away from the enzymatic site and cause a structural change in the enzyme which results in a loss of enzymatic activity. Aromatase inhibitors further include non-steroidal compounds that interfere with cytochrome P450 mediated hydroxylations such as those described by Brodie, et al., J. Steroid Biochem. 27: 899-903 (1987). The following compounds are known
non-steroidal aromatase inhibitors as disclosed by the associated reference. The reference will also directly contain a method for making the compound or will direct one who wishes to use the compound to a method for producing the compound. The aromatase inhibitors of the instant invention known in the art include, but are not limited to, the following compounds:
[(1H-imidazol-1-yl)phenylmethyl]-1 methyl-1H-benzotriazole, 6-[(4-chlorophenyl)(12-1,2,4-triazol-1-yl)methyl]-1-methyl-1H-benzotriazole as described in EPO Publication No. 293,978, and USP 4,943,574; 2,2-[5-(1H-1,2,4,-triazol-1-ylmethyl)-1,3-phenylene]-di(2-methylpropiononitrile),2,2-[5-(imidazol-1-yl- methyl)-1,3-phenylene]-di(2-methylpropiononitrile), 2-[3-(1-hydroxy-1-methylethyl)-5-(1H-1,2,4-triazol-1-ylmethylphenyl]-2-methylpropiononitrile,2,2-[5-dideuterio-(1H-1,2,4-triazol-1-yl)methyl-1,3-phenylene]di-(2-trideuteriomethyl-3,3,3-(trideuterio-propiononitrile), and 2,2-[5-dideuterio(1H-1,2,4-triazol-1-ylmethyl-1,3-phenylene)di(2-methyl-propiononitrile) as disclosed in European Patent Application,
Publication No. 296,749; 1,1-dimethyl-8-(1H-1,2,4-triazol-1-ylmethyl)-2(12)-naphtho[2,1-b]furanone, 1,2,-dihydro-1,1-dimethyl-2-oxo-8-(12-1,2,4-triazol-1-ylmethyl)naphtho-[2,1-b]-furan-7-carbonitrile, 1,2-dihydro-1,1-dimethyl-2-oxo-8-(1H-1,2,4-triazol-1-ylmethyl)-naphtho[2,1-b]furan-7-carboxamide, and1 ,2-dihydro-1,1-dimethyl-2-oxo-8-[di(1H-1,2,4-triazol-1-yl)methyl]naphtho[2,1-b]furan-7-carbonitrile as disclosed in European Patent Application, Publication No. 316,097; 2-(4-chlorobenzyl)-2-fluoro-1,3-di(1,2,4-triazol-1-yl) propane, 2-fluoro-2-(2-fluoro-4-chlorobenzyl)-1,3-di (1,2,4-triazol-1-yl)propane, 2-fluoro-2-(2-fluoro-4- trifluoromethylbenzyl)-1,3-di(1,2,4-triazol-1-yl)- propane, 3-(4-chlorophenyl)-1-(1,2,4-triazol-1-yl)- 2-(1,2,4-triazol-1-ylmethyl)butan-2-ol, 2-(4-chloro- -α-fluorobenzyl)-1,3-di(1,2,4-triazol-1-yl)propan- 2-ol, 2-(4-chlorobenzyl)-1,3-bis(1,2,4-triazol-1-yl)- propane, 4-[2-(4-chlorophenyl)-1,3-di(1,2,4-triazol- 1-ylmethyl)ethoxymethyl]-benzonitrile, 1-(4-fluorobenzyl)-2-(2-fluoro-4-trifluoromethylphenyl)-1,3-di- (1,2,4-triazol-1-yl)propan-2-ol, 2-(4-chlorophenyl)- 1-(4-fluorophenoxy)-1,3-di(1,2,4-triazol-1-yl)propan- 2-ol, 1-(4-cyanobenzyl)-2-(2,4-difluorophenyl)-1,3-di- (1,2,4-triazol-1-yl)-propan-2-ol and 2-(4-chlorophenyl)-1-phenyl-1,3-di(1,2,4-triazol-1-yl)-propan- 2-ol as described in European Patent Application, Publication No. 299,684; 5-bis(4-chlorophenyl) methylpyrimidine as disclosed in U.S. Patent
No. 4,762,836; α,α-bis(4-chlorophenyl)-2- pyrazinemethanol as described in U.S. Patent No.
4,764,376; N-(2,4-difluorophenyl)-N-benzyl-3-pyridinemethanamine and N-(2,chlorophenyl-α-(4-fluorophenyl)-3-pyridinemethanamine as disclosed in U.S. Patent No. 4,744,251; 1-(10,11-dihydro-4H-dibenzo[a,d]cyclohepten-4-yl)-1H-imidazole and
1-(9H-fluoren-9-yl-1H-imidazole as disclosed in
U.S. Patent No. 4,757,082; 3-bis(4-chlorophenyl)-3-methylpyridine and α,α-bis(4-chlorophenyl)-3-pyridinemethanol as disclosed in U.S. Patent No.
4,757, 076; 5H-5-(4-cyanophenyl)-6,7-dihydropyrrolo
[1,2-c]imidazole and 5H-5-(4-cyanophenyl)-6,7,8,9- tetrahydroimidazo[1,5-a]azepine and disclosed in U.S. Patent No. 4,728,645; 5-[(1H-imidazol-1-yl)
phenylmethyl]-2-methyl-1H-benz-imidazole and 5- [(3-chlorophenyl)(1H-imidazol-1-yl)-methyl-1H-benzimidazole as disclosed in European Patent
Application, Publication No. 260,744; (Z)-α-(1, 2,4-triazol-1-ylmethyl)stilbene-4,4'-dicarbonitrile, (Z)-4'-chloro-α-(l,2,4-triazol-1-ylmethyl)stilbene- 4-carbonitrile, (Z)-α-1,2,4-triazol-1-ylmethyl)-4'-(trifluoromethyl)stilbene-4-carbonitrile, (E)-ß-fluoro-α-(1,2,4-triazol-1-ylmethyl)stilbene-4,4'-dicarbonitrile, (Z)-4'-fluoro-α-(imidazol-1-ylmethyl)stilbene-4-carbonitrile, (Z)-2',4'-dichloro-α-(imidazol-1-ylmethyl)-stilbene-4-carbonitrile, (Z)-4'-chloro-α-(imidazol-1-ylmethyl)stilbene-4-carbonitrile, (Z)-α-(imidazol-1-ylmethyl)stilbene 4,4'-dicarbonitrile, (Z)-α-(5-methylimidazol-1-ylmethyl)stilbene-4,4'-dicarbonitrile,and (Z)-2-[2-(4-cyanophenyl)-4-(1,2,4-triazol-1-yl)-propenyl] pyridine-4-carbonitrile as disclosed in European
Patent Application, Publication No. 299,683; (1R*, 2R*)-6-fluoro-2-(4-fluorophenyl)-1,2,3,4-tetra-hydro-1-(1H-1,2,4-triazol-1-ylmethyl)naphthalene, (1R*,2R*)-6-fluoro-2-(4-fluorophenyl)-1,2,3,4-tetra-hydro-1-(lS-imidazolylmethyl)-naphthalene, (1E*,2E*)-and (1R*,2S*)-2-(4-fluorophenyl)1,2,3,4-tetrahydro-1- (1H-1,2,4-triazol-1-ylmethyl)naphthalene-6-carbonitrile, (1R*,2R*)-and (1R*,2S*)-2-(4-fluorophenyl)-1,2-3,4-tetrahydro-1-(1H-imidazolylmethyl)naphthalene-6-carbonitrile, (1R*,2R*)-and (1R*,2S*)-1,2,3,4-tetra-hydro-1-(1H-1,2,4-triazol-1-ylmethyl)naphthalene-2,6- dicarbonitrile, (1R*,2R*)-and (1R*,2S*)-1,2,3,4-tetra- hydro-1-(lS-imidazol-1-ylmethyl)naphthalene-2,6-di- carbonitrile, and (1R*, 2S*)-2-(4-fluorophenyl)-1,2,- 3,4-tetrahydro-1-(4-methyl-1H-imidazolylmethyl)naphthalene-6-carbonitrile as disclosed in European Patent Application, Publication No. 281,283; 8-chloro-5-(4- chlorophenyl)-5E-indeno[1,2-d]pyridine as disclosed in U.S. Patent No. 4,769,378; 5-bis(4-chlorophenyl) methylpyrimidine as disclosed in U.S. Patent No.
4,762,836; 10-(2-propynyl)-estr-4-ene-3,17-dione as disclosed in U.S. Patent No. 4,322,416; 6-[(4- chlorophenyl)(1H-1,2,4-triazol-1-yl)methyl]-1- methyl-1H-benzotriazole as described in European
Patent Application, Publication No. 293,978;
1-methyl-androsta-1,4-dien-3,17-dione (Schering AG) as disclosed in U.S. Patent No. 4,591,585; 3-ethyl- 3-(4-pyridyl)piperdine-2,6-dione as disclosed in
British Patent GB 2,151,266; 4-hydroxyandrostene- 3,17-dione as disclosed in U.S. Patent No. 4,500,523; 4-(5,6,7,8-tetrahydroimidazo-[1,5-α]pyridin-5-yl) benzonitrile (fadrazole) as disclosed in U.S. Patent No. 4,728,645, and 4-[alpha-(4-cyanophenyl)-1-(1,2,4-triazolyl)methyl]benzonitrile as disclosed in USP 4,978,672 both to Ciba-Geigy; 6-methyleneandrosta-1,4-diene-3,17-dione, 4-aminoadrostan-1,4,6-trien-3,17-dione and 4-aminoandrosta-4,6-diene-3,17-dione as disclosed in U.S. Patent No. 4,757,061; 3-(1H-imidazol-1-yl-methyl)-2-methyl-1H-indole-1-propanoic acid as disclosed in U.S. Patent No. 4,273,782;
5-[3-chlorophenyl) (1H-imidazol-1-yl)methyl]-1H-benzimidazole as disclosed in European Patent Application, Publication No. 260,744; 10ß-thiiranylestr-4-ene- 3,17-dione and 10ß-oxiranylestr-4-ene-3,17-dione as disclosed in J. Organ. Chem. 53: 5947-5951 (1988); 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione as described in U.S. Patent No. 4,668,689; 3-(4-aminophenyl)-3-ethylpyrrolidine-2,5-dione as disclosed in J. Med. Chem. 29: 520-523 (1986); 1-(7-carboxyheptyl)-imidazole as described in U.S. Patent No. 4,320,134; 1,1-dimethyl-8-(1H-1,2,4-triazol-1-ylmethyl)-2(1H)-naphtho[2,1-b]-furanone (la) as disclosed in European Patent Application, Publication No. 316,097; 1,3,5-andros-tatriene-3,17-dione disclosed in Biochem.
Pharmac. 31: 2017-2023 (1982) and other compounds well known in the art of aromatase inhibiton and cancer therapy such as bis-(p-cyanophenyl)-imidazo-1-yl-methane hemisuccinate and pharmaceutically acceptable derivatives, acid addition salts and possible sterochemically isomeric forms therof, if and where appropriate. Preferred for use in the instant invention is
fadrazole. The invention is also intended to include any biologically active equivalents of an aromatase inhibitor as described above. Preferred is where the 4-aza steroid has the formula:
Figure imgf000014_0001
wherein the dotted line represents a double bond when present, R1 and R3 are independently hydrogen, methyl or ethyl,
R2 is a hydrocarbon radical selected from straight or branched chain substituted or unsubstituted alkyl, cycloalkyl, or aralkyl of from 1-12 carbons or monocyclic aryl optionally containing 1 or more lower alkyl substituents of from 1-2 carbon atoms and/or 1 or more halogen substituents,
R' is hydrogen or methyl,
R' 's hydrogen or ß-methyl,
R''' is hydrogen, α-methyl or ß-methyl, and
pharmaceutically acceptable salts or esters thereof.
A preferred embodiment of the compound of formula I applicable in the process of our invention is represented by the formula:
Figure imgf000015_0001
wherein
R1 is hydrogen, methyl or ethyl, and
R2 is branched chain alkyl cycloalkyl, aralkyl of from 4-12 carbons, phenyl, optionally substituted by methyl, chloro or fluoro, substituted or unsubstituted 1-, 2-adamantyl, 1-,
2-adamantylmethyl, 1-, 2- or 7-norbornanyl, 1-, 2- or 7-norbornanymethyl.
Representative compounds of the present invention include the following:
17ß-(N-tert-amylcarbamoyl-4-aza-5α-androst-1-en- 3-one,
17ß-(N-tert-hexylcarbamoyl)-4-aza-5α-androst-1-en- 3-one.
17ß-(N-tert-butylcarbamoyl)-4-aza-5α-androst-1-en- 3-one,
17ß-(N-isobutylcarbamoyl)-4-aza-5α-androst-1-en- 3-one,
17ß-(N-tert-octylcarbamoyl)-4-aza-5α-androst-1-en- 3-one,
17ß-(N-octylcarbamoyl)-4-aza-5α-androst-1-en- 3-one, 17ß-(N-1,1-diethylbutylcarbamoyl)-4-aza-5α-androst- 1-en-3-one,
17ß-(N-neopentylcarbamoyl)-4-aza-5α-androst-1-en- 3-one,
17ß-(N-2-adamantylcarbamoyl)-4-aza-5α-androst-1-en- 3-one,
17ß-(N-1-adamantylcarbamoyl)-4-aza-5α-androst-1-en- 3-one,
17ß-(N-2-norbornylcarbamoyl)-4-aza-5α-androst-1-en- 3-one,
17ß-(N-1-norbornylcarbamoyl)-4-aza-5α-androst-1-en- 3-one,
17ß-(N-phenylcarbamoyl)-4-aza-4-methyl-5α-androst- 1-en-3-one,
17ß-(N-benzylcarbamoyl)-4-aza-4-methyl-5α-androst- 1-en-3-one,
17ß-(N-tert-amylcarbamoyl-4-aza-4-methyl-5α-androst- 1-en-3-one,
17ß-(N-tert-hexylcarbamoyl)-4-aza-4-methyl-5α- androst-1-en-3-one,
17ß-(N-tert-butylcarbamoyl)-4-aza-4-methyl-5α- androst-1-en-3-one,
17ß-(N-isobutylcarbamoyl)-4-aza-4-methyl-5α-androst- 1-en-3-one,
17ß-(N-tert-octylcarbamoyl)-4-aza-4-methyl-5α- androst-1-en-3-one,
17ß-(N-1,1,3,3-tetramethylbutylcarbamoyl)-4-aza- 5α-androst-1-en-3-one,
17ß-(N-octylcarbamoyl)-4-aza-4-methyl-5α- androst-1-en-3-one,
17ß-(N-1,1-diethylbutylcarbamoyl)-4-aza-4-methyl-5α- androst-1-en-3-one, 17ß-(N-neopentylcarbamoyl)-4-aza-4-methyl-5α-androst- 1-en-3-one,
17ß(N-1-adamantylcarbamoyl)-4-aza-5α-androstan- 3-one;
17ß(N-1-adamantylcarbamoyl)-4-methyl-4-aza-5α- androst-1-en-3-one;
17ß(N-1-adamantylcarbamoyl)-4-methyl-4-aza- 5α-androstan-3-one;
17ß-(N-1-adamantylmethylcarbamoyl)-4-aza-5α- androst-1-en-3-one;
17ß-(N-2-adamantylcarbamoyl)-4-aza-5α-androstan- 3-one;
17ß-(N-methyl-N-2-adamantylcarbamoyl)-4-methyl-4-aza- androstan-3-one;
17ß-(N-2-adamantylcarbamoyl)-4-methyl-4-aza- 5α-androstane-3-one;
17ß-(N-2-adamantylcarbamoyl)-4-methyl-4-aza- 5α-androst-1-en-3-one;
17ß-(N-methyl-N-2-adamantyl)carbamoyl-4-methyl-4-aza- androst-1-en-3-one;
17ß-(N-(3-methyl)-1-adamantyl-carbamoyl)-4-aza-4- methyl-5α-androst-an-3-one;
17ß-(N-exo-2-norbornanylcarbamoyl)-4-aza-4-methyl-5α- androst-1-en-3-one;
17ß-(N-exo-2-norbornanylcarbamoyl)-4-aza-5α-androst-1-en-3-one; 17ß-(N-2-adamantylcarbamoyl)-4-aza-5α- androst-en-3-one;
17ß-(N-methyl-N-2-adamantylcarbamoyl)-4-aza-4-methyl- androstan-3-one;
17ß-(N-2-adamantylcarbamoyl)-4-methyl-4-aza- 5α-androstan-3-one; and
17ß-(N-methyl-N-2-adamantyl)carbamoyl-4-methyl-4-aza- androst-1-en-3-one. The corresponding compounds of those above wherein the 4-aza substituent is substituted in each of the above named compounds with a hydrogen, methyl or an ethyl radical, to form a different
N-substituent, and wherein a double bond can be optionally present as indicated by the dotted line in position 1.
The alkyl, cycloalkyl, aralkyl, monocyclic aryl, 1-, 2-adamantyl or 1-, 2-norbornanyl moieties can be substituted with one or more substi- tuents of the following: C1-C4 linear/branched alkyl, including methyl, ethyl, isopropyl, n-butyl; nitro; oxo; C7-C9 aralkyl, including benzyl; (CH2)n COOR where n is 0-2 and R is H or C1-C4 linear/branched alkyl including methyl, ethyl; CH2OH; OH; OR where R is C1-C4 linear/branched alkyl including methyl, ethyl; halo, including fluoro, bromo, iodo; COOH;
COOR, where R is linear/branched C1-C4 alkyl;
-CONH2; CH2NH2; CH2NHCOR where R is C1-C4 linear/branched alkyl including methyl, ethyl; phenyl;
o, m, p-substituted phenyl including p-nitro,
p-amino and p-sulfo; or cyano. The amino group of the adamantyl or norbornanyl moiety can also be substituted as R1 with methyl and ethyl, as well as hydrogen.
Also included within the scope of this invention are pharmaceutically acceptable salts or esters, where a basic or acidic group is present on the substituted alkyl, cycloalkyl, aralkyl, adamantyl or norbornanyl moiety. When an acidic substituent is present, i.e. -COOH, there can be formed the
ammonium, sodium, potassium, calcium salt, and the like, for use as the dosage form.
Where a basic group is present, i.e. amino, acidic salts, i.e. hydrochloride, hydrobromide, acetate, pamoate, and the like, can be used as the dosage form.
Also, in the case of the -COOH group being present, pharmaceutically acceptable esters can be employed, e.g. acetate, maleate, pivaloyloxymethyl , and the like, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.
Representative examples include for R2
(where AD is adamantyl):
3, 5, 7-trinitro-1-AD; 4-oxo-1-AD; 1-benzyl-1-AD;
4 , 4-dimethyl-1-Ad; 3,7-dimethyl-5-carboxymethyl-1-AD; 3-carboxymethyl-1-AD; 3-chloro-1-AD; 1,3-dihydroxy-6,6-dimethyl-2-AD; 3-chloro-1-AD; 4-carbethoxy-2-AD; 4-carboxy-2-AD; 3-isopropyl-1-AD; 3-n-butyl-1-AD;
3-propyl-1-AD; 3-,5-diethyl-1-AD; 3-hydroxymethyl-1-AD; 2-carboxy-1-AD; 3-methyl-1-AD; 5-hydroxy-2-AD; 2-hydroxy-1-AD; 1-aminomethyl-1-hydroxy-2-AD;
2-oxo-1-AD; 2-phenyl-2-AD; 1-amino-methyl-2-AD;
l-carboxy-2-AD; 1-aminocarbonyl-2-AD; 3-hydroxy-5,7-dimethyl-1-AD; 4-fluoro-1-AD; 3-fluoro-1-AD;
4-hydroxy-2-AD; 3-phenyl-1-AD; 3-(p-aminophenyl)-1-AD; 3-(p-nitrophenyl)-1-AD; 3-methyl-5-hydroxymethyl-1-AD; 3,5-dimethyl-4-hydroxy-1-AD;
2-hydroxymethyl-2-AD; 3-(p-sulfophenyl)-1-AD; 3-methyl-5-ethyl-1-AD; 2-carboxy-2-AD; 3,5-7-trimethyl-1-AD; 4-iodo-2-AD; 4-bromo-2-AD; 4-chloro-2-AD; 1-acetylaminomethyl-2-AD; 1-carboxymethyl-2-AD;
1-methyl-2-AD; 1-aminocarboxylmethyl-2-AD;
1-aminocarboxyl-1-AD; 2-cyano-2-AD; 3,5-dimethyl- 7-ethyl-1-AD; 4-hydroxy-1-AD; 1-hydroxy-2-AD;
5-carboxy-3-methyl-1-AD; 3,5-dimethyl-7-carboxy- 1-AD; 3-carboxy-1-AD; 3-hydroxy-1-AD; and the like.
Representative examples include for R2 as substituted norbornanyl moieties are (where NB is norbornanyl):
2-NB; 1,7,7-trimethyl-4-phenyl-2-NB; 3-carboxy-2- NB; 3-phenyl-2-carboxy-2-NB; 2-cyano-3-phenyl-2-NB; 3-hydroxy-4,7,7-trimethyl-2-NB; 6-hydroxymethyl-2- NB; 5-cyano-2-NB; 3-allyl-2-NB; 1-NB; 7,7-dimethyl-1-hydroxymethyl-2-NB; 3-methoxy-4,7,7-trimethyl-2-NB; 3-aminocarbonyl-2-NB; 3-ethoxycarbonyl-2-NB; 3,3- dimethyl-2-NB; 7-oxo-1-NB; 3-phenyl-2-NB; 1-carboxy-methyl-7,7-dimethyl-2-NB; 1-ethyl-2-NB; 1-methyl-2-NB; 2,2,3,3,5,5,6,6,7,7-decafluoro-1-NB; 3-hydroxy-2-NB; 3-chloro-2-NB; 3-(p-methoxyphenyl)-2-NB; 2,2-dimethyl-3-methylene-7-NB; 3-oxo-2-NB; 1-methoxy-2-NB; 7-NB; 3-isopropyl-2-NB; 2-bromo-1-NB; 3-chloro-1-NB; and the like.
Procedures for preparing the compounds of Formula I useful in this invention, including the above, are well known in the art.
The novel compounds of formula I of the present invention can be prepared by a method
starting with the known steroid ester (IIIA) of the formula:
Figure imgf000021_0001
17ß-(carbomethoxy)-4-aza-5-α-androstan-3-ones which includes the stages of optionally 1) dehydrogenating said starting material to produce the corresponding compound containing a double-bond in the 1,2-position of the A-ring, 2) converting the 17-carbomethoxy substituent into an N-substituted alkyl, cycloalkyl, aralkyl, monocylic acyl, or adamantylcarbamoyl substituent and, if desired, 3) alkylating the A-ring nitrogen to introduce a N-methyl or N-ethyl
substituent into the A ring 4-position. For the dehydrogenatin step, it is preferable that the 4-aza nitrogen be unsubstituted. The alternate pathways can consist of one or more discrete chemical steps and if desired can take place before step (1) or following step (1) or step (3).
In accordance with the process of the present invention (see flow sheet), the products of our invention are formed by optionally: (1) heating a 17ß-alkoxycarbonyl-4-aza-5α-androstan-3-ones, com pound III, (prepared in the literature as described in the reference US Patent 4,377,584) with a dehydrogenating agent such as benzeneseleninic anhydride in a refluxing inert solvent, e.g. chlorobenzene, to form a 17ß-alkoxycarbonyl-4-aza-5α-androst-1-ene-3-one IV (alternately, the dichlorodicyanobenzoquinone process of Dolling, et al., JACS 1988, Vol. 110, pp.
3318-3319, can be used); (2) the formed 5α-androst- 1-en-3-one compound from Step 1 can be reacted with, e.g. sodium hydride under anhydrous conditions in a neutral solvent such as dimethylformamide; (3) contacting the resulting reaction mixture with an alkyl (methyl or ethyl) iodide to form the corresponding 17-ß-alkoxy-adamantyl-carbamoyl-4-alkyl-4-aza-5α- androst-1-en-3-one V; (4) subsequently hydrolyzing said 17ß-alkoxycarbonyl-4-alkyl-4-aza-5α-androst- 1-en-3-one with a strong base, such as aqueous
methanolic potassium hydroxide at the reflux temperature, followed by acidification and isolation of the resulting steroidal acid to yield 17ß-carboxy 4-alkyl-4-aza-5α-androst-1-en-3-one VI; (5) said steroidal acid can be then converted to its corresponding
2-pyridylthio ester by refluxing with triphenyl phosphine and 2,2'-dipyridyl disulfide in an inert solvent such as toluene and the resulting product
17ß-(2-pyridylthiocarbonyl)-4-alkyl-4-aza-5α-androst-1-en-3-one VII can be isolated by chromatography on e.g. silica gel; and (6) said pyridylthio ester can be thenreacted with 1-adamantyl-, 2-adamantylamine or norbornanylamine in an inert solvent e.g. tetrahydrofuran, to form the desired product 17ß-N-adamantyl- carbamoyl-4-alkyl-4-aza-5α-androst-1-en-3-one VIII which can be isolated by chromatography e.g. on silica gel. When the previous reaction is carried out in the absence of first forming the double bond at position 1, the corresponding 17B-(N-adamantyl-carbamoyl)-4-alkyl-4-aza-5α-androstan-3-one (or
N-norbornanyl carbamoyl compound) is prepared.
In accordance with an alternate process of our invention the corresponding N-unsubstituted-17ß(N-adamantyl-carbamoyl)-4-aza-5α-androst-1-en-3-one XIV is readily prepared from the 17ß (alkoxycarbonyl)-4-aza-5α-androstone-3-one IV by repeating the above series of reaction steps but omitting the alkylation Step 2 herein above, i.e. treatment of the 4-aza-5-α-androst-1-en-3-one with e.g. sodium amide followed by methyl or ethyl iodide via intermediates XII and XIII.
In accordance with a further alternate process of preparing the compounds of our invention having only hydrogen as the sole substituent on the ring A - nitrogen, the double bond in the A ring is introduced as the last step of the process. Thus, a 17ß-alkoxycarbonyl 4-aza-5α-androstan-3-one III is hydrolyzed to the corresponding steroidal acid IX 17ß-carboxy-4-aza-5α-androstan-3-one which in turn is converted to the corresponding pyridylthio ester, 17ß (2-pyridylthiocarbonyl)-4-aza-5α-androstan-3-one, X followed by treatment of the ester with an amine of formula R2-NH2 wherein R2 is as defined hereinabove as 1- or 2-adamantyl or 1-, 2-, or 7-norbornanyl to form a 17ß (N-adamantyl-carbamoyl)-4-aza-5α- androstone-3-one XI which is dehydrogenated as previously described to produce compound XIV,
17ß-(N-adamantyl-carbamoyl)-4-aza-androst-1-en- 3-one or corresponding norbornanyl derivative.
In another alternate method of introducing the 17ß-(N-adamantyl-carbamoyl)substituent into a 17ß-carboxy androstane compound of formula VI, XII or IX, each is treated in a manner similar to the procedure described in Steroids. Vol. 35 #3, March 1980, p. 1-7 with dicyclohexylcarbodiimide and
1-hydroxybenzo-triazole to form the 17ß-(1-benzotriazoloxycarbonyl)-4-aza-5α-androst-1-en-3-one, VII, XIII or compound X, wherein the substituent X is benzotriazoloxy group.
The 16-methyl derivative wherein R''' is methyl are prepared from known 16-methyl-17-acyl-4-methyl-4-aza-5α-androstan-3-ones, e.g.
4,16β-dimethyl-17β-acetyl-4-aza-5α-androstan-3-one by known dehydrogenation procedures for 4-methyl-4-aza compounds to produce the corresponding
4,16β-dimethyl-17β-acetyl-4-aza-5α-androst-1-en-3-one .
The above reactions are schematically represented in the following flowsheet.
Figure imgf000025_0001
X is 2-pyridylthio or 1-benzotriazoloxy. R2 is 1- or 2-adamantyl or norbornanyl. Also a preferred 4-azasteroid is a 17ß-acyl-4-aza- 5α-androst-1-ene-3-one compound of the formula:
Figure imgf000026_0001
wherein the dotted line represents a double bond when present;
R is selected from hydrogen, methyl and ethyl; R2 is (a) a monovalent radical selected from
straight or branched chain alkyl, or cycloalkyl, of from 1-12 carbons, which can be substituted by one or more of
C1-C2 alky! or halo;
(b) an aralkyl radical selected from benzyl or phenethyl;
(c) a polycyclic aromatic radical which can be substituted with one or more of:
-OH, protected -OH, -OC1-C4 alkyl, C1-C4 alkyl, halo or nitro;
(d) a monocyclic aromatic radical which can be substituted with one or more of: (l) -OH, -OC1-C4 alkyl, C1-C4 alkyl,
-(CH2)mOH, -(CH2)n, COOH, including protected hydroxy, where m is 1-4, n is 1-3, providing C1-C4 alkyl is only present when one of the above
oxygen-containing radicals is present; (2) -SH, -SC1-C4 alkyl, -SOC1-C4 alkyl,
-SO2C1-C4 alkyl, -SO2N(C1-C4-alkyl)2, C1-C4 alkyl -(CH2)mSH, -S-(CH2)n-O- COCH3, where m is 1-4 n is 1-3, providing C1-C4 alkyl is only present when one of the above sulfur containing radicals is present;
(3) N(R3)2, which can be protected, where R3 is independently H or C1-C4 alkyl, where the monoaryl ring can also be further substituted with C1-C4 alkyl; and
(4) heterocyclic radical selected from 2- or 4-pyridyl, 2-pyrrolyl, 2-furyl or thiophenyl;
and R', R'' and R''' are each selected from hydrogen and methyl, and pharmaceutically acceptable salts thereof.
A preferred embodiment of the compounds of our invention process is: the compound of above Structure IA,
wherein the dotted line is a double bond,
R is hydrogen or methyl, and R2 is branched chain alkyl, or cycloalkyl of from 4-10 carbons, and R'' and R''' are hydrogen. Another embodiment of the invention is the compounds of above Structure I where R2 is phenyl, or phenyl substituted by substituents described above, including where
R2 is phenyl, 2-, 3-, or 4-tolyl, xylyl,
2-bromophenyl, 2-chlorophenyl,
2,6-dichlorophenyl, 2,6-dibromophenyl, aminophenyl, N-alkylaminophenyl, N-N-dialkyl- aminophenyl, 4-biphenyl, 3-biphenyl, naphthyl, anthracyl, phenanthryl,
thiophenyl, methylthiophenyl,
methylsulfinyl, phenyl, methylsulfophenyl, aminosulfophenyl, thioethylphenyl, acetoxymethylthiophenyl,
17ß-(4-hydroxyphenyl), 17ß-(3-hydroxyphenyl), 17ß-(3,4-dihydroxyphenyl), or 17ß-(3,5- dimethyl-4-hydroxyphenyl).
Representative compounds of the invention are:
17ß-(phenylcarbonyl)-4-aza-4-methyl-5α-androst- 1-ene-3-one;
17ß-(2-tolylcarbonyl)-4-aza-4-methyl-5α-androst- 1-ene-3-one;
17ß-(3-tolylcarbonyl)-4-aza-4-methyl-5α-androst- 1-ene-3-one;
17ß-(4-tolylcarbonyl)-4-aza-4-methyl-5α-androst- 1-ene-3-one;
17ß-(2-bromophenylcarbonyl)-4-aza-4-methyl-5α- androst-1-ene-3-one;
7ß-(2-chlorophenylcarbonyl)-4-aza-4-methyl-5α- androst-1-ene-3-one; 17ß-(2 , 6-dichlorophenylcarbonyl)-4-aza-4-methyl-5α- androst-1-ene-3-one ;
17ß-(2 , 6-dibromophenylcarbonyl)-4-aza-4-methyl-5α- androst-1-ene-3-one ;
17ß-(xylylcarbonyl)-4-aza-4-methyl-5α-androst- 1-ene-3-one ;
17ß-(t-butylcarbonyl)-4-aza-5α-androst-1-ene-3-one ; 17ß-(isobutylcarbonyl)-4-aza-5α-androst-1-ene-3-one ; 17ß-(isooctylcarbonyl)-4-aza-5α-androst-1-ene-3-one ; 17ß-(n-octylcarbonyl)-4-aza-5α-androst-1-ene-3-one ; 17ß-(1 , 1-diethylbutylcarbonyl)-4-aza-5α-androst-1- ene-3-one ;
17ß-(neopentylcarbonyl)-4-aza-5α-androst-1-ene-3-one ; 17ß-(tert-amylcarbonyl)-4-aza-4-5α-androst-1-ene-3- one ;
17ß-(tert-hexylcarbonyl)-4-aza-4-5α-androst-1-ene-3- one ;
17ß-(cyclohexylcarbonyl)-4-aza-5α-androst-1-ene-3- one;
17ß-(cyclopentylcarbonyl)-4-aza-5α-androst-1-ene-3- one;
17ß-(benzylcarbonyl)-4-aza-5α-androst-1-ene-3-one; 17ß-(2-pyridylcarbonyl)-4-aza-5α-androst-1-ene-3-one; 17ß-(4-pyridylcarbonyl)-4-aza-5α-androst-1-ene-3-one; 17ß-(2-pyrrolylcarbonyl)-4-aza-5α-androst-1-ene-3- one;
17ß-(2-furylcarbonyl)-4-aza-5α-androst-1-ene-3-one; 17ß-(2-thiophenylcarbonyl)-4-aza-5α-androst-1-ene-3- one;
17ß-(2-adamantylcarbonyl)-4-aza-5α-androst-1-ene-3- one; 17ß-(phenylcarbonyl)-4-aza-5α-androst-1-ene-3-one ; 17ß-(2-tolylcarbonyl)-4-aza-5α-androst-1-ene-3-one; 17ß-(3-tolylcarbonyl)-4-aza-5α-androst-1-ene-3-one; 17ß-(4-tolylcarbonyl)-4-aza-5α-androst-1-ene-3-one; 17ß-(2-bromophenylcarbonyl)-4-aza-5α-androst-1-ene-3- one;
17ß-(2-chlorophenylcarbonyl)-4-aza-5α-androst-1-ene- 3-one;
17ß-(2,6-dichlorophenylcarbonyl)-4-aza-5α-androst-1- ene-3-one;
17ß-(2, 6-dibromoρhenylcarbonyl)-4-aza-5α-androst-1- ene-3-one ;
17ß-(xylylcarbonyl)-4-aza-5α-androst-1-ene-3-one ;
17ß-(phenylethyl)carbonyl-4-aza-5α-androst-1-ene-3- one;
17ß-(4-dimethylaminophenylcarbonyl)-4-aza-5a-androst- 1-en-3-one;
17ß-(3-dimethylaminophenylcarbonyl)-4-aza-5a-androst- 1-en-3-one.
17ß-(3,4-diethylaminophenylcarbonyl)-4-aza-androst-1- en-3-one.
17ß-(3,5-dimethyl-4-diethylaminophenylcarbonyl)-4-aza- 5a-androst-1-en-3-one;
17ß-(4-N-methylaminomethylphenylcarbonyl)-4-aza-5a- androst-1-en-3-one; or
17ß-(2-N-ethylamino-4-ethylphenylcarbonyl)-4-aza-5a- androst-1-en-3-one.
17ß-(4-phenylbenzoyl)-4-aza-5a-androst-1-en-3-one; 17ß-(3-phenylbenzoyl)-4-aza-5a-androst-1-en-3-one; 17ß-(4-biphenyl)-4-aza-5a-androst-1-en-3-one; 17ß-(3-biphenyl)-4-aza-5a-androst-1-en-3-one;
17ß-(1-naphthyl)-4-aza-5a-androst-1-en-3-one;
17ß-(2-naphthyl)-4-aza-5a-androst-1-en-3-one;
17ß-(1-phenanthryl)-4-aza-5a-androst-1-en-3-one;
17ß-(2-phenanthryl)-4-aza-5a-androst-1-en-3-one;
17ß-(1-biphenyl)-4-aza-5a-androst-1-en-3-one;
17ß-(9-anthracyl)-4-aza-5a-androst-1-en-3-one;
17ß-(4-thiophenylcarbonyl)-4-aza-5α-androst-1-en-3- one;
17ß-(3-thiophenylcarbonyl)-4-aza-5α-androst-1-en-3- one;
17ß-(4-methylthiophenylcarbonyl)-4-aza-5α-androst-1- en-3-one;
17ß-(4-methylsulfinylphenylcarbonyl)-4-aza-5α- androst-1-en-3-one;
17ß-(4-methylsulfophenylcarbonyl)-4-aza-5α-androst-1- en-3-one;
17ß-(3-methylsulfinylphenylcarbonyl)-4-aza-5α- androst-1-en-3-one;
17ß-(4-N,N-dimethylaminosulfophenylcarbonyl)-4-aza- 5α-androst-1-en-3-one;
17ß-(2-ethyl-4-methylthiophenylcarbonyl)-4-aza-5α- androst-1-en-3-one;
17ß-(4-thioethylphenylcarbonyl)-4-aza-4-methyl-5α- androst-1-en-3-one;
17ß-(4-acetoxymethylthiophenylcarbonyl)-4-aza-4- methy15α-androst-1-en-3-one;
17ß-(2-methyl-4-methylthiophenylcarbonyl)-4-aza-4- methyl-5α-androst-1-en-3-one;
17ß-(2-methyl-4-methylsulfinylphenylcarbonyl)-4-aza- 4-methyl-5α-androst-1-en-3-one; 17ß-(2-isopropyl-4-methylsulfophenylcarbonyl)-4-aza- 4-methyl-5α-androst-1-en-3-one;
17ß-(4-methylthiophenylcarbonyl)-4-aza-4-methyl-5α- androstan-3-one;
17ß-(4-methylsulfinylphenylcarbonyl)-4-aza-4-methyl- 5α-androstan-3-one;
17ß-(4-methylsulfophenylcarbonyl)-4-aza-4-methyl-5α- androstan-3-one;
17ß-(4-hydroxyphenyl)-4-aza-5α-androst-1-en-3-one; 17ß-(3-hydroxyphenyl)-4-aza-5α-androst-1-en-3-one; 17ß-(3,4-dihydroxyphenyl)-4-aza-5α-androst-1-en-3- one;
17ß-(3,5-dimethyl-4-hydroxyphenyl)-4-aza-5α-androst- 1-en-3-one;
17ß-(4-hydroxymethylphenyl)-4-aza-5α-androst-1- en-3-one;
17ß-(2-hydroxyethylphenylcarbonyl)-4-aza-5α- androst-1-en-3-one;
17ß-(4-methoxyphenyl)-4-aza-5α-androst-1-en-3-one; 17ß-(4-carboxymethylphenyl)-4-aza-5α-androst-1-en-3- one;
17ß-(4-hydroxyphenyl)-4-aza-4-methyl-5α-androst-1-en- 3-one;
17ß-(3-hydroxyphenyl)-4-aza-4-methyl-5α-androst-1-en- 3-one;
17ß-(3,4-dihydroxyphenyl)-4-aza-4-methyl-5α-androst- 1-en-3-one;
17ß-(3,5-dimethyl-4-hydroxyphenyl)-4-aza-4-methyl-5α- androst-1-en-3-one;
17ß-(4-hydroxymethylphenyl)-4-aza-4-methyl-5α- androst-1-en-3-one; 17ß-(2-hydroxyethylphenylcarbonyl)-4-aza-4-methyl-5α- androst-1-en-3-one;
17ß-(4-methoxyphenyl)-4-aza-4-methyl-5α-androst-1-en- 3-one;
17ß-(4-carboxymethylphenyl)-4-aza-4-methyl-5α- androst-1-en-3-one; and
17ß-(4-carboxyphenyl)-4-aza-5α-androst-1-en-3-one, and the corresponding compounds wherein the
4-hydrogen substituent is replaced in each of the above named compounds by a methyl or an ethyl radical.
The compounds of formula IA of the present invention are prepared by a method starting with the known steroid ester of the formula:
Figure imgf000033_0001
named 17ß-(carbomethoxy)-4-aza-5α-androstan-3-one, which includes the stages of (1) dehydrogenating said starting material to produce the corresponding compound containing a double bond in the 1,2-position of the A-ring, (2) converting the 17-carbomethoxy substituent into a 17ß-acyl substituent and, if desired (3) alkylating the A-ring nitrogen to introduce 4-methyl or 4-ethyl substituents into the A-ring. For the dehydeogenation step, it is preferable that the 4-aza nitrogen be unsubstituted, The dehydrogenation step can be carried out, e.g. according to the procedure of Dolling, et al. involving dichlorodicyanobenzoquinone, JACS (1988) Vol. 110, pp. 3318-3319. Stage (2) may consist of one or more chemical steps and if desired may take place before stage (1) or following stage (1) or stage (3).
In accordance with the process of the present invention, the products of our invention are formed by (1) heating a 17ß-alkoxycarbonyl-4-aza-5α- androstan-3-one compound III with a dehydrogenating agent such as benzeneseleninic anhydride in refluxing chlorobenzene to form a 17ß-alkoxycarbonyl-4-aza-5α-androst-1-en-3-one (IV), (2) the formed 5α-androst- 1-en-3-one compound from step (1) is reacted with sodium hydride and under anhydrous conditions in a neutral solvent such as dimethylformamide, (2) contacting the resulting reaction mixture with an alkyl (methyl or ethyl) iodide to form the corresponding 17ß-alkoxycarbonyl-4-alkyl-4-aza-5α-androst-1-en-3-one (V), (3) subsequently hydrolyzing said 17ß-alkoxycarbonyl-4-alkyl-4-aza-5α-androst-1-en-3-one with a strong base such as aqueous methanolic potassium hydroxide at the reflux temperature, followed by acidification and isolation of the resulting steroidal acid, 17ß-carboxy-4-alkyl-4-aza-5α-androst-1-en-3-one (VI), (4) said steroidal acid is then converted to its corresponding 2-thiopyridyl ester by refluxing with triphenyl phosphine and 2,2'-dipyridyl disulfide in an inert solvent and the product 17ß-(2- pyridylthiocarbonyl)-4-alkyl-4-aza-5α-androst-1-en-3- one (VII) is isolated by chromatography on silica, (5) said pyridylthio ester is then reacted with an R2-Li or an R2MgX (X=Cl, Br) compound, such as sec- butylmagnesium chloride in tetrahydrofuran, to form the desired product, e.g., 17ß-(sec-butylcarbonyl)- 4-alkyl-4-aza-5α-androst-1-en-3-one (VIII) which is isolated by chromatography on silica gel. When the previous reaction is carried out using an R2MgX or, an R2-Li compound in place of sec-butylmagnesium chloride, the corresponding 17B-(acyl)-4-alkyl-4-aza-5α-androst-1-en-3-one is prepared wherein acyl is R2 carbonyl.
In accordance with the process of our invention, the corresponding 17ß-acyl-4-aza-5α-androst-1-en-3-one XV is readily prepared from the 17ß(alkoxycarbonyl)-4-aza-5α-androsten-3-one (IV) by repeating the above series of reaction steps but omitting step 2 hereinabove, i.e., treatment of the 4-aza-5α-androst-1-en-3-one with sodium amide followed by methyl or ethyl iodide.
In accordance with a further alternate process of preparing the compounds of our invention, having only hydrogen as the sole substituent on the ring A-nitrogen, the 1,2-double bond in the A-ring is introduced as the last step of the process. Thus, a 17ß-alkoxycarbonyl-4-aza-5α-androstan-3-one (III) is hydrolyzed to the corresponding steroidal acid,
17ß-carboxy-4-aza-5α-androstan-3-one, (IX) which, in turn, is converted to the corresponding thiopyridyl ester, 17ß-(2-pyridylthiocarbonyl)-4-aza-5α- androstan-1-one (X) followed by treatment of the ester with an R2MgX or R2Li compound wherein R2 is as defined hereinabove to form a 17ß-(acyl)-4-aza-5α- androstan-3-one (XI) which is dehydrogenated as previously described to produce compound XIV,
17ß-(acyl)-4-aza-5α-androst-1-en-3-one.
In an additional alternative process for making the compounds of formula I when the starting material is an ester, particularly methyl ester as shown in formula III-V in the schematic, reaction with a Grignard reagent R2MgX, gives the ketone, 17ß-R2CO-, corresponding to the R2 moiety associated with the Grignard reagent.
The 16-methyl derivative wherein R''' is methyl are prepared from known 16-methyl-17-acyl-4-methyl-4-aza-5α-androstan-3-ones, e.g.
4,16ß-dimethyl-17ß-acetyl-4-aza-5α-androstan-3-one by known dehydrogenation procedures for 4-methyl-4-aza compounds to produce the corresponding 4,16ß-dimethyl-17ß-acetyl-4-aza-5α-androst-1-en-3-one.
The above reactions are schematically represented in the following structural outline
Figure imgf000037_0001
wherein X is a 2-pyridylthio substituent and R2 is defined as hereinabove.
In the above described reaction Scheme, where R2 is p-hydroxybiphenyl, this can be derived by starting with an appropriate bromobiphenylylphenol, e.g. p-bromobiphenylphenol, protecting the phenolic -OH with a conventional blocking group, e.g.
trioganosilyl, i.e. t-butyldimethylsilyl, carrying out the Grignard reaction and then deblocking
the silyl group by the use of, e.g. refluxing aqueous tetrabutylammonium fluoride.
Other halo substituted benzenes to form the appropriate Grignard reagent useful in the instant invention will be obvious to one skilled in the art from this disclosure.
By the term "protected hydroxy" as used herein, is meant the alcoholic or carboxylic -OH groups which can be protected by conventional
blocking groups in the art as described in
"Protective Groups In Organic Synthesis" by Theodora W. Greene, Wiley-Interscience, 1981, New York.
Preferred are the triorganosilyl groups, e.g. t-butyldimethylsilyl, phenyldimethylsilyl, diphenylmethylsilyl, and the like.
By the term "C1-C4 alkyl" is used herein, is meant linear or branched alkyl, including methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and t-butyl.
When this reaction scheme is carried out using an R2MgX or R2-Li compound containing an
thiophenyl substituted R2, e.g. p-methylthiophenyl magnesium chloride, the corresponding 17ß- (substituted thio-benzoyl)-4-alkyl-4-aza-5α-androst- 1-en-3-one is prepared wherein phenyl is R2.
The Grignard reagent, R2MgX, for all the species included within the scope of this invention, are available or can readily be made by one skilled in the art. For example, where R2 is C1-C4 alkyl thiophenyl, can be formed from the appropriate C1-C4 alkyl thiobromobenzene, e.g. p-methylthiobromobenzene
The formed C1-C4 alkyl thiobenzene can be used to further prepare C1-C4 alkyl sulfoxides by oxidation with e.g. m-chloroperbenzoic acid. The resulting sulfoxide can be further oxidized by the use of the m-chloroperbenzoic acid reaction to proceed for a longer period of time to form the C1-C4 alkyl sulfone.
Further, the sulfoxide can be used in the Pummerer rearrangement to form the corresponding thiol.
The -SO2N(C1-C4 alkyl)2 substituted phenyl
(R2) is formed from the appropriate bromobenzene, e.g. p-N,N-dimethylaminosulfobromobenzene which is used directly in the Grignard reaction to form the final product.
The thioalkyl groups on the phenyl ring, i.e. -(CH2)mSH, where m is 1-4, are readily formed via a four step procedure from an alkoxy alkyl phenyl bromide, Br-C6H4-(CH2)mOCH3. Direct addition of the Grignard reagent prepared from above-bromoalkyl phenyl derivative to the thiopyridyl ester results in the keto derivative, i.e. 17ß(4-methoxyalkyl- benzoyl)-4-aza-5α-androst-1-ene-3-one. This can be readily converted into thio analogue via BBr3 at -70ºC to form the hydroxyalkyl derivative, followed by displacement by halogen, e.g. bromo and then converting the halogenated compound through NaSH displacement to give the final mercapto compound. Where in the Reaction Scheme said pyridylthio ester is reacted with an aminophenyl containing R2-Li or an R2MgX (X=Cl, Br) compound, such as p-dimethyl- aminophenyl magnesium chloride, this is carried out in tetrahydrofuran to form the desired product
17ß-(p-dimethylaminophenyl-carbonyl)-4- alkyl-4-aza-5a-androst-1-en-3-one (VTII) which is isolated by chromatography on silica gel.
The Grignard reagent, R2MgX, for all of the aminophenyl species included within the scope of this invention, are available and can be made readily by one skilled in the art.
Where in the process said Grignard reagent contains a phenolic type R2 moiety, then said
pyridylthio ester is then reacted with an R2-Li or an R2MgX (X=Cl, Br) Grignard reagent, such as
p-methoxyphenyl-magnesium chloride in tetrahydrofuran to form the desired product, e.g. 17ß-(p-methoxy-phenylcarbonyl)-4-alkyl-4-aza-5α-androst-1-en-3-one (VIII) which is isolated by chromatography on silica gel. When this reaction is carried out using another R2MgX or, an R2-Li compound in place of
p-methoxyphenylmagnesium chloride, the corresponding 17ß-(substituted benzoyl)-4-alkyl-4-aza-5α-androst-1-en-3-one is prepared wherein phenyl is R2. The Grignard reagent, R2MgX, for all of the species included within the scope of this invention, are available and can be made readily by one skilled in the art.
For example, where R2 is hydroxyphenyl, this can be derived by starting with an appropriate bromophenol, e.g. p-bromophenol, protecting the phenolic -OH with a conventional blocking group, e.g. trioganosilyl, i.e. t-butyldimethylsilyl, carrying out the Grignard reaction and then deblocking the silyl group by the use of, e.g. refluxing aqueous tetrabutylammonium fluoride.
For R2 being hydroxyethylphenyl, the same blocking procedure can be analogously conducted starting with the appropriate hydroxyalkyl
bromophenol, e.g. p-hydroxymethylbromobenzene, or p-hydroxyethylbromobenzene.
Where R2 is carboxyphenyl, this can be obtained by the chromic acid oxidation of the
appropriate hydroxymethylbenzene, e.g.
p-bromo-hydroxymethylbenzene, formed as described above.
Where R2 is -O-C1-C4 alkyl, the appropriate bromo-O-C1-C4 alkyl benzene, e.g. p-methoxybromo-benzene, is utilized for the Grignard reaction.
Other halo substituted benzenes to form the appropriate Grignard reagent useful in the instant invention will be obvious to one skilled in the art from this disclosure.
By the term "protected hydroxy" as used herein, is meant the alcoholic or carboxylic -OH groups which can be protected by conventional
blocking groups in the art as described in
"Protective Groups In Organic Synthesis" by Theodora W. Greene, Wiley-Interscience, 1981, New York.
Preferred are the triorganosilyl groups, e.g. t-butyl- dimethylsilyl, phenyldimethylsilyl,
diphenylmethylsilyl, and the like.
Also within the scope of the present invention is the use of ketone reduction products of IA, in combination with an aromatase inhibitor for treatment of BPH being secondary alcohols of the formula:
Figure imgf000042_0001
wherein R is selected from hydrogen, methyl and
ethyl;
R2 is (a) a monovalent radical selected from
straight or branched chain alkyl, or cycloalkyl, of from 1-12 carbons, which can be substituted by one or more of C1-C2 alkyl or halo; (b) an aralkyl radical selected from benzyl or phenethyl;
(c) a polycyclic aromatic radical which can be substituted with one or more of: -OH, protected -OH, -OC1-C4 alkyl, C1-C4 alkyl, halo or nitro;
(d) a monocyclic aromatic radical which can be substituted with one or more of : (1) -OH, -OC1-C4 alkyl, C1-C4 alkyl,
-(CH2)mOH, -(CH2)n COOH, including protecting hydroxy, where m is 1-4, n is 1-3, providing C1-C4 alkyl is only present when one of the above
oxygen-containing radicals is present;
(2) -SH, -SC1-C4 alkyl, -SOC1-C4 alkyl,
-SO2C1-C4 alkyl, -SO2N(C1-C4-alkyl)2, C1-C4 alkyl -(CH2)mSH, -S-(CH2)n-O- COCH3, where m is 1-4 n is 1-3,
providing C1-C4 alkyl is only present when one of the above sulfur containing radicals is present; (3) N(R3)2, which can be protected, where
R3 is independently H or C1-C4 alkyl, where the monoaryl ring can also be further substituted with C1-C4 alkyl; and (4) heterocyclic radical selected from 2- or 4-pyridyl, 2-pyrrolyl, 2-furyl or thiophenyl;
R', R'' and R''' are hydrogen or methyl, wherein the dotted line represents a double bond which can be present, and pharmaceutically
acceptable salts and esters thereof.
These compounds can be made by conventional sodium borohydride reduction of the carbonyl attached to R2 without reducing the amide carbonyl in Ring A or the 1,2-double bond, if present. If the R2 phenyl contains a carbonyl function, it can be selectively blocked and then regenerated after the borohydride reduction by conventional methods.
The borohydride reduction can be carried out in, e.g. water or aqueous methanol, at a temperature of room temperature to 50ºC and the product then isolated and purified by conventional means. The compounds are also active as 5-alpha reductase inhibitors in the treatment of patterned alopecia.
The compounds of the present invention, prepared in accordance with the method described above, are, as already described, potent agents in combination with an aromatase inhibitor for the treatment of BPH. In this invention, the aromatase inhibitor, and the 5α-reductase inhibitor are administered in combination separately or as one single combined pharmaceutical composition via parenteral or oral means. Preferably the aromatase inhibitor and the 5α-reductase inhibitor are administered orally as separate compositions.
The amount of each component administered is determined by the attending clinicians taking into consideration the etiology and severity of the disease, the patient's condition and age, the potency of each component and other factors.
The aromatase inhibitor compositions are generally administered in a dosage range of about ιo to 400 mg/kg (body weight) per day with 50 to 250 mg per day in a single dose being preferred.
17β-substituted steroidal 5a-reductase inhibitors which are non-4-aza steroids are known in the art and include those developed by SmithKline Beckmann as disclosed in U.S. Pat. 4,882,319 to Holt, et al.; U.S. Pat. 4,910,226 to Holt, et al; EPO
Publn. 0 289 327 now USP 4,910,226; EPO Publn. 0 277 002 now USP 4,888,336; EPO Publn. 0 343 954; EPO Publn. 0 375 344 now USP 4,937,237; EPO Publn. 0 375 347; now USP 4,970,205; EPO Publn. 0 375 349; now USP 5,026,882. In the method the 17β-substituted non-aza steroids are of the formula:
Figure imgf000046_0001
in which:
the A ring has up to 2 double bonds;
the B, C, and D rings have optimal double bonds where indicated by the broken lines, provided that the A, B, and C rings do not have adjacent double bonds and the D ring does not have a C16-C17 double bond when R3 represents two substituents or a divalent substituent;
Z is (CH2)n and n is 0 or 2, provided that Z is (CH)n when adjacent to a double bond;
X is H, Cl, F, Br, I, CF3, or C1-6alkyl;
Y is H, CF3, F, Cl, or CH3, provided that Y is H when there is no C5-C6 double bond;
R1 is H or C1-8alkyl;
R2 is absent or present as H or CH3, provided R2 is absent when the carbon to which it is attached is unsaturated; and R3 is
(1) α-hydrogen, or α-hydroxyl, or α-acetoxy and/or
Figure imgf000047_0001
where W is a bond or C1-12 alkylidene, andR4 is
(i) hydrogen,
(ii) hydroxyl,
(iii) C1-8alkyl,
(iv) hydroxylic C1-8alkyl, (v) C1-8alkoxy,
(vi) NR5R6, where R5 and R6 are each independently selected from hydrogen, C1-8alkyl,
C3-6cycloalkyl, phenyl; or R5 and R6 taken together with the nitrogen to which they are attached represent a 5-6 membered saturated ring,
(vii) OR7, where R7 is hydrogen, alkali metal, C1-8alkyl, benzyl, or (b) -Alk-OR8, where Alk is C1-12 alkylidene, and R8 is
(i) phenyl C1-6alklycarbonyl,
(ϋ) C5-10 cycloalkylcarbonyl,
(iii) benzoyl,
(iv) C1-8 alkoxycarbonyl,
(v) aminocarbonyl, or C1-8alkyl
substituted aminocarbonyl, (vi) hydrogen, or
(vii) C1-8 alkyl,
(2) =CH-W-CO-R4 or =CH-W-OR8, where W is a bond of C1-12 alkylidene and R4 and R8 have the same meaning as above and R8 also is hydrogen or C1-20 alkylcarbonyl,
Figure imgf000048_0001
where the dashed bond replaces the 17-α-hydrogen,
(4) α-hydrogen and NHCOR9 where R9 is C1-12alkyl or NR5R6 where R5 and R6 have the same meaning as above,
(5) α-hydrogen and cyano,
(6) α-hydrogen and tetrazolyl, or
(7) keto;
or a pharmaceutically acceptable salt thereof; except compounds in which:
(i) the B ring has a C5-C6 double bond, R1 is CH3, and R3 is keto,
methoxycarbonyl, or acetyl; or
(ii) the A-nor ring has a C3-C4 double bond and R3 is acetoxy or acetyl;
(iii) R1 is CH3 and R3 is acetoxy or acetyl; or
(iv) the A-nor ring has a C3-C4 double bond and R1 is methyl; or (v) the B ring has a C3-C4 double bond and R3 is ß-hydroxy.
Representative compounds whose synthesis and properties are disclosed in the above issued US patents include the following and pharmaceutically acceptable salts thereof:
4-methyl-4-aza-5a-8(14)-pregnen-3-one-(20R)-20- carboxylic acid;
(20R)-hydroxymethyl-4-methyl-4-aza-5a-8(14)- pregnen-3-one;
4-methyl-4-aza-5a-8(14)-androsten-3-one-17ß- N,N-diisopropylcarboxamide;
17ß-(N,N-diisopropylcarboxamide)-estr-1,3,5(10)- triene-3-phosphonic acid;
17ß-(N-tert-butylcarboxamide)-estr-1,3,5(10)-triene- 3-phosphonic acid;
17ß-(N,N-diisopropylcarboxamide)-estr-1,3,5(10),16- tetraene-3-phosphonic acid;
17ß-(N-tert-butylcarboxamide)-estr-1,3,5(10),16- tetraene-3-phosphonic acid;
17ß-(N,N-diisopropylcarboxamide)-estr-1,3,5(10),6,8- pentaene-3-phosphonic acid;
17ß-(N,N-diisopropylcarboxamide)-2-methyl-estr-1,3,5 (10)triene-3-phosphonic acid;
17ß-(N,N-diisopropylcarboxamide)-4-methyl-estr-1,3,5 (10)-triene-3-phosphonic acid;
17ß-(N-N-diisopropylcarboxamide)-estr-1,3,5(10),6- tetraene-3-phosphonic acid;
17ß-(N-N-diisopropylcarboxamide)-2-chloro-estr-1,3,5 (10)-triene-3-phosphonic acid; 17ß-(N-N-diisopropylcarboxamide)-4-chloro-estr-1,3,5 (10)-triene-3-phosphonic acid;
17ß-(N-butylcarboxamide)-estr-1,3,5(10)-triene-3 carboxylic acid;
17ß-(N-butylcarboxamide)-estr-1,3,5(10)16-tetraene- 3-carboxylic acid;
17ß-(N,N-diisopropylcarboxamide)-estr-1,3,5(10)- triene-3-phosphinic acid;
17ß-(N-tert-butylcarboxamide)-estr-1,3,5(10)-triene- 3-phosphinic acid;
17ß-(N,N-diisopropylcarboxamide)-2-methyl-estr-1,3,5 (10)-triene-3-phosphinic acid;
17ß-(N,N-diisopropylcarboxamide)-4-methyl-estr-1,3,5 (10)-triene-3-phosphinic acid;
17ß-(N,N-diisopropylcarboxamide)-2-chloro-estr-1,3,5 (10)-triene-3-phosphinic acid;
17ß-(N,N-diisopropylcarboxamide)-4-chloro-estr-1,3,5 (10)-triene-3-phosphinic acid;
17ß-(N,N-diisopropylcarboxamide)-1,3,5(10),16- tetraene-3-phosphinic acid;
17ß-(N-tert-butylcarboxamide)-estr-1,3,5(10),16- tetraene-3-phosphinic acid;
17ß-(N,N-diisopropylcarboxamide)-estr-1,3,5(10),6,8- pentaene-3-phosphinic acid;
17ß-(N,N-diisopropylcarboxamide)-estr-1,3,5(10),6- tetraene-3-phosphinic acid;
17ß-(N,N-diisopropylcarboxamide)-estr-1,3,5(10)- triene-3-phosphonic acid;
17ß-(N-tert-butylcarboxamide)-estr-1,3,5(10)-triene-3- phosphonic acid;
7ß-(N,N-diisopropylcarboxamide)-estr-1,3,5(10),16- tetraene-3-phosphonic acid; 17ß-(N-tert-butylcarboxamide)-estr-1,3,5(10),16- tetraene-3-phosphonic acid;
17ß-(N,N-diisopropylcarboxamide)-estr-1,3,5(10),6,8- pentaene-3-phosphonic acid;
17ß-(N,N-diisopropylcarboxamide)-2-methyl-estr-1,3,5 (10)-triene-3-phosphonic acid;
17ß-(N,N-diisopropylcarboxamide)-4-methyl-estr-1,3,5 (10)-triene-3-phosphonic acid;
17ß-(N,N-diisopropylcarboxamide)-estr-1,3,5(10),6- tetraene-3-phosphonic acid;
17ß-(N,N-dii8opropylcarboxamide)-2-chloro-estr-1,3,5 (10)-triene-3-phosphonic acid;
17ß-(N,N-diisopropylcarboxamide)-4-chloro-estr-1,3,5 (10)-triene-3-phosphonic acid;
17ß-(N,N-diisopropylcarboxamide)-estr-1,3,5(10)- triene-3-sulfonic acid;
17ß-(N-tert-butylcarboxamide)-estr-1,3,5(10)-triene-3- sulfonic acid;
17ß-(N,N-diisopropylcarboxamide)-estr-1,3,5(10),16- tetraene-3-sulfonic acid;
17ß-(N-tert-butylcarboxamide)-estr-1,3,5(10), 16- tetraene-3-sulfonic acid;
17ß-(N,N-diisopropylcarboxamide)-estr-1,3,5(10),6,8- pentaene-3-sulfonic acid;
17ß-(N,N-diisopropylcarboxamide)-2-methyl-estr-1,3,5 (10)-triene-3-sulfonic acid;
17ß-(N,N-diisopropylcarboxamide)-4-methyl-estr-1,3,5 (10)-triene-3-sulfonic acid;
17ß-(N,N-diisopropylcarboxamide)-2-chloro-estr-1,3,5 (10)-triene-3-sulfonic acid;
17ß-(N,N-diisopropylcarboxamide)-4-chloro-estr-1,3,5 (10)-triene-3-sulfonic acid; 17ß-(N,N-diisopropylcarboxamide)-androst-3,5-diene- 3-phosphinic acid;
17ß-(N-t-butylcarboxamide)-androst-3,5-diene-3- phosphinic acid;
17ß-(N,N-diisopropylcarboxamide)-5α-androst-3- ene-3-phosphinic acid;
17ß-(N,N-diisopropylcarboxamide)-5α-androst-2-ene- 3-phosphinic acid;
17ß-(N,N-diisopropylcarboxamide-androst-2,4-diene-3- phosphinic acid;
methyl(17ß-N,N-diisopropylcarboxamide)-androst-3,5- diene-3-phosphinic acid;
20α-(hydroxymethyl)-5α-pregn-3-ene-3-phosphinic
acid;
17ß-(N,N-diisopropylcarboxamide)-4-fluoro-5α- androst-3-ene-3-phosphinic acid;
20α-(hydroxymethyl)-4-fluoro-5α-pregn-3-ene-3- phosphinic acid;
20α-(hydroxymethyl)-A-nor-5α-pregn-1-ene-2- phosphinic acid;
17ß-(N,N-diisopropylcarboxamide)-5α-androst-1,3- diene-3-phosphinic acid;
17ß-(N,N-diisopropylcarboxamide)-5α-androstane-3ß- phosphinic acid;
17ß-(N,N-diisopropylcarboxamide)-estr-3,5(10)-diene- 3-phosphinic acid;
17ß-(N,N-Diisopropylcarboxamide)-estr-3,5-diene-3- phosphinic acid;
17ß-(N,N-Diisopropylcarboxamide)-androst-3,5-1l- triene-3-phosphinic acid.
20α-(hydroxymethyl)-5α-pregn-3-ene-3-carboxylic
acid; N,N-diisopropyl-5α-androst-3-ene-17ß-carboxamide- 3 carboxylic acid;
N,N-diisopropyl-androst-3,5-diene 17ß-carboxamide-3- carboxylic acid;
17ß-(N,N-diisopropylcarboxamide)-4-fluoro-5α- androst-3-ene-3-carboxylic acid;
20α-(hydroxymethyl)-4-fluoro-5α-pregn-3-ene-3- carboxylic acid;
20α-(hydroxymethyl)-A-nor-5α-pregn-1-ene-2- carboxylic acid;
17ß-N,N-diisopropylcarboxamide-5α-androst-1,3-diene- 3-carboxylic acid;
N-t-Butyl Androst-3,5-diene-17ß-carboxamide-3- carboxylic acid;
N,N-Diisopropyl-5α-Androst-2-ene-17-ß-carboxamide-3- carboxylic acid;
N,N-Diisopropyl Androst-2,4,-diene-17ß-carboxamide-3- carboxylic acid;
N,N-Diisopropyl 5α-Androstane-17ß-carboxamide
carboxylic acid;
N,N-Diisopropyl Estr-3,5(10)-diene-17ß-carboxamide-3- carboxylic acid;
N,N,-Diisopropyl Estr-3,5-diene-17ß-carboxamide-3- carboxylic acid;
20α(hydroxymethyl)-5α-pregn-3-ene-carboxylic acid
N,N-diisopropyl-5α-androst-3-ene-17ß-carboxamide-3- carboxylic acid;
N,N-diisopropyl-androst-3,5-diene-17ß-carboxamide-3- carboxylic acid;
17ß-(N,N-diisopropylcarboxamide)-4-fluoro-5α- androst-3-ene-3-carboxylic acid; 17ß-(N,N-Diisopropylcarboxamide)-androst-3,5,11- triene-3-carboxylic acid;
17ß-(N,N-Diisopropylcarboxamide)-androst-3,5-diene- 3-thiocarboxylic acid;
17ß-(N-t-Butylcarboxamide)-androst-3,5,11-triene-3- carboxylic acid;
17ß-(N-t-Butylcarboxamide)-androst-3,5-diene-3- thiocarboxylic acid,
N-t-butyl-androst-3,5-diene-17B-carboxamide-3-carboxylic acid,
N,N-diisopropyl-androst-3,5-diene-17ß-carboxamide-3- carboxylic acid,
20-α-(hydroxymethyl)-3-α-pregn-3-ene-3-carboxylic acid,
20-α-(hydroxymethyl)-4-fluoro-5-α-pregn-3-ene-3-carboxylic acid,
3-carbomethoxy-N,N-diisopropyl-androst-3, 5-diene- 17β-carboxamide,
17β-N,N-diisopropylcarboxamide-5-α-androst-1,3-diene- 3-carboxylic acid,
N,N-Diisopropyl 5-α-androst-2-ene-17β-carboxamide-3- carboxylic acid,
N,N-diisopropyl androst-2-4-diene-17β-carboxamide-3- carboxylic acid,
N,N-diisopropyl 5-α-androstane-17β-carboxamide-3β- carboxylic acid,
N,N-diisopropyl estr-3,5(10)-diene-17β-carboxamide-3- carboxylic acid,
N,N-diisopropyl estr-3,5-diene-17β-carboxamide-3-car- boxylic acid,
N-t-butyl-androst-3,5-diene-17β-carboxamide-3-carboxylic acid, N,N-diisopropyl-androst-3,5-diene-17β-carboxamide-3- carboxylic acid,
20-α-(hydroxymethyl)4-fluoro-5-α-pregn-3-ene-3-car- boxylic acid,
N,N-diisopropyl-5-α-androst-3-ene-17β-carboxamide-3- carboxylic acid,
17β-(N,N-diisopropylcarboxamide)-4-fluoro-5-α-androst- 3-ene-3-carboxylic acid,
17β-(N,N-diisopropylcarboxamide)-4-flouro-androst-3,5- diene-3-carboxylic acid,
3-carbomethoxy-N,N-diisopropyl-androst-3,5-diene-17β- carboxamide,
17β-N,N-diisopropylcarboxamide-5-α-androst-1,3-diene¬
-3-carboxylic acid,
N,N-Diisopropyl-5-α-androst-2-ene-17β-carboxamide-3- carboxylic acid.
N,N-diisopropyl androst-2,4-diene-17β-carboxamide-3- carboxylic acid,
N,N-diisopropyl 5-α-androstane-17β-carboxamide-3β- carboxylic acid,
N,N-diisopropyl estr-3,5(10)-diene-17ß-carboxamide-3- carboxylic acid,
N,N-diisopropyl estr-3,5-diene-17ß-carboxamide-3- carboxylic acid,
17ß-(N-t-butylcarboxamide)-androst-3,5-1l-triene-3- carboxylic acid,
17ß-(N-t-butylcarboxamide)-androst-3,5-diene-3-thio- carboxylic acid,
N-t-Butyl-5-α-androst-3-ene-17ß-carboxamide-3-carboxylic acid,
17ß-(N-t-Butylcarboxamide)-6-fluoro-5-α-androst-3- ene-3-carboxylic acid, 17ß-(N-t-Butylcarboxamide)-6-fluoro-androst-3,5-diene-3-carboxylic acid,
3-Carbomethoxy-N-t-butyl-androst-3,5-diene-17ß-carboxamide,
17ß-N-t-Butylcarboxamide-5-α-androst-1,3-diene-3-carboxylic acid
N-t-Butyl-5-α-androst-2-ene-17ß-carboxamide-3-carboxylic acid
N-t-Butyl-androst-2,4-diene-17ß-carboxamide-3-carbox- ylic acid,
N-t-Butyl-5-α-androstane-17ß-carboxamide-3-carboxylic acid, and
20-α-(hydroxymethyl)-A-nor-5-α-pregn-1-ene-2- carboxylic acid,
17ß-(N-t-butylcarboxamide)-androst-3,5,11-triene-3- carboxylic acid,
17ß-(N-t-butylcarboxamide)-androst-3,5-diene-3-thio- carboxylic acid,
N-t-Butyl-5-α-androst-3-ene-17ß-carboxamide-3- carboxylic acid,
17ß-(N-t-Butylcarboxamide)-6-fluoro-5-α-androst-3- ene-3-carboxylic acid
17ß-(N-t-Butylcarboxamide)-6-fluoro-androst-3,5- diene-3-carboxylic acid,
3-Carbomethoxy-N-t-butyl-androst-3,5-diene-17B- carboxamide,
17ß-N-t-Butylcarboxamide-5-α-androst-1,3-diene-3- carboxylic acid,
N-t-Butyl-5-α-androst-2-ene-17ß-carboxamide-3- carboxylic acid,
N-t-Butyl-androst-2,4-diene-17ß-carboxamide-3- carboxylic acid, N-t-Butyl-5-α-androstane-17ß-carboxamide-3-carboxylic acid,
N-t-Butyl-estr-3,5(10)-diene-17ß-carboxamide-3-carboxylic acid,
N-t-Butyl-estr-3,5-diene-17ß-carboxamide-3-carboxylic acid,
N-t-Butyl-estr-3,5(10)-diene-17ß-carboxamide
acid-3-carboxylic acid,
N-t-Butyl-estr-3,5-diene-17ß-carboxamide-3-carboxylic acid,
20-α-(t-butyldimethylsiloxymethyl)-3-(trifluoromethylsulfonate)-5-α-pregn-3-ene,
17ß-(t-butyldimethylsilyloxymethyl)-3-(trifluoromethylsulfonate)-5-α-androst-3-ene, 17ß-(N,N-diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-androst-3,5-diene,
17ß-(N,N-diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-4-fluoro-5-α-androst-1,3-diene, 20-α-(t-butyldimethylsiloxymethyl)-4-fluoro-3(trifluoromethylsulfonate)-5-α-pregn-1,3-diene, 17ß-(N,N-diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-5-α-androst-1,3 diene,
17ß-(N-t-butylcarboxamide)-3-(trifluoromethylsulfonate)-androst-3,5-diene,
17ß-(N,N-diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-5-α-androst-2-ene,
17ß-(N,N-diisopropylcarboxamide)-3-(trifluoromethylsulfonate)-androst-2,4-diene,
N-t-butyl-androst-3,5-diene-3-bromo-17ß-carboxamide, and
N,N-diisopropyl-androst-3,5-diene-3-bromo- 17B-carboxamide. Also provided are 17β-acyl 3-carboxy-androst-3,5- diene of the formula:
Figure imgf000058_0001
wherein R1 is (a) C1-C6 linear or branched alkyl;
C3-C12 cycloalkyl, which can be substituted with C1-C4 alkoxy or C1-C4 linear/branched alkyl; C6-C12 aryl, or C7-C13 aralkyl which can be substituted with one or more of: -OH, -OC1-C4 alkyl, C1-C4 alkyl, -(CH2)mOH, -(CH2)n COOH, including protected -OH, where m is 1-4, n is 1-3;
(b) C1-C6 linear or branched alkyl;
C3-C12 cycloalkyl, which can be substituted with C1-C4 alkoxy or C1-C4 linear/branched alkyl; C5-C12 aryl, or C7-C13 aralkyl which can be substituted with one or more of: -OH, -OC1-C4 alkyl, C1-C4 alkyl, -(CH2)mOH, -(CH2)n COOH, including protected -OH, where m is 1-4, n is 1-3, and R2 is selected from COOH, SO3H, PO(OH)2, PH(O)OH.
Specifically provided is wherein R1 is t-butyl, cyclokalkyl, phenyl, p-hydroxyphenyl, 1-adamantyl, 2-adamantyl, NH-t-butyl, NH-isobutyl, NH-cyclohexyl, NH-phenyl, NH-p-hydroxy-phenyl, NH-1-adaxmantyl, NH-2-adamantyl, and R2 is COOH,
Representative compounds include:
17ß(4-hydroxyphenylcarbonyl)-androsta-3,5-diene-3- carboxylic acid;
17ß-benzoyl-androsta-3,5-diene-3-carboxylic acid; 17ß-cyclohexylcarbonyl-androsta-3,5-diene-3-carboxylic acid;
17ß-isobutylcarbonyl-androsta-3,5-diene-3-carboxylic acid;
17ß-(4-hydroxymethylphenylcarbamyl)-androsta-3,5- diene-3-carboxylic acid;
17ß-(2-hydroxyethylphenylcarbonyl)-androsta-3,5- diene-3-carboxylic acid;
17ß-(4-methoxyphenylcarbonyl)-androsta-3,5-diene- 3-carboxylic acid;
17ß-(4-carboxymethylphenylcarbonyl)-androsta-3,5- diene-3-carboxylic acid;
N-t-butyl-androst-3,5-diene-17ß-carboxamide-3- carboxylic acid;
N-phenyl androst-3,5-diene-17ß-carboxamide-3- carboxylic acid;
N-1-adamantyl androst-3,5-diene-17ß-carboxamide
3-carboxylic acid; N-2-adamantyl androst-3,5-diene-17ß-carboxamide 3-carboxylic acid;
Also included and known in the art are non-steroidal 5a-reductase inhibitors as developed by ONO Pharmaceutical Co., LTD., Osaka, Japan and as described in US patents 4,780,469; 4,847,275;
4,939,141 and EPO Publication Nos. 0 173 516 and EPO 0 291 245, and USP 4,980,372; and EPO Publn. 291,247 and USP 5,037,852 disclosing certain novel fused benz(thio)amides and benzylaminophenylbutanoic derivatives, respectively.
The benzoylaminophenoxy butanoic acid derivatives are of the formula:
Figure imgf000060_0001
wherein R' is hydrogen or alkyl of from 1 to 4 carbon atom(s); A is oxygen atom, sulfur atom or sulfinyl (SO) group; both R1's are methyl or chlorine, or the two R1's and the carbon atoms of the benzene ring to which the two R1's are linked together are
cyclopentane, cyclohexane or a benzene ring; and R2 represents a group of formula;
Figure imgf000061_0001
wherein B is oxygen, sulfur or a group of formula: NR11 wherein R11 is hydrogen or alkyl of from 1 to 4 carbon atom(s),
R3, R4, R5, R6, R7, and R8 are, independently, hydrogen, alkyl of from 1 to 4 carbon atom(s), halogen, trifluoromethyl or cyclobutylmethyl,
m is 0 or 1,
n is an integer of from 1 to 5, and
R9 is a hydrogen, alkyl of from 1 to 5 carbon atom(s) or a group of formula:
Figure imgf000062_0001
or
Figure imgf000062_0002
wherein R12, R13, R14, and R15 are, independently, hydrogen, alkyl of from 1 to 4 carbon atom(s), halogen, trif luoromethyl or cyclobutylmethyl, and 1 is an integer of from 1 to 4, and
R10 is a group of formula:
Figure imgf000062_0003
or
Figure imgf000062_0004
wherein R12, R13, R14, and R*5 are,
independently, hydrogen, alkyl of from 1 to 4 carbon atom(s), halogen, trifluoromethyl or cyclobutylmethyl, and 1' is an integer of from 1 to 4; or non-toxic salts thereof.
Representative examples of each of these two classes of compounds whose synthesis and properties are disclosed in the above cited US issued patents include the following:
4-[2-(4-benzyloxy-2,3-dimethylbenzoylamino)phenoxy] butanoic acid;
4-[2-[4-(2-methylbenzyloxy)-2,3-dimethylbenzoylamino] butanoic acid;
4-[2-[4-(3-methylbenzyloxy)-2,3-dimethylbenzoylamino] phenoxy]butanoic acid;
4-[2-[(4-methylbenzyloxy)-2,3-dimethylbenzoylamino] phenoxy]butanoic acid;
4-[2-[4-(2.6-dimethylbenzyloxy)-2,3-dimethylbenzoylamino]phenoxy]butanoic acid;
4-[2-[4-(4-ethylbenzyloxy)-2,3-dimethylbenzoylamino] phenoxy]butanoic acid;
4-[2-[4-(4-propylbenzyloxy)-2,3-dimethylbenzoylamino] phenoxy]butanoic acid;
4-[2-[4-(4-isopropylbenzyloxy)-2,3-dimethylbenzoylamino]phenoxy]butanoic acid;
4-[2-[4-(4-isobutylbenzyloxy)-2,3-dimethylbenzoylamino]phenoxy]butanoic acid;
4-[2-[4-(4-chlorobenzyloxy)-2,3-dimethylbenzoylamino] phenoxy]butanoic acid;
4-[2-[4-(4-cyclobutylmethylbenzyloxy)-2,3-dimethylbenzoylamino]phenoxy]butanoic acid; 4-[2-[4-(2-phenylethoxy)-2,3-dimethylbenzoylamino] phenoxy]butanoic acid;
4-[2-[4-(3-phenylpropoxy)-2,3-dimethylbenzoylamino] phenoxy]butanoic acid;
4-[2-[4-(4-phenylbutoxy)-2,3-dimethylbenzoylamino] phenoxybutanoic acid;
4-[2-[4-(5-phenylpentyloxy)-2,3-dimethylbenzoylamino] phenoxy]butanoic acid;
4-[2-[4-(1-(4-isobutylphenyl)ethoxy)-2,3-dimethylbenzoylamino]phenoxy]butanoic acid;
4-[2-[4-(4-propylbenzyloxy)-2,3-dimethylbenzoylamino) phenylthio]butanoic acid;
4-[2-[1-(4-isobutylphenyl)ethoxy)-2,3-dimethylbenzoyl amino]phenylthio]butanoic acid;
4-[2-[4-(4-propylbenzyloxy)-2,3-dimethylbenzoylamino] phenylsulfinyDbutanoic acid;
4-[2-[4-[N-(4-trifluoromethylphenylmethyl)amino)2.3-dimethylbenzoylamino]phenoxy]butanoic acid;
4-[2-[4-(4-isobutylbenzyloxy)-5,6,7,8-tetrahydro naphthalene-1-carbonylamino)phenoxybutanoic acid; 4-[2-[4-(4-isobutylbenzyloxy)naphthalene-1-carbonylamino)phenoxy)butanoic acid;
4-[2-[8-(4-isobutylbenzyloxy)-5,6,7,8-tetrahydronaphthalene-1-carbonylamino)phenylthio]butanoic acid;
4-[2-[4-[bis(4-propylphenyl)methoxy]2,3-dimethylbenzoylamino)phenoxy]butanoic acid;
4-[2-(4-diphenylmethoxy)-2,3-dimethylbenzoylamino) phenoxy]butanoic acid;
4-[2-[4-[bis(4-propylphenyl)methylamino]-2,3- dimethylbenzoylamino]phenoxy]butanoic acid; 4-[2-[4-[bis-(4-propylphenyl)methylthio]-2,3- dimethylbenzoylamino]phenoxy]butanoic acid;
4-[2-[4-[N,N-bis(4-propylphenylmethyl)amino]-2,3- dimethylbenzoylamino]phenoxy]butanoic acid;
4-[2-[4-[N,N-bis(4-trifluoromethylphenylmethyl)amino]- 2,3-dimethylbenzoylamino]phenoxy]butanoic acid;
4-[2-[4-N-methyl-N-(5,6,7,8-tetrahydronaphth-1-yl] aminomethyl]-2,3-dimethylbenzoylamino]phenoxy]- butanoic acid;
8-(p-pentylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-pentylbenzoyl)amino-2-(5-tetrazolyl)-6 chloro- 1,4-benzodioxane;
8-(m-octylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(o-pentylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-butylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-hexylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-heptylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-octylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-nonylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-decylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-undecylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane; 8-(p-dodecylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-pentyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(m-pentyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(o-pentyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-butyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-nonyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-propoxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-hexyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-heptyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-octyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(o-decyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-isopentyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-isohexyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-[p-(1-methylbutoxy)benzoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane;
8-(N-methyl-N-(p-octynyloxy)benzoyl])amino-2-(5- tetrazolyl)-1,4-benzodioxane;
8-(p-oxtyloxybenzoyl)amino-1,4-benzodioxane-2- carboxylic acid and methyl ester thereof; 8-(p-i soheptyloxybenzoyl )amino-2- (5-tetrazolyl )-1 , 4- benzodioxane;
8-(p-isooctyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-[p-(3,7-dimethyloctyloxy)benzoyl]amino-2-(5- tetrazolyl)-1,4-benzodioxane;
8-(p-octyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-heptyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane-7-carboxylic acid and methyl ester thereof, and the like.
Also included as a 5α-reductase inhibitor in this invention is a cinnamoylamide of the
following formula:
Figure imgf000067_0001
wherein R2 and R3 each independently represents a hydrogen or methyl group with the proviso that
(i) when R2 represents a methyl group, R3
represents hydrogen and (R1)n represents a member selected from the group consisting of 3-group, 4-pentyl group, 4-neopentyl group, 4-(2-ethylbutyl) group and
4-(2-methylpentyl) group, or (ii) when R2 represents hydrogen, R3 represents a methyl group and (R1)n represents a 3-pentyl group, or non-toxic salts thereof.
Representative compounds include:
4-[2-(4-butylthio-β-methylcinnamoylamino)phenoxy]
butanoic acid
4-[2-(4-cyclobutylmethy)β-methylcinnamoylamino)
phenoxy]butanoic acid
4-[2-(4-cyclohexylmethyl)β-methylcinnamoylamino)
phenoxy]butanoic acid
4-[2-(4-{4-phenylbutyl)-β-methylcinnamoylamino)
phenoxy]butanoic acid
4-[2-(4-phenoxy-β-methylcinnamoylamino)phenoxy]
butanoic acid
4-[2-(3-pentyl-α-methylcinnamoylamino)phenoxy]
butanoic acid
4-[2-(4-phenethyl-α-methylcinnamoylamino)phenoxy]
butanoic acid
4-[2-(3-pentyl-β-methylcinnamoylamino)phenoxy]
butanoic acid
4-[2-(4-neopentyl]-β-methylcinnamoylamino)phenoxy] butanoic acid
4-[2-{4-(2-ethylbutyl)-β-methylcinnamoylamino)phenoxy] butanoic acid,
4-[2-{4-(2-m-thylpentyl)-β-methylcinnamoylamino)
phenoxy]butanoic acid, and
4-[2-(2-fluoro-4-pentyloxy-β-methylcinnamoylamino)
phenoxy]butanoic acid. Also included in this invention are fused benz(thio) amides of the formula:
Figure imgf000069_0001
wherein A represents a single bond or a group of methylene, ethylene, trimethylene, tetramethylene, vinylene, propenylene, butenylene, butadienylene or ethynylene group optionally being substituted by one, two or three of straight or branched alkyl group(s) of from 1 to 10 carbon atom(s) and/or phenyl group(s);
B represents a heterocyclic ring of from 4 to 8 members containing one, two or three hetero atom(s) selected from the group consisting of oxygen, nitrogen and sulphur atom(s), wherein the said ring may
optionally be substituted by group(s) selected from oxo, thioxo and/or hydroxy group(s) including a ring of formula:
or
Figure imgf000069_0002
Figure imgf000069_0003
Figure imgf000069_0004
T represents an oxygen atom or a sulphur atom;R1 represents a group of general formula:
Figure imgf000070_0001
Figure imgf000070_0002
or
Figure imgf000070_0003
(iv) a straight or branched alkyl, alkenyl or
alkynyl group of from 1 to 20 carbon atom(s), wherein R5 and R6 independently represent a hydrogen atom or a halogen atom or a straight or branched alkyl, alkenyl or alkynyl group of from 1 to 20 carbon atom(s) being unreplaced or replaced by one, two, three, four or five optional carbon atom(s), by oxygen atom(s), sulphur atom(s), halogen atom(s), nitrogen atom(s), benzene ring(s), thiophene ring(s), naphthalene ring(s), carbocyclic ring(s) of from 4 to 7 carbon atom(s), carbonyl group(s), carbonyloxy group(s), hydroxy group(s), carboxy group(s), azido group(s) and/or nitro group(s); R2 represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s);
R3 represents a hydrogen atom, a halogen atom, a hydroxy group, a nitro group, a group of general formula: ╌COOR7, wherein R7 represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s), or a straight or branched alkyl, alkoxy or alkylthio group of from 1 to 6 carbon atom(s);
R4 represents a group of general formula:
Figure imgf000071_0001
or
Figure imgf000071_0002
wherein U represents an oxygen atom or a sulphur atom, R8 represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s), n and m represent an integer of from 1 to 10, respectively, p and q represent zero or an integer of from 1 to 10, respectively, or non-toxic salts thereof. Representative compounds include:
7-(p-hexyloxybenzoyl)amino-2-(5-tetrazolyl)benzofuran, 7-(p-octyloxybenzoyl)amino-2-(5-tetrazolyl)benzofuran, 7-(p-heptyloxybenzoyl)amino-2-(5-tetrazolyl)benzofuran,
7-(p-nonyloxybenzoyl)amino-2-)5-tetrazoyly)benzofuran, 7-[p-(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)- benzofuran,
7-[p-(2E,7,-octadienyl)benzoyl]amino-2-(5-tetrazolyl)- benzofuran,
7-[p-(6-chlorohexyloxy)benzoyl]amino-2-(5-tetrazolyl)- benzofuran and
7-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)benzofuran, 7-(p-hexyloxybenzoyl)amino-2-(5-tetrazolyl)-2,3-dihydro-1-benzofuran,
7-(p-heptyloxybenzoyl)amino-2-(5-tetrazolyl)-2,3-dihydro-1-benzofuran,
7-(p-octyloxybenzoyl)amino-2-(5-tetrazolyl)-2,3-dihy¬ro-1-benzofuran,
7-(p-nonyloxybenzoyl)amino-2-(5-tetrazolyl)-2,3-dihy- dro-1-benzofuran,
7-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)-2,3-dihydro-1-benzofuran,
8[p-2E,7-octadienyloxy)benzoyl]amino-2-(5-tetrazolyl) quinoline,
8-[p-(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)- quinoline,
8-[p-(6-chlorohexyloxy)benzoyl]amino-2-(5-tetrazolyl)- quinoline,
8-Cp-(2E,7-octadienyloxy)benzoyl]amino-4-hydroxy- quinoline-2-carboxylic acid, 8-[p-(4-phenylbutoxy)benzoyl]amino-4-hydroxyquinoline2-carboxylic acid,
8-[p-[4-(2-thienyl)butoxy)benzoyl]amino-4-hydroxyquinoline-2-carboxylic acid,
8-[p-(2E,7-octadienyloxy)benzoyl]amino-4-hydroxy2-(tetrazolyl)quinoline,
8-[p-[4-(2-phenylbutoxy)benzoyl]amino-4-hydroxy¬
2-(5-tetrazolyl)quinoline and,
8-(p-pentylcinnamoyl)amino-4-hydroxy-2-(5-tetrazolyl) quinoline and,
4-(p-heptyloxybenzoyl)amino-2-(5-tetrazolyl)-1,3-benzodioxole,
4-(p-hexyloxybenzoyl)amino-2-(5-tetrazolyl)-1,3-benzodioxole,
4-[p-[4-(phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl) 1,3-benzodioxole,
4-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)-1,3-benzodioxole,
9-[p-(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)- 3,4-dihydro-2H-1,5-benzodioxepin,
9-[p-(2E,7-octadienyloxy)benzoyl]amino-2-(5-tetrazolyl)-3,4-dihydro-2H-1,5-benzodioxepin,
9-[p-(7-octenyloxy)benzoyl]amino-2-(5-tetrazolyl)
-3, 4-dihydro-2H-1, 5-benzodioxepin,
8-(p-heptyloxybenzoyl)amino-2-(5-tetrazolyl)-2,3- dihydro-1,4-benzoxazine,
8-[p-(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)- 2,3-dihydro-1,4-benzoxazine and
8-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)-2,3- dihydro-1,4-benzoxazine,
8-[p-(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)- 4-oxo-4H-1-benzothiopyran, 8-[p-(4-phenylbutoxy)benzoly]amino-2-(5-tetrazolyl )- 3,4-dihydro-2H-1-benzopyran,
8-[p-(7-octenyloxy)benzoyl]amino-2-(5-tetrazolyl)- 3,4-dihydro-2H-1-benzopyran,
8-(p-pentylbenzoyl)amino-2-(5-tetrazolyl)-4-oxo-4H- 1-benzopyran,
8-(p-pentylbenzoyl)amino-4-oxo-4H-1-benzopyran-2- carboxylic acid and ethyl ester thereof,
8-(p-hexylbenzoyl)amino-2-(5-tetrazolyl)-4-oxo- 4H-1-benzopyran,
8-(p-heptylbenzoyl)amino-2-(5-tetrazolyl)-4-oxo- 4H-1-benzopyran,
8-(p-octylbenzoyl)amino-2-(5-tetrazolyl)-4-oxo- 4H-1-benzopyran and
8-(p-nonylbenzoyl)amino-2-(5-tetrazolyl-4-oxo- 4H-1-benzopyran
8-(p-butoxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo- 4H-1-benzopyran,
8-(p-pentyloxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo- 4H-1-benzopyran,
8-(p-hexyloxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo- 4H-1-benzopyran,
8-(p-heptyloxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo- 4H-1-benzopyran,
8-(p-nonyloxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo- 4H-1-benzopyran,
8-(p-octyloxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo- 4H-1-benzopyran,
8-(p-heptyloxybenzoyl)amino-2-(5-tetrazolyl)-6-fluoro- 4-oxo-4H-1-benzopyran,
8-(p-octyloxybenzoyl)amino-2-(5-tetrazolyl)-6-methyl- 4-oxo-4H-1-benzopyran and 8-(p-heptyloxybenzoyl )amino-2-(5-tetrazolyl)-6-methyl- 4-oxo-4H-1-benzopyran and
8[p-(2E,7-octadienyloxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran,
8-(p-geranyloxybenzoyl)amino-2-(5-tetrazolyl)-4-oxo- 4H-1-benzopyran,
8[p-(2E-nonenyloxy)benzoyl]amino-2-(5-tetrazolyl)- 4-oxo-4H-1-benzopyran,
8[p-(2E-octenyloxy)benzoyl]amino-2-(5-tetrazolyl)- 4-oxo-4H-1-benzopyran,
8[p-(7-octenyloxy)benzoyl]amino-2-(5-tetrazolyl)- 4-oxo-4H-1-benzopyran,
8[p-(2E-heptenyloxy)benzoyl]amino-2-(5-tetrazolyl)- 4-oxo-4H-1-benzopyran,
8[p-(2E-hexenyloxy)benzoyl]amino-2-(5-tetrazolyl)- 4-oxo-4H-1-benzopyran,
8[p-(2E,7-octadienyloxy)benzoyl]amino-2-(5-tetraz- olyl)-6-fluoro-4-oxo-4H-1-benzopyran,
8[p-(2E-octenyloxy)benzoyl]amino-2-(5-tetrazolyl)- 6-methyl-4-oxo-4H-1-benzopyran,
8[p-(2E,7-octadienyloxy)benzoyl]amino-2-(5-tetrazolyl)-6-chloro-4-oxo-4H-1-benzopyran,
8[p-(2-octynyloxy)benzoyl]amino-2-(5-tetrazolyl)- 4-oxo-4H-1-benzopyran, thereof
8[p-(4-chlorobutoxy)benzoyl]amino-2-(5-tetrazolyl)- 4-oxo-4H-1-benzopyran,
8[p-(5-chloropentyloxy)benzoyl]amino-2-(5-tetrazolyl)- 4-oxo-4H-1-benzopyran,
8[p-(6-chlorohexyloxy)benzoyl]amino-2-(5-tetrazolyl)- 4-oxo-4H-1-benzopyran,
8[p-(6-chlorohexyloxy)benzoyl]amino-2-(5-tetrazolyl)- 4-oxo-4H-1-benzopyran, 8[p-(7-chloroheptyloxy)benzoyl]amino-2-(5-tetrazolyl)- 4-oxo-4H-1-benzopyran,
8[p-(8-chlorooctyloxy)benzoyl]amino-2-(5-tetrazolyl)- 6-methyl-4-oxo-4H-1-benzopyran,
8[p-(7-chloroheptyloxy)benzoyl]amino-2-(5-tetrazolyl)- 6-methyl-4-oxo-4H-1-benzopyran and
8[p-(8-chlorooctyloxy)benzoyl]amino-2-(5-tetrazolyl)- 4-oxo-4H-1-benzopyran,
8[p-(3-phenylpropoxy)benzoyl]amino-2-(5-tetrazolyl)- 4-oxo-4H-1-benzopyran,
8[p-(3-phenyl-2E-propenyloxy)benzoyl]amino-2-(5- tetrazolyl)-4-oxo-4H-1-benzopyran,
8[p-(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)- 4-oxo-4H-1-benzopyran,
8[p-(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)- 6-methyl-4-oxo-4H-1-benzopyran,
8[p-[2-(2-naphthy)ethoxy])benzoyl]amino-2-(5- tetrazolyl)-4-oxo-4H-1-benzopyran,
8[p-[2-(2-naphthyl)ethoxy])benzoyl]amino-2-(5- tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran,
8[p-[3-(3,4-dichlorophenyl)propoxy]benzoyl]amino-2-(5- tetrazolyl)-4-oxo-4H-1-benzopyran,
8[p-[3-(3,4-dichlorophenyl)propoxy]benzoyl]amino-2-(5- tetrazolyl)-4-oxo-4H-1-benzopyran,
8[p-[3-(p-chlorophenyl)butoxy]benzoyl]amino-2-(5- tetrazolyl)-4-oxo-4H-1-benzopyran,
8[p-[3-(p-chlorophenyl)butoxy]benzoyl]amino-6- methyl-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8[p-[3-(p-chlorophenyl)propoxy]benzoyl]amino-6- methyl-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8[p-[4-(2-thienyl)butoxy]benzoyl]amino-2-(5- tetrazolyl)-4-oxo-4H-1-benzopyran, 8 [p-[4-(2-thienyl)butoxy]benzoyl]amino-2-(5- tetrazolyl)-6-methyl-4-oxo-4H-1-benzopyran, 8-(p-pentylcinnamoyl)amino-4-oxo-4H-1-benzopyran- 2-carboxylic acid and methyl ester thereof, 8-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)-4-oxo- 4H-1-benzopyran,
8-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)-6- methyl-4-oxo-4H-1-benzopyran,
8-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)-6- fluoro-4-oxo-4H-1-benzopyran,
8-(p-pentylcinnamoyl)amino-6-methyl-4-oxo-4H-1- benzopyran-2-carboxylic acid and ethyl ester thereof,
8-(p-butylcinnamoyl)amino-2-(5-tetrazolyl)-4-oxo- 4H-1-benzopyran,
8-(p-hexylcinnamoyl)amino-2-(5-tetrazolyl)-4-oxo- 4H-1-benzopyran,
8-(p-heptylcinnamoyl)amino-2-(5-tetrazolyl)-4-oxo- 4H-1-benzopyran,
8-cinnamoylamino-2-(5-tetrazolyl)-4-oxo- 4H-1-benzopyran,
8-(p-hexyloxycinnamoyl)amino-2-(5-tetrazolyl)-4-oxo- 4H-1-benzopyran,
8-(p-heptyloxycinnamoyl)amino-2-(5-tetrazolyl)-4-oxo- 4H-1-benzopyran,
8-(p-isohexyloxycinnamoyl)amino-2-(5-tetrazolyl)-4 -oxo-4H-1-benzopyran,
8[p-(2-octynyloxy)cinnamoyl]amino-4-oxo-4H-1- benzopyran-2-carboxylic acid,
8[p-(5-chloropentyloxy)cinnamoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran,
8[p-(6-chlorohexyloxy)cinnamoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran, 8-(p-pentylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-pentylbenzoyl)amino-2-(5-tetrazolyl)-6 chloro- 1,4-benzodioxane;
8-(m-octylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(o-pentylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-butylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-hexylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-heptylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-octylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-nonylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-decylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-undecylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-dodecylbenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-pentyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(m-pentyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(o-pentyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-butyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane; 8-(p-nonyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-propoxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-hexyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-heptyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-octyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(o-decyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-isopentyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-isohexyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-[p-(1-methylbutoxy)benzoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane;
8-(N-methyl-N-(p-octynyloxy)benzoyl])amino-2-(5- tetrazolyl)-1,4-benzodioxane;
8-(p-octyloxybenzoyl)amino-1,4-benzodioxane-2- carboxylic acid and methyl ester thereof;
8-(p-isoheptyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-(p-isooctyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane;
8-[p-(3,7-dimethyloctyloxy)benzoyl]amino-2-(5- tetrazolyl)-1,4-benzodioxane;
8-(p-octyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane-7-carboxylic acid,
8-[p-(2E-octyloxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane, 8-[p-(3-butenyloxy)benzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-[p-(3Z-hexenyloxy)benzoyl)amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(2Z-octenyloxy)benzoyl)amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(2E-nonenyloxy)benzoyl)amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[N-methyl-N-[p-(2E-cctenyloxy)benzoyl)amino-2-(5- tetrazolyl)-1,4-benzodioxane,
8-[p-(2E-hexenyloxy)benzoyl)amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(3E-heptenyloxy)benzoyl)amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(2E-octenyloxy)benzoyl)amino-1,4-benzodioxane- 2-carboxylic acid and methyl ester thereof,
8-.[p-(2E-heptenyloxy)benzoyl)amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(4-pentenyloxy)benzoyl)amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(2E-decenyloxy)benzoyl)amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-(p-geranyloxy)benzoyl)amino-2-(5-tetrazolyl)- 1,4-benzodioxane- 8-[p-(2E,7-octadienyloxy)benzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-(2E-pentenyloxy)benzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-(2E-butenyloxy)benzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane
8-[p-(3E-octenyloxy)benzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-[p-(7-octenyloxy)benzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-(2E, 4E-octadienyloxy)benzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane and
8-[p-(2E-octadienyloxy)benzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-(2-octynyloxy)benzoyl)amino-2-(5-tetrazolyl)- 1,4-benzodioxane
8-[p-(2-octynyloxy)benzoyl]amino-1,4-benzodioxane-2- carboxylic acid and methyl ester thereof and
8-[p-(2-isooctynyloxy)benzoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane
8-(p-pentylthiobenzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-(m-pentylthiobenzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane
8-(o-pentylthiobenzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane and
8-(p-heptylthiobenzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane
8-[p-(6-chlorohexyloxy)benzoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(5-chloropentyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-(4-chlorobutoxy)benzoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(7-chloroheptyloxy)benzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-(8-chlorooctyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-(9-chlorononyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane and 8-[p-(t-bromopentyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4,-benzodioxane-2-carboxylic acid and methyl ester thereof
8-[p-hexyloxymethyl)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane
8-[p-(cyclohexylmethoxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-(4-cyclohexylbutoxy)benozyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane, and
8-[p-(2-cyclohexylethoxy)benzoyl')amino-2-(5-tetrazolyl)-1,4-benzodioxane, and
8-[p-(p-butylphenyl)methoxybenoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-(5-phenylpentyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-(3-phenylpropoxy)benzoyl')amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-(p-propylphenyl)methoxybenzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-(3-phenyl-2-propenyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)¬
1,4-benzodioxane,
8-[p-(o-pentylphenyl)methoxybenzoylamino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-(m-butylphenylmethoxybenzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-(p-phenylmethoxybenzoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-[p-(2-phenylethoxy)benzoyl')amino-2-(5-tetrazolyl) 1,4-benzodioxane, 8-[p-4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)- 1,4-rbenzodioxane,
8-[p[-2-(2-naphthyl)ethoxy]benzoyl')amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-[3-(p-chlorophenyl)propoxy]benzoyl]amino-2-(5- tetrazolyl)-1,4-benzodioxane and
8-[p-[4-(p-chlorophenyl)butoxy]benzoyl]amino-2-(5- tetrazolyl)-1,4-benzodioxane,
8-[p-(5-methoxycarbonylpentyloxy)benzoyl]amino-2- (5-tetrazolyl)-1,4-benzodioxane,
8-[p-(6-acetyloxyhexyloxy)benzoyl]amino-2-(5-tetrazxolyl)-1,4-benzodioxane,
8-[p-(6-hydroxyhexyloxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benozdioxane,
8-[p-(2E-octenoyloxy)benzoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane and
8_(p-octanoylbenzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane
8-[p-(3-p4enylthiopropoxy)benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-(3-phenoxypropoxy)benzoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(2-phenylthioethoxy)benzoyl')amino-2-(5-tetrazolyl)-1,4-benzodioxane and
8-[p-(2-phenoxyethoxy)benzoyl')amino-2-(5-tetrazolyl)- 1,4-benzodioxane
8-[p-[2-(3-thienyl)ethoxy]benzoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane and
8-[p-[4-(2-thienyl)butoxy]benzoyl')amino-2-(5-tetrazolyl)-1,4-benodioxane
8-[p-(5-azidopenyloxy)benozyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane, 8-[p-(5-dimethylaminopentyloxy)benzoyl]amino-2-(5- tetrazolyl)-1,4-benzodioxane,
8-[p-(4-nitrobutoxy)benzoylamino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(2-azidoethoxy)benzoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(4-azidobutoxy)benzoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(2-octenoylamino)benzoyl')amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-(p-pentyloxy-m-methoxybenzoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-(2E-octenyloxy)-m-chlorobenzoy]amino-2-(5-tetrazolyl)-1,4-benzodioxane
8-(2-naphthylcarbonyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-(p-pentylcinnamoyl)amino-1,4-benzodioxane-2- carboxylic acid and methyl ester thereof,
8-(p-heptylcinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-[N-methyl-[N-(pentylcinnamoyl)]amino]-2-(5-tetra
zolyl)-l,4-benzodioxane,
5-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)-7-chloro- 1,4-benzodioxane,
8-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)-6-chloro- 1,4-benzodioxane,
8-(p-ethylcinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-(p-propylcinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane, 8-(p-butylcinnamoyl)amino-2-(5-tetrazolyl)-1 , 4-ben. zodioxane,
8-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)-6-methyl- 1,4-benzodioxane,
8-(o-pentylcinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-(m-octylcinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane-5-carboxylic acid and methyl ester thereof,
5-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane-8-carboxylic acid and methyl ester thereof,
8-(p-hexylcinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-(p-nonylcinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane-6-carboxylic acid and methyl ester thereof,
5-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane-7-carboxylic acid and methyl ester thereof,
8-(p-octylcinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-(p-decylcinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-P-isopropylcinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-(p-isobutylcinnamoyl)ammo-2-(5-tetrazolyl)-1,4- benzodioxane, 8-(p-isopentylcinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-(p-pentyl-2-methylcinnamoyl)amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-(p-pentyl-3-methylcinnamoyl)amino-2-(5-tetrazolyl)- 1,4-benzodioxane and
8-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)methyl- 1,4-benzodioxane
8-(p-pentyloxycinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-(m-pentyloxycinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-(o-pentyloxycinnamoyl)amino-2-(5-tetrazoly)-1,4- benzodioxane,
8-(p-propoxycinnamoyl)amino-2-(5-tetrazolyl)-1,4,- benzodioxane,
8-(p-butoxycinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-(p-octyloxycinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-(p-hexyloxycinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-(p-heptyloxycinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-(p-isopentyloxycinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-(p-isohexyloxycinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-[p-(1-methylbutoxy)cinnamoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-(p-isoheptyloxycinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane, 8-(p-isooctyloxycinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-(p-isohexyloxy-2-methylcinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane and
8-(p-isohexyloxy-2-phenylcinnamoyl)amino-2-(5- tetrazolyl)-1,4-benzodioxane,
8-[p-(2E-octenyloxy)cinnamoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(2-propenyloxy)cinnamoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(3-butenyloxy)cinnamoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(3Z-hexenyloxy)cinnamoyl]amino-2-(5-tetrazolyl) 1,4-benzodioxane,
8-[p-2Z-pentenyloxycinnamoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(2E-nonenyloxy)cinnamoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(3E-heptenyloxy)cinnamoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(2E-heptenyloxy)cinnamoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(2E-hexenyloxy)cinnamoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(2E-pentenyloxy)cinnamoyl]amino-2-(5-tetrazolyl) 1,4-benzodioxane,
8-[p-(4-pentenyloxy)cinnamoyl]amino-2-(5-tetrazolyl) 1,4-benzodioxane,
8-[p-(2E-butenyloxy)cinnamoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane and
8-[p-(2E-decenyloxy)cinnamoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane 8-[p-(2-octynyloxy)cinnamoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane and
8-[p-(2-pentynyloxy)cinnamoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-(p-pentylthiocinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-(m-pentylthiocinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane and
8-(o-pentylthiocinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-[p-(6-chlorohexyloxy)cinnamoyl]amino-2-(5-tetra- zolyl)1,4-benzodioxane,
8-[p-(4-chlorobutoxy)cinnamoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(5-chloropentyloxy)cinnamoyl]amino-2-(5-tetra- zolyl)-1,4-benzodioxane and
8-[p-(7-chloroheptyloxy)cinnamoyl')amino-2-(5-tetrazolyl)-1,4-benzodioxane
8-(p-isopentyloxymethyl-cinnamoyl)amino-2-(5-tetra- zolyl)-1,4-benzodioxane,
8-(p-cyclohexylcinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-(p-cyclohexylmethoxycinnamoyl)amino-2-(5-tetra- zolyl)-1,4-benzodioxane,
8-[p-(4-cyclohexylbutoxy)cinnamoyl')amino-2-(5-tetrazolyl)-1,4-benzodioxane and
8-[p-(2-cyclohexylethoxy)cinnamoyl]amino-2-(5-tetra- zolyl)-1,4-benzodioxane,
8-(p-phenylmethylcinnamoyl)amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-(p-phenylmethoxycinnamoyl)amino-2-(5-tetrazolyl)- 1,4-benzodioxane, 8-[p-(2-phenylethoxy)cinnamoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(4-phenylbutoxy)cinnamoyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane,
8-[p-(5-phenylpentyloxy)cinnamoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane and
8-[p-(3-phenylpropoxy)cinnamoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-(6-acetyloxyhexyloxy)cinnamoyl]amino-2-(5-tetrazolyl)-1,4-benzodioxane,
8-[p-[2-(2-thienyl)ethoxy)-cinnamoyl]-amino-2-(5- tetrazolyl)-1,4-benzodioxane,
8-(m,p-dimethoxycinnamoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-(m-methoxy-p-pentyloxycinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane and
8-(p-pentyloxy-m-chlorocinnamoyl)amino-2-(5-tetrazolyl)-1,4-benzodioxane
8-[3-(5-indanyl)acryloyl]amino-2-(5-tetrazolyl)-1,4- benzodioxane,
N-(2-hexadecenoyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-(p-pentylphenylacetyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane and
8-[3-(p-pentylphenyl)propionyl]amino-2-(5-tetrazolyl)- 1,4-benzodioxane
8-(p-hexylphenylpropioloyl)amino-2-(5-tetrazolyl)-1,4- benzodioxane,
8-[5-(p-propoxyphenyl)penta-2E,4E-dienoyl]amino-2- (5-tetrazolyl)-1,4-benzodioxane and
8-[5-(p-butylphenyl)penta-2E,4E-dienoyl]amino-2-(5- tetrazolyl)-1,4-benzodioxane, 8-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)-2,3-dihydro-14-dithianaphthalene and
5-(p-pentylcinnamoyl)amino-2-(5-tetrazolyl)-2,3-dihydro-1,4-dithianaphthalene and sodium salts thereof.
Also included are aromatic 1,2-di(thio)ethers of the formula:
Figure imgf000090_0001
wherein
A is an 1,2-disubstituted aromatic ring; preferably a benzene ring; wherein
X is independently O, S, SO, or SO2;
R is H,
C1-C4 alkyl,
phenyl or substituted phenyl,
halo,
haloalkyl, hydroxy,
carboxy,
cyano,
C1-C4 alkoxy,
C1-C4 alkylthio,
C1-C4 alkylsulfinyl,
C1-C4 alkylsulfonyl,
nitro,
amino,
C1-C4 mono or di-alkylamino;
R' and R" are independently
H,
halo,
C1-C4 alkyl or C1-C4 alkoxy,
amino, or oxo, where CH-R' or CH-R''
in the formula become -C=O; y is 1-6; z is 6-20; and
wherein
Figure imgf000091_0001
and can independently represent substituted
Figure imgf000091_0002
or unsubstituted alkyl radicals or alkenyl radicals containing at least one alkene bond; and pharmaceutically acceptable salts and esters thereof. The compounds of the instant invention are inhibitors of the human testosterone-5α-reductase enzyme.
The scope of the compounds of the instant invention are described by the above-described formula.
In the description of the formula the following terms are used which are hereby defined:
X in the general formula above is O or S, preferably where one X is 0, and particularly where both Xs are 0, e.g., resulting in the catechol
structure.
"C1-C4 alkyl" includes linear or branched species, e.g. methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, t-butyl.
"C1-C4 alkoxy" includes linear or branched
species, e.g., methoxy, ethoxy, n-propoxy,
isopropoxy, n-butoxy, isobutoxy, sec-butoxy, t-butoxy.
"Halo" includes fluoro, chloro, bromo or iodo.
"Substituted phenyl" includes phenyl substituted by one or more of C1-C4 alkyl, C1-C4 alkoxy, or halo, and the like, as defined above, representative examples include o, m-, p-methoxy phenyl; 2,4-dimethoxyphenyl; 2-chloro-4-ethoxyphenyl; 3,5-dimethoxyphenyl; 2,4-dichlorophenyl; 2-bromo-4-methylphenyl, o-fluorophenyl, and the like.
"Haloalkyl" includes C1-C4 alkyl, defined above, substitued with one or more "halo" as
defined above and includes: trifluoromethyl,
2,2-dichloroethyl and the like. "C1-C4 alkylthio" includes C1-C4 alkyl, defined above, substituted with at least one
divalent thio (-S-) grouping including; methylthio, ethylthio, isopropylthio, n-butylthio, and the like.
"C1-C4 alkylsulfinyl" includes C1-C4 alkyl, defined above, substituted with at least one -SO-grouping including; methylsulfinyl, ethylsulfinyl; isopropylsulfinyl, and the like.
"C1-C4 alkylsulfonyl" includes C1-C4 alkyl, defined above, substituted with at least one sulfonyl group, -SO2-, including; methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, and the like.
"C1-C4 mono or dialkyl amino" includes amino, substituted with one or more C1-C4 alkyl groups as defined hereinabove, including: methylamino,
ethylamino, n-butylamino, t-butylamino, N,N-dimethylamino, N,N-diethylamino, methyl-t-butylamino, and the like.
The R group or groups on the benzene ring can be present initially in the process, such as in starting material I in Flow Chart A, e.g. phenyl, methyl, methoxy, cyano, trifluoromethyl,
carbomethoxy, or added later by a conventional
reaction, e.g. chloro, as by chlorination, nitro by nitration, or created from a starting or added
functional group present, e.g. converting a nitro to an amino group by catalytic reduction, then
alkylating to a mono or dialkylamine. An amino group can be subjected to diazotization to a hydroxy group, which can be followed by methylation to a methoxy group. Similarly, a hydroxy group can be converted to a thiol by the analogous procedures described in J. Org. Chem. 31, PP 3980-3984 (1966) by Newman and Karnes, and J. Org. Chem. 21, PP 410 (1966) by Kwart, H. and Evans, E.S. The resulting thiol can be alkylated to alkylthio, which can be oxidized to the corresponding sulfoxide or sulfone. Preferred substituents are H, C1-C4 alkyl, C1-C4 alkoxy and phenyl. These reactions and sequences are
conventional in the art and it will be obvious to one skilled in the art to modify the benzene ring to arrive at an R radical disclosed herein.
By the term "pharmaceutically acceptable salts and esters thereof" is meant, salts and esters of the acid groups in the final molecule which can be used as part of the human drug delivery system and include the salts: sodium, potassium, calcium, ammonium, substituted ammonium, quaternary ammonium, and esters: ethyl ester, aceturate, besylate, edetate, phenpropionate, acetate, pamoate, and esters which serve as "prodrug" formulations which will hydrolyze in the body at physiological pH's to regenerate the acid, including pivaloylates, e.g. pivoxetil and pivoxil, and Kanebo esters, and the like.
Figure imgf000094_0001
y, where y is 1-6, preferably 3, can contain at least one R' substituent as defined above, and can be, e.g., -CH2-; -CH2-CH2-; -CH2-CH2-CH2-, ; -; -; -; ;
Figure imgf000094_0002
Figure imgf000094_0003
Figure imgf000094_0004
Figure imgf000094_0005
Figure imgf000094_0006
and the like. An alkene bond can also be present in R' (CH)y-, e.g., CH2-CH=CH-; CH2-CH=CH-CH2-;
-CH2-CH=CH-(CH2)2-; and the like.
Figure imgf000095_0001
, where z is 6-20, preferably 10-16, can contain at least one R" substituent as defined above, and can be; e.g., -(CH2)6-, -(CH2)20-, ;
Figure imgf000095_0002
; ;
Figure imgf000095_0004
Figure imgf000095_0003
and the like.
An alkene bond can also be present in
Figure imgf000095_0005
, e.g., CH2-CH=CH-(CH2)8-; -(CH2)8-CH=CH(CH2)2-; -(CH2)9-CH=CH-(CH2)9-; (CH2)4-CH=CH-(CH2)4-; and the like.
R' and R" can also be -NHCOCH3, which can be hydrolyzed to amino by conventional acid or base hydrolysis in the final molecule; R' and R" can also be oxo, obtained by, for example, HBr addition to an alkene followed by conversion to an alcohol and subsequent oxidation to the ketone.
Preferred is where one R' or R" is H and particularly preferred is where both and
are alkyl.
Figure imgf000095_0006
Figure imgf000095_0007
Preferred compounds of the instant invention are given by the following formulas;
Figure imgf000096_0002
wherein
one X is O and R, R' , R" , y and z are defined above ; and particularly preferred are the compounds ,
Figure imgf000096_0001
wherein
X is O or S and n is 10-16.
The compounds of the instant invention can be made by the procedure outlined in the following Flowchart A-1.
Figure imgf000097_0001
As seen in Flow Chart A-1, Compound I is the starting substrate in the invention process and is a 1,2-substitυted benzene ring. X can be independently 0 or S and "PG" represents a hydroxy or thio protecting group which is inactive during Step (A) but can be subsequently removed by, e.g. palladium on carbon catalyst in ethanol under a pressurized H2 atmosphere.
Examples of "PG" protecting groups which are conventional and known in the art (See "Protective Groups in Organic Synthesis" by Theodora W. Greene - 1981 - John Wiley - Chapter 2, "Protection for the Hydroxyl Group, Including 1,2- and 1,3-Diols" pp.
16-87 and Chapter 6 "Protection for the Thiol Group" pp. 193-218).
Representative examples of "PG" include:
benzyl, p-methoxybenzyl, p-halobenzyl; including p-chlorobenzyl, p-fluorobenzyl, and the like. Other protective groups which are known will be obvious to one skilled in the art to carry out the function of Step (A).
Representive examples of compounds useful as I in the instant invention, include, but are not limited to the following:
2-(benzyloxy)-phenol,
2-benzyloxy-thiophenol,
2-(benzylthio)-phenol,
2-(benzylthio)thiophenol,
3-methoxy-2-benzyloxyphenol,
2-benzyloxy-4-methoxyphenol,
3-methyl-2-benzyloxyphenol,
2-benzyloxy-5-methylphenol, 2-benzyloxy-4-methylphenol,
2-benzyloxy-5-methylphenol,
2-benzyloxy-3,5-diisopropylphenol,
2-benzyloxy-3,5-di-t-butylphenol,
2-benzyloxy-4-t-butylphenol,
2-benzyloxy-3-ethylphenol,
2-benzyloxy-5-phenylphenol,
2-benzyloxy-4-methyl-1-thiophenol,
2-benzyloxy-5-trifluoromethyl-1-thiophenol,
2-benzyloxy-6-methoxy-1-thiophenol,
2-benzylthio-4-methyl-thiophenol,
2-benzylthio-5-methylsulfonyl-phenol, and the like.
Representative examples of II useful in the invention process where L is a leaving group, e.g., halogen, including bromo, chloro, or sulfonate, and the like, and Ra is a C1-C4 linear or branched alkyl portion of the ester, including methyl, ethyl, isopropyl, t-butyl, sec-butyl, and the like, and where R1 and Y are or defined above, include, but are not limited to:
Br-CH2-COOMe,
Cl-CH2CH2CH2COOCH2CH3,
Br-CH2CH2CH2CH2COOMe,
Br-CH2CH2CH2CH2CH2COOEt,
Br-CH2CH2CH2CH2CH2CH2COOCH2CH2CH2CH3,
Br-(CH2)2CH(CH3)COOMe,
Br-CH2CH(CH3)CH2COOEt,
Br-CH2CH2CH2COOMe,
Br-CH2CH(OCH3)CH2COOCH(CH3)2, C1-CH2CH(OCH2CH3)CH2COOMe,
Br-CH2CH(F)CH2COOMe,
Cl-CH2CH2COOEt,
and the like. In Step (A) the condensation of I and II to produce III takes place in an non-hydroxylated polar organic solvent, e.g., acetone, ethyl acetate, methylethylketone, dioxan, THF, diethyIketone, and the like, A proton acceptor is also present, e.g. potassium carbonate, sodium bicarbonate, pyridine, triethylamine, and the like. Generally, the reaction is carried out under an inert atomosphere, e.g. dry nitrogen, and heated at reflux or allowed to sit for an extended period of time at room temperature. Workup is conventional.
In Step (B) the protecting group, "PG", is catalytically removed at ambient temperature under a pressurized, hydrogen atmosphere in an organic solvent to produce IV, being a phenol or thiophenol. Operable catalysts include 5% Pd/C, and the like. The organic solvent should be inert under the reaction conditions and includes ethyl acetate, ethanol, methanol, dioxane, and the like.
Step (C) involves reacting IV with V to produce VI, the diester. The reaction conditions are similar to those described in Step (A) utilizing an inert organic solvent for the reactants and a proton acceptor.
Representative examples of V useful in the invention are:
Br(CH2)6COOMe, Br(CH2)7COOMe,
Br(CH2)8COOMe,
Br(CH2)9COOMe,
Br(CH2)10COOMe,
Br(CH2)11COOMe,
Cl(CH2)12COOEt,
C1(CH2)13COOCH(CH3)2,
C1(CH2)14COOCH2CH2CH3,
Br-(CH2)15COOMe
Br-(CH2)16COOMe
Br(CH2)16COOCH2CH3,
Br(CH2)17COOC(CH3)3,
Br(CH2)18COOMe,
Br(CH2)19COOEt,
Br(CH2)20COOMe,
Br(CH2)2CH(CH3)-(CH2)10COOMe,
Br-CH2CH(CH3)(CH2)10COOMe,
Br-CH2CH3CH(CH3)CH2COOEt,
Br-CH2CH(OCH3)(CH2)7COOCH(CH3)2,
Cl-CH2CH(OCH2CH3)CH2CH2COOMe,
Br-CH2CH(NHCOCH3)-(CH2)10-CH2-COOMe,
,
Figure imgf000101_0002
Br-CH2-CH=CH(CH2)8-COOEt,
,
Figure imgf000101_0001
Br-CH2-(CH2)9-CH=CH-COOMe,
and the like.
In Step (D), the diester can be deesterified by aqueous basic hydrolysis, e.g. NaOH in MeOH/H2O to yield the diacid VII upon acidification.
Figure imgf000102_0001
Figure imgf000103_0001
Flow Sheet B-1 illustrates the specific synthesis of 7.
As seen, 2-benzyloxyphenol 1, ethyl 4-bromo- butyrate 2 and anhydrous K2CO3 in e.g., dry acetone are heated at reflux or stirred for an extended period of time at room temperature, under a nitrogen atmosphere to give product ethyl 4-(2-benzyloxyphenoxy) butyrate 3, in Step (A).
A solution of 3 in e.g., ethyl acetate is catalytically hydrogenated at room temperature under e.g. 40 psig of H2 in the presence of a 5% Pd/C catalyst to yield ethyl 4-(2-hydroxyphenoxy) butyrate 4 in Step (B).
Step (C) comprises reacting 4 and methyl 12-bromododecanoate 5. with potassium carbonate in acetone as in Step (A) to obtain the monomethyl ester 6.
In Step (D), the diester & is de-esterified by e.g., 2.5 N NaOH in MeOH/H2O to yield the final product, diacid 2,upon acidification.
Flow Sheet C-1 illustrates the synthesis of the sulfur analog of 7 as 7A. This analogous procedure uses substantially the same steps as involved in Flow Sheet B.
It is also obvious from the above Flow
Sheets that suitable replacement compounds for II and 2. with other substituted and unsubstituted halo alkyl esters, known in the art and described herein, and that suitable replacement of V and 5. with other bromoesters, available in the art and also described above will yield all of the compounds within the scope of the instant claims. Representative examples of compounds produced by this process include:
4-(2-(20-Carboxyeicosyloxy)phenoxy)butyric acid;
4-(2-(19-Carboxynonadecyloxy)phenoxy)butyric acid; 4-(2-(18-Carboxyoctadecyloxy)phenoxy)butyric acid;
4-(2-(17-Carboxyheptadecyloxy)phenoxy)butyric acid;
4-(2-(16-Carboxyhexadecyloxy)phenoxy)butyric acid;
4-(2-(15-Carboxypentadecyloxy)phenoxy)butyric acid;
4-(2-(14-Carboxytetradecyloxy)phenoxy)butyric acid; 4-(2-(13-Carboxytridecyloxy)phenoxy)butyric acid;
4-(2-(12-Carboxydodecyloxy)phenoxy)butyric acid;
4-(2-(11-Carboxyundecyloxy)phenoxy)butyric acid;
4-(2-(10-Carboxydecyloxy)phenoxy)butyric acid;
4-(2-(9-Carboxynonyloxy)phenoxy)butyric acid;
4-(2-(8-Carboxyoctyloxy)phenoxy)butyric acid;
4-(2-(7-Carboxyheptyloxy)phenoxy)butyric acid;
4-(2-(6-Carboxyhexyloxy)phenoxy)butyric acid;
4-(2-(20-Carboxyeicosyloxy)phenylthio)butyric acid;
4-(2-(19-Carboxynonadecyloxy)phenylthio)butyric acid; 4-(2-(18-Carboxyoctadecyloxy)phenylthio)butyric acid;
4-(2-(17-Carboxyheptadecyloxy)phenylthio)butyric acid;
4-(2-(16-Carboxyhexadecyloxy)phenylthio)butyric acid;
4-(2-(15-Carboxypentadecyloxy)phenylthio)butyric acid;
4-(2-(14-Carboxytetradecyloxy)phenylthio)butyric acid; 4-(2-(13-Carboxytridecyloxy)phenylthio)butyric acid;
4-(2-(12-Carboxydodecyloxy)phenylthio)butyric acid; 4-(2-(11-Carboxyundecyloxy)phenylthio)butyric acid; 4-(2-(10-Carboxydecyloxy)phenylthio)butyric acid;
4-(2-(9-Carboxynonyloxy)phenylthio)butyric acid;
4-(2-(8-Carboxyoctyloxy)phenylthio)butyric acid;
4-(2-(7-Carboxyheptyloxy)phenylthio)butyric acid;
4-(2-(6-Carboxyhexyloxy)phenylthio)butyric acid;
4-(2-(20-Carboxyeicosylthio)phenoxy)butyric acid;
4-(2-(19-Carboxynonadecylthio)phenoxy)butyric acid; 4-(2-(18-Carboxyoctadecylthio)phenoxy)butyric acid; 4-(2-(17-Carboxyheptadecylthio)phenoxy)butyric acid; 4-(2-(16-Carboxyhexadecylthio)phenoxy)butyric acid; 4-(2-(15-Carboxypentadecylthio)phenoxy)butyric acid; 4-(2-(14-Carboxytetradecylthio)phenoxy)butyric acid; 4-(2-(13-Carboxytridecylthio)phenoxy)butyric acid; 4-(2-(12-Carboxydodecylthio)phenoxy)butyric acid;
4-(2-(11-Carboxyundecylthio)phenoxy)butyric acid;
4-(2-(10-Carboxydecylthio)phenoxy)butyric acid;
4-(2-(9-Carboxynonylthio)phenoxy)butyric acid;
4-(2-(8-Carboxyoctylthio)phenoxy)butyric acid;
4-(2-(7-Carboxyheptylthio)phenoxy)butyric acid;
4-(2-(6-Carboxyhexylthio)phenoxy)butyric acid;
4-(2-(20-Carboxyeicosylthio)phenylthio)butyric acid; 4-(2-(19-Carboxynonadecylthio)phenylthio)butyric acid; 4-(2-(18-Carboxyoctadecylthio)phenylthio)butyric acid; 4-(2-(17-Carboxyheptadecylthio)phenylthio)butyric
acid;
4-(2-(16-Carboxyhexadecylthio)phenylthio)butyric
acid;
4-(2-(15-Carboxypentadecylthio)phenylthio)butyric
acid; 4-(2-(14-Carboxytetradecylthio)phenylthio)butyric acid;
4-(2-(13-Carboxytridecylthio)phenylthio)butyric
acid;
4-(2-(12-Carboxydodecylthio)phenylthio)butyric
acid;
4-(2-(11-Carboxyundecylthio)phenylthio)butyric
acid;
4-(2-(10-Carboxydecylthio)phenylthio)butyric acid; 4-(2-(9-Carboxynonylthio)phenylthio)butyric acid;
4-(2-(8-Carboxyoctylthio)phenylthio)butyric acid;
4-(2-(7-Carboxyheptylthio)phenylthio)butyric acid;
4-(2-(6-Carboxyhexylthio)phenylthio)butyric acid;
3-(2-(16-Carboxyhexadecyloxy)phenoxy)propionic acid; 3-(2-(15-Carboxyisohexadecyloxy)phenoxy)butyric acid;
?-(2-(14-Carboxytetradecyloxy)phenoxy)butyric acid;
5-(2-(13-Carboxytridecyloxy)phenoxy)valeric acid;
5-(2-(12-Carboxydodecyloxy)phenoxy)valeric acid;
5-(2-(11-Carboxyisododecyloxy)phenoxy)valeric acid; 4-(2-(11-Carboxyundecyloxy)phenoxy)valeric acid;
4-(2-(10-Carboxydecyloxy)phenoxy)valeric acid;
4-(2-(9-Carboxynonyloxy)phenoxy)valeric acid;
6-(2-(9-Carboxynonyloxy)phenoxy)caproic acid;
6-(2-(8-Carboxyoctyloxy)phenoxy)caproic acid;
6-(2-(7-Carboxyisooctyloxy)phenoxy)caproic acid;
7-(2-(7-Carboxyheptyloxy)phenoxy)enanthic acid;
7-(2-(6-Carboxyhexyloxy)phenoxy)enanthic acid;
7-(2-(5-Carboxyisohexyloxy)phenoxy)enanthic acid;
2-(2-(12-Carboxydodecylthio)phenoxy)acetic acid;
2-(2-(11-Carboxydecylthio)phenoxy)acetic acid;
2-(2-(10-Carboxydecylthio)phenoxy)acetic acid; 3-(2-(9-Carboxynonyloxy)phenylthio)propionic acid; 3-(2-(12-Carboxydodecyloxy)phenylthio)propionic
acid;
3-(2-(11-Carboxyundecyloxy)phenylthio)propionic
acid;
3-(2-(11-Carboxyundecyloxy)phenylthio)butyric acid; 3-(2-(11-Carboxyundecylthio)-4-methyl-phenylthio) butyric acid;
3-(2-(12-Carboxydodecylthio)phenylthio)butyric
acid;
5-(2-(11-Carboxyundecylthio)phenylthio)valeric
acid;
5-(2-(10-Carboxydecyloxy)phenylthio)valeric acid; 5-(2-(9-Carboxynonyloxy)phenylthio)valeric acid; 3-(2-(12-Carboxydodecyloxy)phenylthio)valeric
acid;
3-(2-(11-Carboxydecyloxy)phenylthio)valeric acid; 3-(2-(10-Carboxydecyloxy)phenylthio)valeric
acid;
6-(2-(9-Carboxynonylthio)phenylthio)caproic acid; 6-(2-(12-Carboxydodecyloxy)phenylthio)caproic
acid;
6-(2-(11-Carboxyundecyloxy)phenylthio)caproic
acid;
6-(2-(11-Carboxyundecyloxy)-3-methylphenylthio)- enanthic acid;
7-(2-(11-Carboxyundecyloxy)-4-methylphenylthio)- enanthic acid;
7-(2-(12-Carboxydodecylthio)phenoxy)enanthic acid; 4-(2-(11-Carboxyundecyloxy)4-methyl-phenoxy)butyric acid; 4-(2-(10-Carboxydecyloxy)3-methylphenoxy)butyric acid; 4-(2-(9-Carboxynonyloxy)5-methylphenoxy)butyric acid; 4-(2-(12-Carboxydodecyloxy)6-methylphenoxy)butyric
acid;
4-(2-(12-Carboxydodecyloxy)6-methylphenoxy)butyric
acid;
4-(2-(11-Carboxyundecylthio)-3-(methylthio)phenoxy)- valeric acid;
4-(2-(11-Carboxyundecylthio)-3-(methylsulfonyl)
phenoxy)butyric acid;
4-(2-(11-Carboxyundecyloxy)-4-(methylsulfonyl)
phenoxy)butyric acid;
4-(2-(12-Carboxydodecyloxy)5-ethyl-phenoxy)butyric
acid;
4-(2-(11-Carboxyundecyloxy)4-phenylphenoxy)butyric
acid;
4-(2-(10-Carboxydecyloxy)-3,5-dimethylphenoxy)butyric acid;
4-(2-(9-Carboxynonyloxy)-4-fluoro-phenoxy)butyric
acid;
4-(2-(12-Carboxydodecyloxy)-5-(trifluoromethyl)- phenoxy)butyric acid;
4-(2-(12-Carboxydodecylthio)-5-nitrophenoxy)butyric acid;
4-(2-(11-Carboxyundecylthio)-4-methylphenoxy)valeric acid;
4-(2-(11-Carboxyundecylthio)-3,5-di-methylphenoxy)- butyric acid;
4-(2-(12-Carboxydodecyloxy)-4-(dimethylamino)phenoxy)- butyric acid; 4-(2-(11-Carboxyundecyloxy)-5-(ethylamino)phenoxy)- butyric acid;
2-(2-(9-Carboxynonyloxy)phenoxy)propionic acid;
3-(2-(12-Carboxydodecyloxy)phenoxy)-3-methylpropionic acid;
4-(2-(10-Carboxydecyloxy)phenylthio)-3-methoxy- butyric acid;
4-(2-(9-Carboxynonyloxy)phenylthio)-3-ethoxy- butyric acid;
4-(2-(11-Carboxyundecyloxy)phenoxy)but-2-enoic acid; 4-(2-(9-Carboxynonyloxy)phenoxy)-2-butenoic acid;
4-(2-(11-Carboxy-2-methylundecyloxy)phenoxy)butyric acid;
4-(2-(11-Carboxyundecyl-7-ene-oxy)phenoxy)butyric
acid;
4-(2-(13-Carboxy-2-methylene-tri-decyloxy)phenoxy)- butyric acid;
4-(2-(11-Carboxyundecyloxy)phenylsulfonyl)butyric acid 4-(2-(11-Carboxyundecyloxy)phenylsulfinyl)butyric acid 4-(2-(11-Carboxyundecylsulfinyl)phenoxy)butyric acid 4-(2-(11-Carboxyundecylsulfonyl)phenoxy)butyric acid 4-(2-(11-Carboxyundecylsulfinyl)phenylsulfinyl)butyric acid
4-(2-(11-Carboxyundecylsulfonyl)phenylsulfonyl)butyric acid
and the like. Also included as a 5α-reductase inhibitor in this invention is an agent for the treatment of patterned baldness in combination with minoxidil is of the following formula:
Figure imgf000111_0001
wherein
A is an 1,2-disubstituted aromatic ring selected from
(a) benzene, 1,2-disubstituted naphthalene;
(b) 5-6 membered heteroaromatic ring, containing 1-2 N atoms, 1 S or 0 atom, or combination thereof;
D and E are independently -COOH, -CONH2, CONHRb, COORb, SO2OH, SO3(OH), SO2NH2, -SSO2ONa, PH(O)(OH), P(O)(OH)2;
X is O, S, SO or SO2;
R is H,
C1-C4 alkyl,
phenyl or substituted phenyl,
halo,
haloalkyl,
hydroxy,
carboxy,
cyano, C1-C4 alkoxy,
C1-C4 alkylthio,
C1-C4 alkylsulfinyl,
C1-C4 alkylsulfonyl,
nitro,
amino,
C1-C4 mono or di-alkylamino;
R' and R" are independently
H,
halo,
C1-C4 alkyl or C1-C4 alkoxy,
amino, or oxo, where CH-R1 or CH-R''
in the formula become -C=O;
Ra is H, C1-C4 alkyl;
Rb is C1-C12 alkyl, phenyl or phenyl C1-C4 alkyl; y is 1-6;
z is 6-20; and wherein and can independently represent substituted
Figure imgf000112_0001
or unsubstituted alkyl radicals or alkenyl radicals containing at least one alkene bond; and pharmaceutically acceptable salts and esters thereof.
The compounds of the instant invention are inhibitors of the human testosterone-5α-reductase . The scope of the compounds of the instant invention are described by the above-described
formula.
In the description of the formula the following terms are used which are hereby defined:
X is preferably O or S, and particularly preferred is O.
"C1-C4 alkyl" includes linear or branched species, e.g. methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, t-butyl and "C1-C12 alkyl" includes, alkyl up to 12 cartons including n-octyl, t-decyl, n-dodecyl.
"Phenyl C1-C4 alkyl" includes benzyl, 2-phenethyl and the like.
"C1-C4 alkoxy" includes linear or branched species, e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, t-butoxy.
"Halo" includes fluoro, chloro, bromo or iodo.
By the term "heteroaromatic ring" as used herein is meant a 5-6 membered ring, containing 1-2 N-atoms, 1 S or 0 atom, or combination thereof, and includes: pyridine, thiophene, furan, imidazole,
1,3-thiazole, 1,3-oxazole, 1,2,3-thiadiazole, and the like. The limitation here being that the
1,2-disubstitution occurs on only ring carbons of the heteroaromatic ring. Preferred heteroaromatic rings are pyridine, furan and thiophene.
"Substituted phenyl" includes phenyl substituted by one or more of C1-C4 alkyl, C1-C4 alkoxy, or halo, and the like, as defined above; representative examples include o, m-, p-methoxy phenyl; 2,4-dimethoxyphenyl; 2-chloro-4-ethoxyphenyl; 3,5-dimethoxyphenyl; 2,4-dichlorophenyl; 2-bromo-4- methylphenyl, o-fluorophenyl, and the like.
"Haloalkyl" includes C1-C4 alkyl, defined above, substitued with one or more "halo" as defined above and inlcudes: trifluoromethyl,
2,2-dichloroethyl and the like.
"C1-C4 alkylthio" includes C1-C4 alkyl, defined above, substituted with at least one
divalent thio (-S-) grouping including; methylthio, ethylthio, isopropylthio, n-butylthio, and the like.
"C1-C4 alkylsulfinyl" includes C1-C4 alkyl, defined above, substituted with at least one -SO- grouping including; methylsulfinyl, ethylsulfinyl; isopropylsulfinyl, and the like.
"C1-C4 alkylsulfonyl" includes C1-C4 alkyl, defined above, substituted with at least one sulfonyl group, -SO2-, including; methylsulfonyl, ethyl- sulfonyl, isopropylsulfonyl, n-butylsulfonyl, and the like.
"C1-C4 mono or dialkyl amino" includes amino, substituted with one or more C1-C4 alkyl groups as defined hereinabove, including: methylamino, ethylamino, n-butylamino, t-butylamino, dimethylamino, diethylamino, methyl-t-butylamino, and the like.
The R group or groups on the benzene or heteroaromatic ring can be present initially in the process, e.g. phenyl, methyl, methoxy, cyano carbomethoxy, trifluoromethyl, ( as in the starting o-nitrophenol 1 in Flow Chart A) or added later by a conventional reaction, e.g. chloro, as by chlorination, nitro by nitration, or created from a starting or added functional group present, e.g. converting a later added nitro group to an amino group by catalytic reduction, then alkylating to a mono or dialkylamine. An amino group can be subjected to diazotization to a hydroxy group, which can be followed by methylation to a methoxy group. Similarly, a hydroxy group can be converted to a thiol by the analogous procedures described in
J. Org. Chem. 31, pp 3980-3984 (1966) by Newman and Karnes, and J. Org. Chem. 21, pp 410 (1966) by Kwart, H. and Evans, E.S. The resulting thiol can be alkylated to alkylthio, which can be oxidized to the corresponding sulfoxide or sulfone. Preferred substituents are H, C1-C4 alkyl, C1-C4 alkoxy and phenyl. These reactions and sequences are conventional in the art and it will be obvious to one skilled in the art to modify the benzene ring to arrive at an R radical disclosed herein.
By the term "pharmaceutically acceptable salts and esters thereof" is meant, salts and esters of the acid groups in the final molecule which can be used as part of the human drug delivery system and include the salts: sodium, potassium, calcium, ammonium, substituted ammonium, quaternary ammonium, and esters: ethyl ester, aceturate, besylate, edetate, phenpropionate, acetate, pamoate, and esters which serve as "prodrug" formulations which will hydrolyze in the body at physiological pH's to regenerate the acid, including pivaloylates, e.g. pivoxetil and pivoxil, and Kanebo esters, and the like. y, where y is 1-6, preferably 3, can
Figure imgf000116_0001
contain at least one R' substituent as defined above, and can be alkyl, e.g., -CH2; -CH2-CH2; -CH2-CH2-CH2,
; ; ;
Figure imgf000116_0002
Figure imgf000116_0003
Figure imgf000116_0004
Figure imgf000116_0005
Figure imgf000116_0006
and the like.
An alkene bond can also be present in , e.g., -CH2-CH=CH;-CH2-CH=CH-CH2;
Figure imgf000116_0007
-CH2-CH2-CH=CH; -(CH2)3 -CH=CH, and the like.
Figure imgf000116_0008
, where z is 6-20, preferably
8-14, can contain at least one R" substituent as defined above, and can be alkyl; e.g., -(CH2)6-
-(CH2)20;
Figure imgf000116_0009
-; ;
Figure imgf000116_0010
Figure imgf000116_0011
and the like.
An alkene bond can also be present in
Figure imgf000116_0012
, e.g., -CH2-CH=CH-(CH2)8-;
-(CH2)8-CH=CH-(CH2)2-; -(CH2)9-CH=CH-(CH2)9-;
(CH2)4-CH=CH-(CH2)4-; and the like. Preferred is where one R' or R" is H and particularly preferred is where both and
Figure imgf000117_0004
Figure imgf000117_0005
are alkyl.
Representative compounds of the instant invention within the above general formula are given by the following, structures;
Figure imgf000117_0001
Figure imgf000117_0002
Figure imgf000117_0003
Figure imgf000118_0001
.
Particularly preferred are the following compounds
Figure imgf000118_0002
Figure imgf000118_0003
Figure imgf000119_0001
Figure imgf000119_0002
Figure imgf000119_0003
where X is O or S and R, R', R", y and z are as defined above.
Preferred compounds within this class are
Figure imgf000120_0001
,
Figure imgf000120_0002
Figure imgf000120_0003
Figure imgf000120_0004
Figure imgf000121_0001
where X is O or S, and n is 8-14. Also preferred compound are within these classes are:
Figure imgf000121_0002
where n is 8-1 4.
Figure imgf000121_0003
Wiere n is 8-1 4.
The compounds of the instant invention can be made by the procedures outlined in the following Flowcharts.
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
Figure imgf000127_0001
Figure imgf000128_0001
FLOW CHART H-2 44
Figure imgf000129_0001
(9) (alternate route to £)
As seen in Flow Chart A-2, o-nitrophenol 1, ethyl 4-bromobutyrate 2 and anhydrous K2CO3 in e.g., dry acetone are heated at reflux or stirred for an extended period of time at room temperature, under a nitrogen atmosphere to product ethyl
4-(2-nitrophenoxy) butyrate 2, in Step (A).
A solution of 2 in e.g., ethyl acetate is catalytically hydrogenated at room temperature under e.g. 40 psig of H2 in the presence of a 57. Pd/C catalyst to yield ethyl 4-(2-aminophenoxy)butyrate 4 in Step (B).
Step (C) comprises reacting diethyl dodecanoate 5 with barium hydroxide octahydrate in methanol at ambient temperature to obtain the
monomethyl ester 6.
In Step (D) the mono ester mono acid 6 is refluxed with thionyl chloride for about 5 hours to produce the mono acid chloride, mono methyl ester 7.
Step (E) comprises the reaction of the mono acid chloride 7 with the amine 4 at e.g., 0-10°C in e.g., dry ether in the presence of a hydrogen acceptor e.g., triethylamine, to produce the amide 8.
In Step (F), the ether-amide diester 8 is de-esterified by e.g., 2.5 N NaOH in MeOH/H2O to yield after acidification the final product, diacid 9.
Flow Chart B-2 illustrates the synthesis of the corresponding thio compounds. Step (G) illustrates the reaction of o-aminobenzenethiol with ethyl 4-bromobutyrate which can be carried out in e.g., dry dimethoxyethane, under dry N2, in the presence of a proton acceptor, e.g., dry powdered K2CO3, to produce 11.
Step (H) illustrates the acylation of the amino group of 11 with ethyl ll-bromoundecanoate in a dry solvent, e.g., dry ether, at 0ºC in the presence of an acid acceptor, e.g., pyridine.
Step (I) illustrates the hydrolysis of the diester to the final diacid 12, which can be
accomplished with, e.g., NaOH/MeOH.
As seen in Flow Chart C-2, o-nitrophenol is benzylated under the same conditions as in Step (A).
Step (K) shows the reduction of the nitro group using e.g., Raney Ni in ethanol/NH3 under 40 psig H2.
Step (L) shows the trifluoroacetylation of 24 using e.g., trifluoroacetic anhydride in dry ether and powdered dry sodium carbonate.
Step (M) shows the N-methylation which can be accomplished using, e.g., methyl iodide in dry acetone and dry powdered KOH followed by removal of the N-trifluoroacetyl group with MeOH/H2O.
Step (N) shows the N-acylation of 27, using an acid chloride, e.g., 7, in e.g., dry methylene chloride and pyridine at 0ºC.
Step (0) shows the debenzylation of 28, which can be accomplished by e.g., 10% Pd/C in MeOH under a H-2 atmosphere.
Step (P) shows the O-alkylation of 29 using e.g., ethyl 4-bromobutyrate and K2CO3 in anhydrous acetone. Step (Q) shows hydrolysis of the diester 2fi to the diacid 31 by hydrolysis as e.g., described for Step (F).
Flow Chart D-2 shows the production of phosphonate type esters and acids.
Step (R) shows the condensation of it with 11-bromoundecanoic acid in anhydrous methylene chloride using N,N'-dicyclohexylcarbodiimide and 4-dimethylaminopyridine to produce the important bromo intermediate 22.
Step (S) shows the reaction of 32 with triethylphosphite at e.g., 180°C under N2 to produce the phosphonate ester 22.
Step (T) converts 22 via bromotrimethylsilane to the monoacid 24.
Step (ϋ) uses the similar hydrolysis conditions of Step (F) to produce the phosphonic-carboxylic diacid 35.
The corresponding phosphinic acids can be analogously made from 32 by known procedures in the art.
Flow Chart E-2 illustrates the synthesis of the sulfonic acid types of the invention compounds.
Step (V) shows reaction of the intermediate 32 with thiourea in EtOH/H2O under N2 at 90°C to yield the isothiouronium salt 36.
Step (W) shows the reaction of 22. with sodium thiosulfate under the conditions of Step (V) to yield the thiosulfate ester 37.
Further oxidation of esters 36 or 37 via the
Showell or Ziegler procedures described in Step W in the examples yields the corresponding sulfonic acid 38. The corresponding sulfinic acid can be prepared from 26. by the procedure of J. M. Sprague and T. B. Johnson, JACS 59, 2440 (1937).
The corresponding sulfonamide can be produced from the sulfonic acid 38, by protecting, e.g., the carboxylic acid via an ester, converting the sulfonic acid to a sulfonyl chloride, treating the sulfonyl chloride with ammonia and then hydrolyzing the protected carboxylic ester to the corresponding acid.
Flow Chart F-2 shows the corresponding synthesis of the pyridine analogs of 2 and £.
In Step (X), the nitrohydroxy pyridine is 0-alkylated first using conditions analogous to Step (A) to produce 40.
Step (Y) shows reducing the nitro group in the same manner as described for Step (B).
Step (Z) shows acylating the amino group in the same manner as described for 2 in Step (E) to produce the diester 42. Hydrolysis produces the diacid 43.
Flow Chart G-2 shows the production of some amides 46 of the invention.
In Step (AA), o-aminophenol is reacted directly with 7 under the conditions of Step (E) to produce the N-acylated phenol 44.
In Step (BB), O-alkylation of 44 as carried out using 4-bromobutyronitrile under conditions similar to Step (A), produces 45.
Step (CC) shows the hydrolysis of the nitrile to the amide 46 using MnO2 in methylene chloride. Flow Chart H-2 illustrates an alternate route to 2. by starting with o-aminophenol, acylating to produce 44, then reacting 44 under the conditions of Step (A) to produce 8, then hydrolysis using Step (F) to yield 1.
Thus, by using the above described methods in the Flow Charts and the reaction starting materials and reagents described herein, all of the compounds described and encompassed by the claim can be synthesized by one skilled in the art.
It is obvious that other nitrophenols can be substituted for 1 in Flow Charts A-2 and C-2 to provide the scope of the compounds covered by this invention and include the following:
2-nitrophenol
2- -nitro-6-methylphenol
2-nitro-5-methylphenol
2-nitro-4-methylphenol
2-nitro-3-methylphenol
2-nitro-4-phenylphenol
2-nitro-5-phenylphenol
2-nitro-4-chlorophenol
2-nitro-4-fluorophenol
2-nitro-4-trifluoromethylphenol
2-nitro-4-hydroxyphenol
2-nitro-4-methoxyphenol
2-nitro-6-ethoxyphenol
2-nitro-4-methylthio-phenol
2-nitro-4-methylsulfinylphenol
2-nitro-4-methylsulfonylphenol 4-nitro-3-hydroxypyridine
3-nitro-4-hydroxy-5-methylpyridine
3-nitro-4-hydroxy-6-methylpyridine
2-methyl-3-nitro-4-hydroxypyridine
2-hydroxy-3-nitro-5-phenylpyridine
2-nitro-3-hydroxy-5-phenylpyridine
2-hydroxy-3-nitro-5-chloropyridine
2-nitro-3-hydroxy-5-trifluoromethylpyridine
2-methoxy-4-nitro-5-hydroxypyridine
3-nitro-4-hydroxy-5-ethoxypyridine
2-methylthio-4-nitro-5-hydroxypyridine
2-nitro-3-hydroxy-thiophene
3-nitro-4-hydroxy-thiophene
3-hydroxy-2-nitro-5-methyl-thiophene
3-hydroxy-2-nitro-4-methyl-thiophene
2-hydroxy-3-nitro-5-phenyl-thiophene
2-nitro-3-hydroxy-4-phenyl-thiophene
2-hydroxy-3-nitro-4-chlorothiophene
2-hydroxy-3-nitro-4-fluorothiophene
and the like.
It is obvious that suitable replacement compounds for 2 with other halo alkyl esters, known in the art, and that suitable replacement of 6 with other diesters, available in the art, will yield all of the ether-amide derivatives within the scope of the claims.
Representative examples of 2 useful in the invention process include, but are not limited to: Br-CH2-COOMe,
Cl-CH2CH2CH2COOCH(CH3)3,
Br-CH2CH2CH2CH2COOMe,
Br-CH2CH2CH2CH2CH2COOEt,
Br-CH2CH2CH2CH2CH2CH2COOCH2CH2CH2CH3,
Br-CH2CH(CH3)COOMe,
Br-CH2CH(CH3)CH2COOEt,
Br-CH2CH2CH2COOMe,
Br-CH2CH(OCH3)CH2COOCH(CH3)2,
Cl-CH2CH(OCH2CH3)CH2COOMe,
Br-CH2CH(F)CH2COOMe,
and the like.
Representative examples of other compounds substitutable for 6. and useful in the invention are
HOOC(CH2)6COOMe,
HOOC(CH2)7COOMe,
HOOC(CH2)8COOMe,
HOOC(CH2)9COOMe,
HOOC(CH2)10COOMe,
HOOC (CH2) 1 1COOMe ,
HOOC(CH2)12COOEt,
HOOC(CH2)13COOCH(CH3)2,
HOOC(CH2)14COOCHCH2CH3,
HOOC(CH2)15COO(CH2)3CH3,
HOOC(CH2)16COOCH3,
HOOC(CH2)17COOCH3,
HOOC(CH2)18COOMe,
HOOC(CH2)19COOEt,
HOOC(CH2)20COOPh, HOOC(CH2)10COOCH2Ph,
HOOCCH(CH3)-(CH2)10COOMe,
HOOC-CH2CH-(CH3)(CH2)10C00Me,
HOOC-CH2CH3CH(CH3)CH2C00Et,
Figure imgf000136_0001
HOOC-CH2CH(OCH3)(CH2)7COOCH(CH3)2,
where Ph is phenyl,
and the like.
Representative examples of compounds produced by this process include those in the following list.
The nomenclature used herein for the acid radicals is:
P(O)(OH)2, phosphono;
-COOH, carboxy;
-CONH2, aminocarbonyl;
-SO3H, sulfo;
-SO2H, sulfino;
-SSO3H, thiosulfato, as the sodium salt.
4-(2-(20-Carboxyeicosanoylamino)phenoxy)butyric acid; 4-(2-(19-Carboxynonadecanoylamino)phenoxy)butyric
acid;
4-(2-(18-Carboxyoctadecanoylamino)phenoxy)butyric
acid;
4-(2-(17-Carboxyheptadecanoylamino)phenoxy)butyric
acid;
4-(2-(16-Carboxyhexadecanoyl-N-methylamino)phenoxy)-butyric acid;
4-(2-(15-Carboxypentadecanoylamino)phenoxy)butyramide; 4-(2-(14-Carboxytetradecanoylamino)phenoxy)butyric acid;
4-(2-(13-Carboxyl-tridecanoylamino)phenoxy)butyric acid;
4-(2-(12-Carboxy-dodecanoylamino)phenoxy)butyric
acid;
4-(2-(11-Carboxy-undecanoylamino)phenoxy)butyric
acid;
4-(2-(10-Carboxy-decanoylamino)phenoxy)butyric
acid;
4-(2-(9-Carboxy-nonanoylamino)phenoxy)butyric acid; 4-(2-(8-Carboxyoctanoylamino)phenoxy)butyric acid; 4-(2-(7-Carboxyheptanoylamino)phenoxy)butyric acid; 4-(2-(6-Carboxyhexanoylamino)butyric acid;
4-(2-(20-Carboxyeicosanoylamino)phenylthio)butyric acid;
4-(2-(19-Carboxynonadecanoylamino)phenylthio)butyric acid;
4-(2-(18-Carboxyoctadecanoylamino)phenylthio)butyric acid;
4-(2-(17-Carboxyheptadecanoyl-N-ethylamino)phenylthio)butyric acid;
4-(2-(16-Carboxyhexadecanoylamino)phenylthio)butyric acid;
4-(2-(15-Carboxypentadecanoylamino)phenylthio)butyric acid;
4-(2-(14-Carboxytetradecanoylamino)phenylthio)butyramide;
4-(2-(13-Carboxytridecanoylamino)phenylthio acid; 4-(2-(12-Carboxy-dodecanoylamino)phenylthio)butyric acid; 4-(2-(11-Carboxy-undecanoylamino)phenylthio)butyric acid;
4-(2-(10-Carboxydecanoylamino)phenylthio)butyric
acid;
4-(2-(9-Carboxynonanoylamino)phenylthio)butyric acid; 4-(2-(8-Carboxyoctanoylamino)phenylthio)butyric acid; 4-(2-(7-Carboxyheptanoylamino)phenylthio)butyric
acid;
4-(2-(6-Carboxyhexanoylamino)phenylthio)butyric acid; 3-(2-(16-Carboxyhexadecanoylamino)phenoxy)propionic acid;
4-(2-(15-Carboxyisohexadecanoylamino)phenoxy)butyric acid;
4-(2-(14-Carboxytetradecanoylamino)phenoxy)butyric acid;
5-(2-(13-Carboxytridecanoylamino)phenoxy)valeric
acid;
5-(2-(12-Carboxydodecanoylamino)phenoxy)valeric acid; 5-(2-(11-Carboxyisododecanoylamino)valeric acid;
4-(2-(11-Carboxyundecanoylamino)isovaleric acid;
4-(2-(10-Carboxydecanoylamino)isovaleric acid;
5-(2-(9-Carboxynonanoylamino)phenoxy)valeric acid; 6-(2-(9-Carboxynonanoylamino)phenoxy)caproic acid; 6-(2-(8-Carboxyoctanoylamino)phenoxy)caproic acid; 6-(2-(7-Carboxyisooctanoylamino)phenoxy)caproic acid; 7-(2-(7-Carboxyheptanoylamino)phenoxy)enanthic acid; 7-(2-(6-Carboxyhexanoylamino)phenoxy)enanthic acid; 7-(2-(5-Carboxyisohexanoylamino)phenoxy)enanthic
acid;
2-(2-(12-Carboxydodecanoylamino)phenoxy)acetic acid; 2-(2-(11-Carboxyundecanoylamino)phenoxy)acetic acid;
2-(2-(10-Carboxydecanoylamino)phenoxy)acetic acid; 3-(2-(9-Carboxynonanoylamino)phenoxy)propionic acid; 3-(2-(12-Carboxydodecanoylamino)phenylthio)propionic acid;
3-(2-(11-Carboxyundecanoylamino)phenylthio)propionic acid;
3-(2-(11-Carboxyundecanoylamino)phenylthio)isobutyric acid;
5-(2-(11-Carboxyundecanoylamino)phenylthio)valeric acid;
5-(2-(10-Carboxydecanoylamino)phenylthio)valeric
acid;
5-(2-(9-Carboxynonanoylamino)phenylthio)valeric acid; 4-(2-(12-Carboxydodecanoylamino)phenylthio)isovaleric acid;
4-(2-(11-Carboxydecanoylamino)phenylthio)isovaleric acid;
4-(2-(10-Carboxydecanoylamino)phenylthio)isovaleric acid;
6-(2-(9-Carboxynonanoylamino)phenoxy)caproic acid; 6-(2-(12-Carboxydodecanoylamino)phenylthio)caproic
acid;
6-(2-(11-Carboxyundecanoylamino)phenylthio)caproic
acid;
7-(2-(11-Carboxyundecanoylamino)-3-methylphenylthio)- enanthic acid;
7-(2-(11-Carboxyundecanoylamino)-4-methylphenylthio)- enanthic acid;
7-(2-(12-Carboxydodecanoylamino)phenoxy)enanthic acid; 4-(2-(11-Carboxyundecanoylamino)4-methyl-phenoxy) butyric acid;
4-(2-(10-Carboxydecanoylamino)3-methylphenoxy)butyric acid;
4-(2-(9-Carboxynonanoylamino)5-methylphenoxy)butyric acid;
4-(2-(12-Carboxydodecanoylamino)6-methyIphenoxy)
butyric acid;
4-(2-(11-Carboxydecanoylamino)3-chloro)phenylthio)butyric acid;
4-(2-(10-Carboxydecanoylamino)4-methyIphenoxy)butyric acid;
4-(2-(9-Carboxynonanoylamino)5-fluoromethyl)phenylthio)butyric acid;
4-(2-(12-Carboxydodecanoylamino)6-methyIphenoxy)- butyric acid;
5-(2-(11-Carboxyundecanoylamino)-3-methylthio)- phenoxy)valeric acid;
4-(2-(11-Carboxyundecanoylamino)-3-methylsulfonylphenoxy)butyric acid;
4-(2-(11-Carboxyundecanoylamino)-4-methylsulfonyl)- phenylthio)butyric acid;
4-(2-(12-Carboxydodecanoylamino)5-ethyl-phenoxy)- butyric acid;
4_( 2-(11-Carboxyundecanoylamino)4-phenylphenoxy)- butyric acid;
4-(2-(10-Carboxydecanoylamino)-3,5-dimethylphenoxy)- butyric acid;
4-(2-(9-Carboxynonanoylamino)-4-fluoro-phenoxy)butyric acid; 4-(2-(12-Carboxydodecanoylamino)-5-trifluromethylphenoxy)butyric acid;
4-(2-(11-Carboxyundecanoylamino)5-hydroxy)phenylthio) butyric acid;
4-(2-(10-Carboxydecanoylamino)-4-hydroxy)phenylthio)- butyric acid;
4-(2-(9-Carboxynonanoylamino)-3,5-dimethoxyphenylthio)butyric acid;
4-(2-(12-Carboxydodecanoylamino)-5-nitrophenoxy)butyric acid;
5-(2-(11-Carboxyundecanoylamino)-4-nitrophenoxy)- valeric acid;
4-(2-(11-Carboxyundecanoylamino)-5-amino-3-methylphenoxy)butyric acid;
4-(2-(11-Carboxyundecanoylamino)-5-amino-4-methylphenylthio)butyric acid;
4-(2-(12-Carboxydodecanoylamino)-4-dimethylaminophenoxy)butyric acid;
4-(2-(11-Carboxyundecanoylamino)-5-ethylaminophenoxy)butyric acid;
3-(2-(12-Carboxydodecanoylamino)phenoxy)-3- methylpropionic acid;
3-(2-(11-Carboxydecanoylamino)phenylthio)-2-chloropropionic acid;
4-(2-(10-Carboxydecanoylamino)phenylthio)-3-methoxybutyric acid;
4-(2-(9-Carboxynonanoylamino)phenylthio)-3-ethoxybutyric acid;
4-(2-(12-Carboxydodecanoylamino)-4-methyl-3-pyridyloxy)butyric acid; 4-(2-(11-Carboxyundecanoylamino)-4-methyl-3-pyridyloxy)butyric acid;
4-(2-(10-Carboxydecanoylamino)-5-methyl-3-pyridyloxy)butyric acid;
4-(2-(9-Carboxynonanoylamino)5-hydroxy-3-pyridyloxy)butyric acid;
4-(2-(12-Carboxydodecanoylamino)-6(dimethylamino)-3- pyridyloxy)butyric acid;
4-(2-(11-Carboxydecanoylamino)-3-pyridylthio)-butyric acid;
4-(2-(10-Carboxydecanoylamino)-6-methylsulfonyl-3- pyridyloxy)butyric acid;
4-(2-(9-Carboxynonanoylamino)5-chloro-3-pyridylthio)- butyric acid;
4-(2-(12-Carboxydodecanoylamino)-5-methylpyridylthio)- butyric acid;
4-(2-(11-Carboxyundecanoylamino)5-methylsulfonyl-3- pyridylthio)butyric acid;
4-(2-(11-Carboxyundecanoylamino)-6-methyl-3-pyridylthio)butyric acid;
4-(2-(11-Carboxyundecanoylamino)-4,6-dimethyl-3- pyridyloxy)butyric acid;
4-(2-(12-Carboxydodecanoylamino)-5-methylthio-3- pyridyloxy)butyric acid;
4-(2-(11-Carboxyundecanoylamino)pyridyloxy)butyric
acid;
4-(2-(10-Carboxydecanoylamino)-5-methoxy-3-pyridyloxy) butyric acid;
4-(2-(9-Carboxynonanoylamino)-4-fluoro-6-methyl-3- pyridyloxy)butyric acid; 4-(2-(12-Carboxydodecanoylamino)5-methylamino-3pyridyloxy)butyric acid;
4-(2-(11-Carboxyundecanoylamino)4-phenyl-3-pyridylthio)butyric acid;
4-(2-(10-Carboxydecanoylamino)5-methyl-3-pyridylthio)butyric acid;
4-(2-(9-Carboxylnonanoylamino)6-methoxy-3-pyridylthio) butyric acid;
4-(2-(12-Carboxydodecanoylamino)-6-trifluoromethyl-3- pyridyloxy)butyric acid;
5-(2-(11-Carboxyundecanoylamino)-4-methyl-3-thienyloxy)valeric acid;
4-(2-(11-Carboxyundecanoylamino)-4-methyl-3-thienyloxy)butyric acid;
4-(2-(11-Carboxyundecanoylamino)-4-methyl)-3- thienylthio)butyric acid;
4-(2-(12-Carboxydodecanoylamino)-5-methyl-3-thienylthio)butyric acid;
4-(2-(11-Carboxyundecanoylamino)-4-methyl-3-thienylthio)butyric acid;
4-(2-(10-Carboxydecanoylamino)-5-methyl-3-thienylthio)butyric acid;
4-(2-(9-Carboxynonanoylamino)-4-hydroxy-3-thienyloxy)butyric acid;
4-(2-(12-Carboxydecanoylamino)-4-methylthio-3-thienyloxy)butyric acid;
4-(2-(11-Carboxydecanoylamino)-4-methylthio-3-thienyloxy)butyric acid;
4-(2-(10-Carboxydecanoylamino)-4-methylsulfonyl-3- thienyloxy)butyric acid; 4-(2-(9-Carboxynonanoylamino)-4-methylsulfonyl-3- thienyloxy)butryic acid;
4-(2-(12-Carboxydodecanoylamino)-5-trifluoromethyl-3~ thienyloxy)butyric acid;
5-(2-(11-Carboxyundecanoylamino)-5-chloro-3-thienyloxy)valeric acid;
4-(2-(11-Carboxyundecanoylamino)-4-methyl-5-phenyl-3- thienyloxy)butyric acid;
4-(2-(11-Carboxyundecanoylamino)-5-methylamino-3- thienyloxy)butyric acid;
4-(2-(12-Carboxydodecanoylamino)-5-dimethylamino-3- thienyloxy)butyric acid;
4-(2-(11-Carboxyundecanoylamino)-3-thienyloxy)butyric acid;
4-(2-(20-Phosphonoeicosanoylamino)phenoxy)butyric
acid;
4-(2-(19-Phosphonononadecanoylamino)phenoxy)butyric acid;
4-(2-(17-Sulfoheptadecanoylamino)phenoxy)butyric
acid;
4-(2-(16-Sulfinohexadecanoyl-N-methylamino)phenoxy)- butyric acid;
4-(2-(15-Thiosulfatopentadecanoylamino)phenoxy)
butyramide sodium salt;
4-(2-(14-Phosphonotetradecanoyl-N-methylamino)phenoxy) butyric acid;
4-(2-(12-Sulfododecanoylamino)phenoxy)butyric acid; 4-(2-(11-Sulfoundecanoylamino)phenoxy)butyric acid; 4-(2-(10-Sulfinodecanoylamino)phenoxy)butyric acid; 4-(2-(9-Thiosulfatononanoylamino)phenoxy)butyric
acid, sodium salt; 4-(2-(8-Thiosulfatoctanoylamino)phenoxy)butyric acid, sodium salt;
4-(2-(7-Sulfinoheptanoylamino)phenoxy)butyric acid; 4-(2-(6-Phosphonohexanoylamino)butyric acid;
4-(2-(19-Sulfononadecanoylamino)phenylthio)butyric acid;
4-(2-(18-Sulfinooctadecanoylamino)phenylthio)butyric acid;
4-(2-(17-Thiosulfatoheptadecanoyl N-ethylamino)phenylthio)butyric acid;
4-(2-(16-Phosphonohexadecanoylamino)phenylthio)
butyric acid;
4-(2-(14-Sulfotetradecanoylamino)phenylthio)butyric acid;
4-(2-(13-Sulfinotridecanoylamino)butyric acid;
4-(2-(12-Thiosulfatododecanoylamino)phenylthio)butyric acid, salt sodium;
4-(2-(11-Phosphonoundecanoylamino)phenylthio)butyric acid;
4-(2-(10-Sulfinodecanoylamino)phenylthio)butyric
acid;
4-(2-(9-Carboxynonanoylamino)phenylthio)butanesulfonic acid;
4-(2-(8-Carboxyoctanoylamino)phenylthio)butanesulfinic acid;
4-(2-(7-Carboxyheptanoylamino)phenylthio)butanethiosulfonic acid;
4-(2-(20-Carboxyeicosanoylamino)thio)phenoxy)butanephosphonic acid;
4-(2-(19-Carboxynonadecanoylamino)phenoxy)butanesulfonic acid; 4-(2-(18-Carboxyoctadecanoyl-N-butylamino)phenoxy)butane-sulfinic acid;
4-(2-(17-Carboxyheptadecanoylamino)phenoxy)butanethiosulfonic acid;
4-(2-(15-Carboxypentadecanoylamino)phenoxy)butanephosphonic acid;
4-(2-(14-Carboxytetradecanoylamino)phenoxy)butanesulfonic acid;
4-(2-(13-n-Carboxytridecanoylamino)phenoxy)butanesulfinic acid;
4-(2-(12-Carboxydodecanoylamino)phenoxy)butanethiosulfonic acid, sodium salt;
4-(2-(10-Carboxydecanoylamino)phenoxy)butanephosphonic acid;
4-(2-(9-Carboxynonanoylamino)phenoxy)butanesulfonic acid;
4-(2-(8-Carboxyoctanoylamino)phenoxy)butanesulfinic acid;
4-(2-(7-Carboxyheptanoylamino)phenoxy)butanethiosulfonic acid, sodium salt;
4-(2-(20-Carboxyeicosanoylamino)phenylthio)butanephosphonic acid;
4-(2-(19-Carboxynonadecanoyl-N-methylamino)phenylthio)butanesulfonic acid;
4-(2-(18-Carboxyoctadecanoylamino)phenylthio)butanesulfonic acid;
4-(2-(17-Carboxyheptadecanoylamino)phenylthio)butanesulfinic acid;
4-(2-(16-Carboxyhexadecanoylamino)phenylthio)butanethiosulfonic acid, sodium salt; 4-(2-(14-Carboxytetradecanoyl N-propylamino)phenylthio)butanephosphonic acid;
4-(2-(13-Carboxytridecanoylamino)phenylthio)butanesulfonic acid;
4-(2-(12-Carboxydodecanoylamino)phenylthio)butanesulfinic acid;
4-(2-(11-Carboxyundecanoylamino)phenylthio)butanethiosulfonic acid, sodium salt;
4-(2-(9-Carboxynonanoylamino)phenylthio)butanephosphonic acid;
4-(2-(8-Carboxyoctanoylamino)phenylthio)butanesulfonic acid;
4-(2-(7-Carboxyheptanoylamino)phenylthio)butanesulfinic acid;
4-(2-(6-Carboxyhexanoylamino)phenylthio)butanethiosulfonic acid, sodium salt;
3-(2-(15-Carboxyisohexadecanoylamino)phenoxy)
isobutanephosphonic acid;
3-(2-(14-Carboxytetradecanoylamino)phenoxy)isobutanoic acid;
5-(2-(13-Carboxytridecanoylamino)phenoxy)pentanesulfinic acid;
5-(2-(12-Phosphonododecanoylamino)phenoxy)valeramide; 5-(2-(11-Sulfoundecanoylamino)valeric acid;
5-(2-(10-Sulfinodecanoyl N-methylamino)phenoxy valeric acid;
5-(2-(9-Thiosulfatononanoylamino)phenoxy)valeric acid, sodium salt;
6-(2-(9-Phosphonononanoylamino)phenoxy)caproic acid; 6-(2-(7-Sulfoisooctanoyl-N-methylamino)phenoxy)
caproic acid; 7-(2-(7-Sulfinoheptanoyl-N-ethylamino)phenoxy) enanthic acid;
7-(2-(6-Thiosulfatohexanoylamino)phenoxy)enanthamide, sodium salt
7-(2-(5-Phosphonoisohexanoylamino)phenoxy)enanthic acid;
2-(2-(11-Sulfoundecanoylamino)phenoxy)acetic
acid;
2-(2-(10-Sulfodecanoyl-N-propylamino)phenoxy)acetic acid;
3-(2-(9-Sulfinononanoylamino)phenoxy)propionic acid; 3-(2-(12-Thiosulfatododecanoylamino)phenylthio)
propionamide, sodium salt;
3-(2-(11-Phosphonoundecanoylamino)phenylthio)
propionic acid;
3-(2-(11-Sulfoundecanoylamino)-4-methyl-phenylthio) isobutyric acid;
3-(2-(12-Sulfinododecanoylamino)phenylthio)
isobutyramide;
5-(2-(11-Thiosulfoundecanoyl-N-butylamino)phenylthio) valeric acid, sodium salt;
5-(2-(10-Phosphonodecanoylamino)phenylthio)valeric acid;
5-(2-(12-Phosphonododecanoylamino)phenylthio)
pentane-sulfonic acid;
5-(2-(11-Carboxydecanoylamino)phenylthio)
pentane sulfinic acid;
5-(2-(10-Phosphonodecanoylamino)phenylthio)pentane- thiosulfonic acid;
6-(2-(12-Phosphonododecanoylamino)phenylthio)hexane- phosphonic acid; 4-(2-(11-Sulfinoundecanoylamino)4-methyl-phenoxy) butane-thiosulfonic acid, sodium salt;
4-(2-(12-Sulfododecanoylamino)6-methylphenoxy)butane sulfonic acid;
4-(2-(11-Sulfodecanoylamino)3-chloro)phenylthio)- butane-sulfinic acid;
4-(2-(10-Sulfodecanoylamino)4-methyIphenoxy)butane- thiosulfonic acid, sodium salt;
4-(2-(12-Sulfododecanoylamino)6-methylphenoxy)- butane-phosphonic acid;
5-(2-(11-Sulfinoundecanoylamino)-3-methylphenyl- thio)pentane-sulfonic acid;
4-(2-(11-Sulfinoundecanoylamino)-3-methylsulfonyl- phenoxy)butane-sulfinic acid;
4-(2-(11-Sulfinoundecanoylamino)-4-methylsulfonyl)- phenylthio)butanesulfόnic acid;
4-(2-(12-Sulfinododecanoylamino)5-ethyl-phenoxy)- butane-phosphonic acid;
4-(2-(10-Sulfinodecanoylamino)-3,5-dimethylphenoxy)- butane-sulfonic acid;
4-(2-(9-Thiosulfatononanoylamino)-4-fluoro-phenoxy) butane-sulfinic acid, sodium salt;
4-(2-(12-Thiosulfatododecanoylamino)-5-trifluromethyl- phenoxy)butane-thiosulfonic acid, sodium salt; 4-(2-(10-Thiosulfatodecanoylamino)-4-hydroxyphenylthio)butane-phosphonic acid, sodium salt; 4-(2-(9-Phosphonononanoylamino)-3,5-dimethoxyphenyl- thio)butyric acid;
5-(2-(11-Sulfoundecanoylamino)-4-nitrophenoxy)- valeric acid; 4-(2-(11-Sulfinoundecanoylamino)-5-amino-3-methylphenoxy)butyric acid;
4-(2-(11-Thiosulfatoundecanoylamino)-5-amino-4-methylphenylthio)butyric acid, sodium salt;
4-(2-(12-Phosphonododecanoylamino)-4-dimethyl-aminophenoxy)butyric acid;
4-(2-(10-Sulfodecanoylamino)-phenoxy)butyric acid; 3-(2-(9-Sulfinononanoylamino)phenoxy)propionic acid; 3-(2-(12-Thiosulfatododecanoylamino)phenoxy)-3-methylpropionic acid, sodium salt;
3-(2-(11-Phosphonodecanoylamino)thienyloxy)-2-chloropropionic acid;
4-(2-(9-Sulfononanoylamino)thienyloxy-3-ethoxybutyric acid;
4-(2-(12-Sulfinododecanoylamino)phenoxy)-2-fluorobutyric acid;
7-(2-(11-Thiosulfatoundecanoylamino)phenoxy)6-aminoenanthic acid, sodium salt;
5-(2-(11-Phosphonoundecanoylamino)-3-methyIphenoxy)-4- oxo-valeric acid;
4-(2-12-Sulfododecanoylamino)phenoxy)but-2-enoic
acid;
4-(2-(11-Sulfinodecanoylamino)phenoxy)but-2-enoic
acid;
4-(2-(10-Thiosulfatodecanoylamino)phenoxy)-4-methylene valeric acid, sodium salt;
4-(2-(9-Phosphonononanoylamino)phenoxy)-4-fluoro-2- butenoic acid;
4-(2-(11-Sulfo-3-methylbutanoylamino)thienyloxy)- butyric acid; 4-(2-(4-Sulfino-3-chlorobutanoylamino)thienyloxy)- butyric acid;
4-(2-(9-Thiosulfato-2-methoxynonanoylamino)thienyloxy)butyric acid, sodium salt;
4-( 2-(4-Phosphono-2-ethoxybutanoylamino)phenoxy)
butyric acid;
4-(2-(14-Sulfo-14-fluoro-2-acetamidotetradecanoylamino)-3-methylphenoxy)butyric acid;
4-(2-13-Sulfino-2-oxotridecanoylamino)-4-methylthio)- phenyloxy)butyric acid;
4-(2-(12-Thiosulfatododecanoyl-3-en-amino)phenoxy) butyric acid;
4-(2-(11-Phosphonoundecanoyl-7-ene-amino)phenoxy)
butyric acid;
4-(2-(4-Sulfo-2-fluoro-2-butenoylamino)phenoxy)- butyric acid;
4-(2-(12-Sulfinododecanoylamino)-4-methyl-3-pyridyloxy)butyric acid;
4-(2-(11-Thiosulfatoundecanoylamino)-4-methyl-3- pyridyloxy)butyric acid;
4-(2-(10-Phosphonodecanoylamino)-5-methyl-3pyridyloxy)butyric acid;
4-(2-(11-Sulfinodecanoylamino)-4-nitro-3-pyridylthio- butyric acid;
4-(2-(10-Thiosulfatodecanoylamino)-6-methylsulfonyl-3- pyridyloxy)butyric acid, sodium salt;
4-(2-(9-Phosphonononanoylamino)5-chloro-3-pyridylthio)butyric acid;
4-(2-(11-Sulfoundecanoylamino)5-methylsulfonyl-3- pyridylthio)butyric acid; 4-(2-(11-Sulfinoundecanoylamino)-6-methyl-3-pyridylthio)butyric acid;
4-(2-(11-Thiosulfatoundecanoylamino)-4,6-dimethyl-3- pyridyloxy)butyric acid, sodium salt;
4-(2-(12-Phosphonododecanoylamino)-5-(methylthio)-3- pyridyloxy)butyric acid;
4-(2-(10-Sulfodecanoylamino)-5-methoxy-3-pyridyloxy) butyric acid;
4-(2-(9-Sulfinononanoylamino)-4-fluoro-6-methyl-3- pyridyloxy)butyric acid;
4-(2-(12-Thiosulfatododecanoylamino)5-(methylamino)-3- pyridyloxy)butyric acid, sodium salt;
4-(2-(11-Phosphonoundecanoylamino)4-phenyl-3-pyridylthio)butyric acid;
4-(2-(9-Sulfounonanoylamino)6-methoxy-3-pyridylthio) butyric acid;
4-(2-(12-Sulfinododecanoylamino)-6-trifluoromethyl-3- pyridyloxy)butyric acid;
5-(2-(11-Thiosulfatoundecanoylamino)-4-methyl-3-thiophenyloxy)valeric acid, sodium salt;
4-(2-(11-Phosphonoundecanoylamino)-4-methyl-3-thiophenyloxy)butyric acid;
4-(2-(12-Sulfododecanoylamino)-5-methyl-3-thiophenylthio)butyric acid;
4-2(-(11-Sulfinoundecanoylamino)-4-methyl-3-thiophenylthio)butyric acid;
4-(2-(10-Thiosulfatodecanoylamino)-5-methyl-3- thienylthio)butyric acid, sodium salt;
4-(2-(9-Phosphonononanoylamino)-4-hydroxy-3- thienyloxy)butyric acid: 4-(2-(11-Sulfodecanoylamino)-4-methylthio-3- thienyloxy)butyric acid;
4-(2-(10-Sulfinodecanoylamino)-4-methylsulfonyl-3- thienyloxy)butyric acid;
4-(2-(9-Thiosulfatononanoylamino)-4-methylsulfonyl-3- thienyloxy)butryic acid, sodium salt;
4-(2-(12-Phosphonododecanoylamino)-5-trifluoromethyl- 3-thienyloxy)butyric acid;
4-(2-(11-Sulfoundecanoylamino)-4-methyl-5-phenyl-3- thienyloxy)butyric acid;
4-(2-(11-Sulfinoundecanoylamino)-5-methylamino-3- thienyloxy)butyric acid;
4-(2-(12-Thiosulfatododecanoylamino)-5-dimethylamino- 3-thienyloxy)butyric acid, sodium salt;
4-(2-(11-Phosphonoundecanoylamino)-4-amino-3- thienyloxy)butyric acid;
Preferred compounds in the invention include: 4-(2-(11-Carboxyundecanoylamino)phenoxy)butyric acid, 4-(2-(11-Carboxyundecanoylamino)phenylthio)butyric
acid,
4-(2-(9-Carboxynonanoylamino)phenoxy)butyric acid, 4-(2-(10-Carboxydecanoylamino)phenoxy)butyric acid, 4-(2-(12-Carboxydodecanoylamino)phenoxy)butyric acid, 4-(2-(13-Carboxytridecanoylamino)phenoxy)butyric acid, 4-(2-(15-Carboxypentadecanoylamino)phenoxy)butyric
acid,
4-(2-(11-Carboxyundecanoylamino)-4-methylphenoxy)- butyric acid,
4-(2-(11-Carboxyundecanoylamino)-5-methylphenoxy)- butyric acid. Also included as a 5α-reductase inhibitor in this invention is an agent of the following formula:
Figure imgf000154_0001
wherein
A is an 1,2-disubstituted aromatic ring, preferably a benzene ring;
D is OH, NH2, NHRC, ORC;
X is O, S, SO, or SO2;
R is H,
C1-C4 alkyl,
phenyl or substituted phenyl,
halo,
haloalkyl,
hydroxy,
carboxy,
cyano,
C1-C4 alkoxy,
C1-C4 alkylthio,
C1-C4 alkylsulfinyl,
C1-C4 alkylsulfonyl,
nitro,
amino,
C1-C4 mono or di-alkylamino; R' and R" are independently
H,
halo,
C1-C4 alkyl or C1-C4 alkoxy,
amino, or oxo, where CH-R' or CH-R''
in the formula become -C=O;
Ra is H, C1-C4 alkyl;
Rb, Rc are independently, C1-C12 alkyl, phenyl, phenyl-C1-C4 alkyl; n is 0-2; y is 1-6; z is 6-20; and wherein and
Figure imgf000155_0001
can independently represent substituted or unsubstituted alkyl radicals or alkenyl radicals containing at least one alkene bond;
and pharmaceutically acceptable salts and esters thereof.
The compounds of the instant invention are inhibitors of the human testosterone 5α-reductase.
The scope of the compounds of the instant invention are described by the above-described formula. In the description of the formula the following terms are used which are hereby defined:
X can be 0 or S, preferably one X being 0, and particularly preferred wherein both Xs are 0, i.e., the catechol structure.
"C1-C4 alkyl" includes linear or branched species, e.g. methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, t-butyl; and "C1-C12 alkyl" includes alkyl up to 12 carbons including n-octyl, t-decyl, n-dodecyl.
"Phenyl C1-C4 alkyl" includes benzyl,
2-phenethyl, and the like;
"C1-C4 alkoxy" includes linear or branched species, e.g., methoxy, ethoxy, n-propoxy,
isopropoxy, n-butoxy, isobutoxy, sec-butoxy, t-butoxy;
"Halo" includes fluoro, chloro, bromo or iodo;
"Substituted phenyl" includes phenyl substituted by one or more of C1-C4 alkyl, C1-C4 alkoxy, or halo, and the like, as defined above;
representative examples include o, m-, p-methoxy phenyl; 2,4-dimethoxyphenyl; 2-chloro-4-ethoxyphenyl; 3,5-dimethoxyphenyl; 2,4-dichlorophenyl; 2-bromo-4-methylphenyl, o-fluorophenyl, and the like.
"Haloalkyl" includes C1-C4 alkyl, defined above, substituted with one or more "halo" as defined above and includes: trifluoromethyl,
2,2-dichloroethyl and the like.
"C1-C4 alkylthio" includes C1-C4 alkyl, defined above, substituted with at least one
divalent thio (-S-) grouping including; methylthio, ethylthio, isopropylthio, n-butylthio, and the like. "C1-C4 alkylsulfinyl" includes C1-C4 alkyl, defined above, substituted with at least one -SO- grouping including; methylsulfinyl, ethylsulfinyl; isopropylsulfinyl, and the like.
"C1-C4 alkylsulfonyl" includes C1-C4 alkyl, defined above, substituted with at least one sulfonyl group, -SO2-, including; methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, and the like;
"C1-C4 mono or dialkyl amino" includes amino, substituted with one or more C1-C4 alkyl groups as defined hereinabove, including: methylamino, ethylamino, n-butylamino, t-butylamino, dimethylamino, N,N-diethylamino, methyl-t-butylamino, and the like.
The R group or groups on the benzene ring can be present initially in the process, e.g. phenyl, methyl, methoxy, cyano, carbomethoxy,
trifluoromethyl, (present as in the starting
6-nitrophenol 1 in Flow Chart A) or added later by a conventional reaction, e.g. chloro, as by
chlorination, nitro by nitration, or created from a starting or added functional group present, e.g.
converting a later added nitro to an amino group by catalytic reduction, then alkylating to a mono or dialkylamine. An amino group can be subjected to diazotization to a hydroxy group, which can be
followed by methylation to a methoxy group.
Similarly, a hydroxy group can be converted to a thiol by the analogous procedures described in J.
Org. Chem. 21, pp 3980-3984 (1966) by Newman and
Karnes, and J. Org. Chem. 21, pp 410 (1966) by Kwart, H. and Evans, E.S. The resulting thiol can be alkylated to alkylthio, which can be oxidized to the corresponding sulfoxide or sulfone. Preferred substituents are H, C1-C4 alkyl, C1-C4 alkoxy and phenyl. These reactions and sequences are
conventional in the art and it will be obvious to one skilled in the art to modify the benzene ring to arrive at an R radical disclosed herein.
By the term "pharmaceutically acceptable salts and esters thereof" is meant salts and esters of the acid groups in the final molecule which can be used as part of the human drug delivery system and include the salts: sodium, potassium, calcium,
ammonium, substituted ammonium, quaternary ammonium, and esters: ethyl ester, aceturate, besylate, edetate, phenpropionate, acetate, pamoate, and esters which serve as "prodrug" formulations which will hydrolyze in the body at physiological pH's to regenerate the acid, including pivaloylates, e.g. pivoxetil and pivoxil, and Kanebo esters, and the like. where y is 1-6, preferably 3, can
Figure imgf000158_0001
contain at least one R' substituent as defined above, and can be, e.g., -CH2-; -CH2-CH2-; -CH2-CH2-CH2-;
-CH-; -CH-CH2-; ; ; ; CH3 CH3
Figure imgf000158_0002
Figure imgf000158_0003
Figure imgf000158_0004
;
Figure imgf000158_0005
and the like. An alkene bond can also be present in
Figure imgf000159_0001
e.g., CH2-CH=CH-; CH2-CH=CH-CH2- ; -CH2-CH=CH-; -(CH2)3-CH=CH- and the like. where z is 6-20, preferably 8-14, can
Figure imgf000159_0002
contain at least one R" substituent as defined above, and can be completely alkyl; e.g., (CH2)n-COOH, where n is 8-14 preferably and the like.
An alkene bond can also be present in e.g., -(CH2)4-CH=CH-(CH2)4-, and the like.
Figure imgf000159_0005
Preferred is where one R' or R" is H and particularly preferred is where both and
Figure imgf000159_0003
Figure imgf000159_0004
are alkyl.
Preferred compounds of the instant invention are given by the following formulas;
Figure imgf000160_0001
wherein R, R' , R", Y, Z, Rb are defined above; and particularly preferred are:
Figure imgf000160_0002
Figure imgf000160_0003
where n is 8-14, and Rb is methyl, ethyl, cyclopropyl, isopropyl, n-propyl, t-butyl, phenyl or benzyl.
The compounds of the instant invention can be made by the procedures outlined in the following Flowcharts.
Figure imgf000161_0001
Figure imgf000162_0001
Figure imgf000163_0001
Figure imgf000164_0001
As seen in Flow Chart A-3, o-nitrophenol 1, ethyl 4-bromobutyrate 2 and anhydrous K2CO3 in e.g., dry acetone are heated at reflux e.g. for 12-100 hours, or stirred for an extended period of time at room temperature, under a nitrogen atmosphere to product ethyl 4-(2-nitrophenoxy) butyrate 3, in Step (A).
A solution of 3 in e.g., ethyl acetate is catalytically hydrogenated at room temperature under e.g. 40 psig of H2 in the presence of a 5% Pd/C catalyst to yield ethyl 4-(2-aminophenoxy)butyrate 4 in Step (B).
Step (C) comprises reacting the 12-bromo dodecanoic acid 5. with isopropyl mercaptan in a suitable solvent, e.g., dimethoxyethane, at about 80-85ºC to obtain the acid 6.
In Step (D) the mono acid & is reacted with the amine it and N'N'-dicyclohexylcarbodiimide (DCC) at e.g., room temperature in e.g., dry methylene chloride, optionally in the presence of 4-dimethyl- aminopyridine, to produce the amide 7.
In Step (E), the ether-amide 7 is
de-esterified by e.g., 2.5 N NaOH in MeOH/H2O to yield the final product, monoacid 8.
The monoacid 8 can be treated with NaI04 in
(acetone/water) at room temperature for (4-24 hours) to produce the corresponding sulfoxide 8a.
Additionally, 8 can be treated with meta-chlorobenzoic acid in (CH2CI2) at a temperature of about 0º to 25ºC for (1-24 hours) to produce the corresponding sulfone 8b. In Step (F) the ester 7 is treated with ammonia in (methanol) at room temperature for, e.g., 1-7 days to produce the amide 9.
Flow Chart B-3 illustrates the synthesis of the sulfur analogs of the invention compounds.
In Step G, the orthoaminothiophenol is reacted with the bromoester 2. under conditions similar to Step A to produce the thioether 11.
In Step (H), the thiother 11 is reacted with an alkylthioalkanoic acid under similar conditions using DCC analogously as in Step D to produce the acylated ester 12.
In Step I, the ester 12. is hydrolyzed to produce the free thio acid 12, which has the
5-α-reductase activity described herein.
As seen in Flow Chart C-3, the compound 13 can further be oxidized to the sulfoxide in Step Ja, starting with the thio compound 14 to produce the sulfoxide 11, which can be hydrolyzed, analogous to the conditions in Step I to produce the active acid
16..
In a similar manner, 14 can be converted to the sulfone-ester 17, which can then be hydrolyzed analogous to the conditions in Step I to the
corresponding acid 18.
Alternatively, the sulfur in o-nitrobenzene thiol as a separate starting material analogous to 1, can be coupled to yield the ester alkylthio compound corresponding to 3 which can be oxidized to the corresponding sulfoxide or sulfone, then followed by reduction of the nitro group to the amino and then coupled with a suitable reagent e.g., 6, to yield the linear amide containing unoxidized sulfur analogous to 7. A further modification is where the
sulfuracylating agent is first oxidized to the
corresponding sulfoxide or sulfone, then coupled with the amino group of e.g., 11 to yield e.g. 13
containing only an oxidized sulfur in the amide chain.
It is obvious that other nitrophenols can be substituted for 1 in Flow Chart A-3 to provide the scope of the compounds covered by this invention and include the following:
2-nitrophenol
2-nitro-6-methylphenol
2-nitro-5-methylphenol
2-nitro-4-methylphenol
2-nitro-3-methylphenol
2-nitro-4-phenylphenol
2-nitro-5-phenylphenol
2-nitro-4-chlorophenol
2-nitro-4-(trifluoromethyl)phenol
2-nitro-4-methoxyphenol
2-nitro-6-ethoxyphenol, and the like,
Starting materials for Flow Charts B-3 and C-3 in addition to Ifi are commercially available and readily made by prior art procedures and include all of the above listed compounds where - SH is
substituted for -OH, ortho to the nitro group. Other starting materials for 2 in both Flow Charts A-3 and B-3 include the following:
Br-CH2-COOMe,
Cl-CH2CH2CH2COOCH(CH3)3,
Br-CH2CH2CH2CH2COOMe,
Br-CH2CH2CH2CH2CH2COOEt,
Br-CH2CH2CH2CH2CH2CH2COOCH2CH2CH2CH3,
Br-CH2CH(CH3)COOMe,
Br-CH2CH(CH3)CH2COOEt,
Br-CH2CH2CH2COOMe,
Br-CH2CH(OCH3)CH2COOCH(CH3)2,
Cl-CH2CH(OCH2CH3)CH2COOMe,
Br-CH2CH(F)CH2COOMe,
and the like.
Other starting materials for the acid & to produce the acid for acylating the amino group in 4 or 11 include the following:
MeS-(CH2)6COOH,
MeS-(CH2)7COOH,
(CH3)2CHS-(CH2)8COOH,
EtS-(CH2)9COOH,
CH3CH2CH2S(CH2)10COOH,
(CH3)2CHS(CH2)11COOH,
MeS-(CH2)12COOH,
EtS-(CH2)13COOH,
CH3CH2CH2S-(CH2)14COOH,
(CH3)2CHS-(CH2)15COOH,
CH3(CH2)3S-(CH2)16COOH,
(CH3)2CH-CH2S-(CH2)17COOH, CH3-CH2-CH2-S-(CH2)18COOH,
(CH3)2CHS-(CH2)19COOH,
EtS-(CH2)20COOH,
MeS-CH(CH3)-(CH2)10COOH,
(CH3)2CHS-CH2CH2CH(CH3)CH2COOH,
Figure imgf000169_0001
EtS-CH2CH(OCH3)(CH2)7COOH,
CH3CH2CH2S-CH2CH(OCH2CH3)CH2CH2COOH,
CH3(CH2)7-S-CH2-COOH
(CH3)2CH(CH2)5-S-CH2-COOH
CH3(CH2)9-S-CH2-COOH
CH3(CH2)11S-CH2COOH, and the like. Representative compounds of the instant invention include, but are not limited to:
4-(2-(20-Isopropylthioeicosanoylamino)phenoxy)butyric acid;
4-(2-(19-Methylthiononadecanoylamino)phenoxy)butyric acid;
4-(2-(18-Ethylthioloctadecanoylamino)phenoxy)butyric acid;
4-(2-(17-Isopropylthioheptadecanoylamino)phenoxy)- butyric acid;
4-(2-(16-Methylthiohexadecanoylamino)phenoxy)butyric acid;
4-(2-(15-Methylsulfinylpentadecanoylamino)phenoxy)- butyric acid;
4-(2-(14-Methylsulfinyltetradecanoylamino)phenoxy)- butyric acid;
4-(2-(13-n-Propylthiotridecanoylamino)phenoxy)- butyric acid; 4-(2-(12-n-Butylsulfinyldodecanoylamino)phenoxy)- butyric acid;
4-(2-(11-sec-Butylthioundecanoylamino)phenoxy)- butyric acid;
4-(2-(10-phenylthiodecanoylamino)phenoxy)-butyric
acid;
4-(2-(10-benzylthiodecanoylamino)phenoxy)-butyric
acid;
4-(2-(10-iso-Butylsulfonyldecanoylamino)phenoxy)- butyric acid;
4-(2-(9-t-Butylthiononanoylamino)phenoxy)butyric
acid;
4-(2-(8-Ethylsulfonyloctanoamino)phenoxy)butyric acid; 4-(2-(7-Isopropylthioheptanoylamino)phenoxy)butyric acid;
4-(2-(6-Methylthiohexanoylamino)butyric acid;
4-(2-(20-Ethylsulfonyleicosanoylamino)phenylthio)- butyric acid;
4-(2-(19-Isopropylthiononadecanoylamino)phenylthio)- butyric acid;
4-(2-(18-Methylthiooctadecanoylamino)phenylthio)- butyric acid;
4-(2-(17-Ethylthioheptadecanoylamino)phenylthio)- butyric acid;
4-(2-(16-Isopropylhexadecanoylamino)phenylthio)~
butyric acid;
4-(2-(15-Methylthiopentadecanoylamino)phenylthio)- butyric acid;
4-(2-(14-Methylsulfinyltetradecanoylamino)phenylthio- butyric acid;
4-(2-(13-Methylsulfonyltridecanoylamino)butyric acid; 4-(2-(12-n-Propylthiododecanoylamino)phenylthio)- butyric acid;
4-(2-(11-n-Butylsulfinylundecanoylamino)phenylthio)- butyric acid;
4-(2-(10-sec-Butylthiodecanoylamino)phenylthio)- butyric acid;
4-(2-(10-phenylthiodecanoylamino)phenylthio)-butyric acid;
4-(2-(10-benzylthiodecanoylamino)phenylthio)-butyric acid;
4-(2-(9-iso-Butylsulfonylnonanoylamino)phenylthio)- butyric acid;
4-(2-(8-t-Butylthiooctanoylamino)phenylthio)butyric acid;
4-(2-(7-EthylsulfinyIneptanoylamino)phenylthio
butyric acid;
4-(2-(6-Isopropylthiohexanoylamino)phenylthio
butyric acid;
3-(2-(16-Methylsulfinylhexadecanoylamino)phenoxy)- propionic acid;
4-(2-(15-Methylsulfonylisohexadecanoylamino)phenoxy)- butyric acid;
3-(2-(14-n-Propylthiotetradecanoylamino)phenoxy)- isobutyric acid;
5-(2-(13-n-Butylsulfinyltridecanoylamino)phenoxy)- valeric acid;
5-(2-(12-sec-Butylthiododecanoylamino)phenoxy)- valeric acid;
5-(2-(11-iso-Butylsulfonylisododecanoylamino)- valeric acid;
5-(2-(11-t-Butylthioundecanoylamino)valeric acid; 5-(2-(10-Ethylsulfinyldecanoylamino)valeric acid; 5-(2-(9-Isopropylthiononanoylamino)phenoxy)valeric acid;
6-(2-(9-Methylthiononanoylamino)phenoxy)caproic acid; 6-(2-(8-Ethylthiooctanoylamino)phenoxy)caproic acid; 6-(2-(7-Isopropylthioisooctanoylamino)phenoxy)caproic acid;
7-(2-(7-Methylheptanoylamino)phenoxy)enanthic acid; 7-(2-(6-Methylsulfinylhexanoylamino)phenoxy)enanthic acid;
7-(2-(5-Methylsulfonylisohexanoylamino)phenoxy)- enanthic acid;
2-(2-(12-n-Propylthiododecanoylamino)phenoxy))acetic acid;
2-(2-(11-n-Butylsulfinylundecanoylamino)phenoxy)acetic acid;
2-(2-(10-sec-Butylthiodecanoylamino)phenoxy)acetic
acid;
3-(2-(9-iso-Butylsulfonylnonanoylamino)propionic
acid;
3-(2-(12-t-Butylthiododecanoylamino)phenylthio)- propionic acid;
3-(2-(11-Ethylsulfinylundecanoylamino)phenylthio)- propionic acid;
4-(2-(11-Isopropylthioundecanoylamino)phenylthio)- butyric acid;
4-(2-(11-Methylthioundecanoylamino)-4-methyl-thio- phenoxy)butyric acid;
4-(2-(12-Ethylthiododecanoylamino)phenylthio)- butyric acid;
5-(2-(11-Isopropylthioundecanoylamino)phenylthio)- valeric acid; 5-(2-(10-Methylthiodecanoylamino)phenylthio)valeric acid;
5-(2-(9-Methylsulfinylnonanoylamino)phenylthio)- valeric acid;
5-(2-(12-Methylsulfonyldodecanoylamino)phenylthio)- valeric acid;
5-(2-(11-n-Propylthiodecanoylamino)phenylthio)- valeric acid;
5-(2-(10-n-Butylsulfinyldecanoylamino)phenylthio)- valeric acid;
6-(2-(9-sec-Butylthiononanoylamino)phenoxy)caproic
acid;
6-(2-(12-iso-Butylsulfonyldodecanoylamino)phenylthio) caproic acid;
6-(2-(11-t-Butylthioundecanoylamino)phenylthio)- caproic acid;
7-(2-(11-Ethylsulfinylundecanoylamino)-3-methylphenylthio)enanthic acid;
7-(2-(11-Isopropylthioundecanoylamino)-4-methylphenyl- thio)enanthic acid;
7-(2-(12-Methylthiododecanoylamino)phenoxy)enanthic acid;
4-(2-(11-Phenylthioundecanoylamino)4-methyl-phenoxy)- butyric acid;
4-(2-(10-Benzylthiodecanoylamino)3-methylphenoxy)- butyric acid;
4-(2-(9-Methylthiononanoylamino)5-methylphenoxy)- butyric acid;
4-(2-(12-Methylsulfinyldodecanoylamino)6-methyl- phenoxy)butyric acid;
4-(2-(11-Methylsulfonyldecanoylamino)3-phenylthio)
butyric acid; 4-(2-(10-n-Propylthiodecanoylamino)4-methylphenoxy)butyric acid;
4-(2-(9-n-Butylsulfinylnonanoylamino)5-fluoromethylphenylthio)butyric acid;
4-(2-(12-sec-Butylthiododecanoylamino)6-methylphenoxy)butyric acid;
5-(2-(11-iso-Butylsulfonylundecanoylamino)-3-methylphenylthio)valeric acid;
4-(2-(11-t-Butylthioundecanoylamino)-3-methylsulfonylphenoxy)butyric acid;
4-(2-(11-Ethylsulfinylundecanoylamino)-4-methylsulfonylphenylthio)butyric acid;
4-(2-(12-Isopropylthiododecanoylamino)5-ethylphenoxy)butyric acid;
4-(2-(11-Methylthioundecanoylamino)4-phenyIphenoxy)- butyric acid;
4-(2-(10-Ethylthiodecanoylamino)-3,5-dimethyIphenoxy)- butyric acid;
4-(2-(9-Isopropylthiononanoylamino)-4-fluoro-phenoxy)- butyric acid;
4-(2-(12-Methylthiododecanoylamino)-5-trifluoromethylphenoxy)butyric acid;
4-(2-(11-Isopropylthio)undecanoylamino)phenoxy)butyric acid,
4-(2-(11-Ethylthio)undecanoylamino)phenylthio)butyric acid,
4-(2-(9-Isopropylthio)nonanoylamino)phenoxy)butyric acid,
4-(2-(10-Isopropylthio)decanoylamino)phenoxy)butyric acid, 4-(2-(12-Isopropylthio)dodecanoylamino)phenoxy)butyric acid,
4-(2-(13-Butylthio)tridecanoylamino)phenoxy)butyric acid,
4-(2-(15-t-Butylthio)pentadecanoylamino)phenoxy)butyric acid,
5-(2-(11-Isopropylthio)undecanoylamino)phenoxy)valeric acid,
4-(2-(11-Ethylsulfinyl)undecanoylamino)-phenoxy)butyric acid ,
4-(2-(11-Isopropylsulfonyl)undecanoylamino)-4-methylphenoxy)butyric acid,
4-(2-(11-Ethylsulfinyl)undecanoylamino)-5-methylphenoxy)butyric acid.
All of the compounds described above in the present invention, prepared in accordance with the methods described above, are, as already described, can be used to treat BPH in combination with an aromatase inhibitor, by oral, parenteral or topical administration.
In this invention, the aromatase inhibitor, and the 5α-reductase inhibitor are administered in combination separately or as one single combined pharmaceutical composition via parenteral or oral means. Preferably the aromatase inhibitor and the 5α-reductase inhibitor are administered orally as separate compositions. The amount of each component administered is determined by the attending clinicians taking into consideration the etiology and severity of the disease, the patient's condition and age, the potency of each component and other factors.
The aromatase inhibitor compositions are generally administered in a dosage range of about 10 to 400 mg/kg (body weight) per day with 50 to
250 mg per day in a single dose being preferred.
The 5α-reductase inhibitor compositions are generally administered in a dosage range of about 0.01 to 1.0 mg/kg (body weight) per day with one to 70 mg per day in one daily total dose being preferred.
In the preferred aspect of this invention, the aromatase inhibitor is fadrazole which is administered orally in a daily dose of about 100 mg/kg.
and the 5α-reductase inhibitor is finasteride, which is administered orally in a daily dose of about 10 mg/kg.
The aromatase inhibitor and the 5α-reductase inhibitor may be compounded into a single dosage form suitable for oral or parenteral administration. A tablet or capsule or caplets are particularly convenient forms for oral administration. Such compositions useful in the present invention are typically formulated with conventional pharmaceutical excipients, e.g., spray dried lactose and magnesium stearate into tablets or capsules for oral administration. One or more of the active substances, with or without additional types of active agents, can be worked into tablets or dragee cores by being mixed with solid, pulverulent carrier substances, such as sodium
citrate, calcium carbonate or dicalciυm phosphate, and binders such as polyvinyl pyrrolidone, gelatin or cellulose derivatives, possibly by adding also lubricants such a magnesium stearate, sodium lauryl sulfate, "Carbowax" or polyethylene glycols. Of course, taste improving substances can be added in the case of oral administration forms.
As further forms of administration, one can use plug capsules, e.g. hard gelatin, as well as closed softgelatin capsules comprising a softener or plasticizer, e.g. glycerine. The plug capsules contain the active substance preferably in the form of a granulate, e.g. in mixtures with fillers, such as lactose, saccharose, mannitol, starches such as potato starch or amylopectin, cellulose derivatives or highly-dispersed silicic acids. In soft gelatin capsules, the active substance is preferably dissolved or suspended in suitable liquids, such as vegetable oils or liquid polyethylene glycols.
The active ingredient components used in accordance with the present invention may also be formulated into once-a-day or even longer sustained release composition by conventional techniques well known in the art. In place of oral administration, the active compounds may be administered parenterally. In such case, one can use a solution of the active substance, e.g., in sesame oil or olive oil.
Following the above treatment using the described regimen, the symptoms of BPH including enlarged prostate volume, nocturia, increased
hesitancy, decreased urinary flow, are inhibited, in some cases prevented when treating androgen- dependent diseases such a benign prostatic
hypertrophy in accordance with this invention.
To assist in determining the effect of the prostatic treatment, blood plasma concentration of testosterone (T), dihydrotestosterone (DHT), estradiol and prostate acid phosphatase (PAP) as well as prostate volume, urinary flow rate, hesitancy and nocturia are measured. Lowered concentrations of DHT, estradiol, prostatic PAP and reduction in prostate volume, are indicative of successful treatment. The concentrations of the above-1isted components in plasma are measured by standard methods well known to those skilled in the art. (See, for example, R. Neri and M. Monahan, Invest. Urology (1972), 10, 123-130 for prostatic P staining and E. Nieschlay and D. L. Loriaux, Z. Klin Chem. Klin Biochem (1972), 4, 164 for radioimmunoassay determinations of T.) The prostate volume is measured by rectal examination and/or by transrectal ultrasonography. Objective assessment of the effect of treatment is also measured by physical methods well known to these skilled in the art of nuclear magnetic resonance imaging, as well as by physical examination.
Using a protocol similar to that described above, clinical trials on the effect of the combination of finasteride and fadrazole will exhibit an even greater effect on alleviating the symptoms of BPH in patients which will be greater than either agent alone. The method of preparing the compounds of the present invention, already described above in general terms, may be further illustrated by the following examples which should not be construed as being limitations on the scope or spirit of the instant invention.
CHAPTER 1
EXAMPLE 1
Methyl 3-oxo-4-aza-5α-andrpst-1-ene-17β-carbpxylate
A suspension of 83.7 g of methyl 3-oxo- 4-aza-5α-androstane-17-carboxylate* and 126.5 g of benzeneseleninic anhydride in 2.09 1 of chlorobenzene was heated at reflux for 2 hours. The reflux condenser was switched to a distillation head and the mixture was distilled slowly to remove water that had formed in the reaction (2 hours). The solution was evaporated to leave 198 g of wet residue. The resi due as a solution in dichloromethane was washed with saturated aqueous NaHCO3 solution and saturated NaCl solution, then dried and evaporated to leave 172.4 g. This material was chromatographed on 2.56 kg of silica gel eluting first with dichloromethane (5 1) and then with 4:1 dichloromethane acetone. The desired product eluted after 8 1 and amounted to 53.4 g. It was rinsed with diethyl ether and dried to leave 49.5 g, of the title compound m.p. 278-280ºC. In a similar fashion the following compounds were converted to their corresponding 1,2-unsaturated derivatives:
Figure imgf000180_0001
m.p.
1a R = CONHC(CH3)3 252-254ºC
1b = CONHC(CH3)2CH2C(CH3)3 224-226º
* Rasmusson Johnston and Arth.
U.S. Patent 4,377,584, March 22, 1983. EXAMPLE 2
Methyl 4-methyl-3-oxo-4-aza-5α-androst-1-ene-17β-carboxylate
A suspension of 25 g of the product of
Example 1 and 2.25 g of sodium hydride in 500 ml of dry dimethylformamide was stirred under nitrogen for 15 minutes. Methyl iodide (15 ml) was added dropwise and the mixture was stirred for 30 minutes at room temperature. Additional (5 ml) methyl iodide was added and the mixture was heated at 50ºC for 2 hours. After cooling the mixture was diluted with water to a volume of 2 liters. The solid was separated after cooling and amounted to 25.4 g, m.p. 159-161ºC.
In a similar fashion the following compounds were converted to their corresponding 4-methyl derivatives:
Figure imgf000181_0001
m.p.
2a R = CONHC(CH3)2CH2C(CH3)3, 148-150ºC
androstane
2b = CONHC(CH3)3; Δ-1-androstene 153-155°
2c = CONHC(CH3)2CH2C(CH3)3 168-170º
Δ-1-androstene EXAMPLE 3
S-(2-Pyridyl) 4-methyl-3-oxo-4-aza-5α-androst-1-ene- 17β-thiocarboxylate
A suspension of 25 g of the product of Example 2 in 125 ml of methanol was treated with a solution of KOH (*12.5 g) in 12.5 ml of water. After refluxing for 4 hours, the solution was acidified with 6 NHCl and then was diluted with water. The crude acid (23.32 g) was separated, dried and had m.p. 300ºC.
The crude, dry acid (23 g), triphenylphosphine (36.45 g) and 2,2'-dipyridyldisulfide
(30.4 g) were suspended in 138 ml of toluene with stirring for 3 hours at room temperature. The reaction mixture was directly chromatographed on a column of 4.5 kg of silica gel eluting with 9:1 ethyl acetate-acetone to give 20.4 g of the desired product, m.p. 218-220ºC.
Continued elution with acetone gave 5.2 g of the methanol addition product, S-(2-pyridyl) 1α-methoxy-4-methyl-3-oxo-4-aza-5α-androstane-17ß-thiocarboxylate, m.p. 221-223ºC as a by-product.
3A. In a similar fashion the product of Example 1 was converted into S-(2-pyridyl)
3-oxo-4-aza-5α-androst-1-ene-17ß-thiocarboxylate, m.p. 230-232ºC.
3B. In a similar manner methyl 3-oxo-4- aza-5α-androstane 17-carboxylate was converted into S-(2-pyridyl) 3-oxo-4-aza-5α-androstane-17β-thio-carboxylate, m.p. 232-234ºC. EXAMPLE 4
N-t-butyl 4-methyl-3-oxo-4-aza-5α-androst-1-ene- 17β-carboxamide
Anhydrous t-butylamine was added to a suspension of 2.5 g of the pyridylthioester of Example 3 in 70 ml of tetrahydrofuran. After 60 minutes exposure, the resulting solution was evaporated and the residue was chromatographed on 125 g of silica gel. Elution with 20:1 ethyl acetate dichloromethane afforded 1.5 g of the product, m.p. 152-154ºC.
When the example is repeated using an appropriate amine and an appropriate pyridylthioester, the following products were obtained:
4b: N-t-butyl 3-oxo-4-aza-5α-androstane-17ß- carboxamide, m.p. 275-276ºC.
4c: N-(2,4,4-trimethyl-2-pentyl) 4-methyl-3-oxo-4- aza-5α-androst-1-ene-17ß-carboxamide, m.p. 168- 170ºC. EXAMPLE 5
5-Oxo-3.5-secoetian-3,20-dioic acid To a solution of 200 g of 3-oxo-4-etien-17ß-oic acid in 3.5 1 of t-butanol at 80º was added a solution of 198.4 g of sodium carbonate in 474 ml of water. A warm (65ºC) solution of 948.5 g of sodium metaperiodate and 6.95 g of permanganate in 3.5 1 of water was added at such a rate that the reaction mixture was maintained at 80ºC. After addition the mixture was heated at reflux for one hour. The mixture stood at room temperature overnight. The inorganic salts were removed by filtration and the cake was washed with 225 ml of water . A solution of 5% aqueous sodium bisulfite was added to reduce the iodine that was present. The t-butanol was removed under reduced pressure and the aqueous residue was acidified with cone, hydrochloric acid. The separated gum was extracted into dichloromethane and was washed with 57. aqueous sodium bisulfite, saturated sodium chloride solution, then dried and concentrated to an off-white residue (214 g). Crystalline material was obtained by suspending the residue in ether and diluting with hexane to give 152 g, m.p. 189-192ºC.
EXAMPLE SB
3-Oxo-4-aza-5-etien-20-oic acid A suspension of 64.7 g of the dioic acid of Step 5 in 350 ml of ethylene glycol was treated with 80 ml of liquid ammonia. The resulting solution was heated at a rate of 3º/min. up to 180ºC and was held at that temperature for 15 minutes. After cooling, 1 liter of water was added and the mixture was
acidified with 10% hydrochloric acid to a pH of 1.5. The product was removed and washed with water, then air dried to leave 57.5 g of the product, m.p. 310ºC.
EXAMPLE 5C
3-Oxo-4-a3a-5α-etian-20-oic acid
A solution of 136 g of the 5-acid of Example 5B in 16.32 ml of acetic acid was hydrogenated at 60ºC in the presence of platinum catalyst (from 16.32 g of PtO2) at 40 psig for 3 hours. The catalyst was removed and the solution concentrated to give 128.2 g of crude product. The material was washed well with 3 1 of water then filtered an air dried to leave 125 g of the white solid, m.p. 310°. This material is also obtained by saponification of methyl 3-oxo-4-aza-5α-androstane-17ß- carboxylate (methyl 3-oxo-4-aza-5α-etien-17ß-oate) in 7% methanolic potassium hydroxide followed by an acidic work-up.
EXAMPLE 5D
N-(2,4,4-trimethyl-2-pentyl)3-oxo-4-aza-5α-andros-tane-17β-carboxamide
A solution of 5.0 g of the product of
Example 5C, 3.35 g of dicyclohexylcarbodiimide and 3.18 g of 1-hydroxybenztriazole in 500 ml of dichloromethane was stirred at room temperature overnight. The solid was separated by filtration and the filtrate was treated with 2,4,4-trimethyl-2-pentylamine (t-octylamine). This solution stood at room temperature for 64 hours. A small amount of solid was removed and the solution was washed successively with 10% aqueous sodium hydroxide, water, 10% hydrochloric acid and saturated aqueous sodium chloride. After drying and concentration the crude product was eluted through 240 g of silica gel with 3:7 acetone-dichloromethane to give 5.5 g of the product, m.p. 250-251°C.
EXAMPLE 5E
Example 5D is repeated using t-butylamine in place of 2,2,4-trimethyl-2-pentylamine to obtain N-t-butyl 3-oxo-4-aza-5α-androstane-17ß-carboxamide, m.p. 274-276ºC. EXAMPLE 6 Synthesis of 17β(N-1-adamantyl-carbamoyl)- 4-aza-5α-androst-1-en-3-one
100 mg of the 17-methyl ester (0.305 mmoles) from Example 1 was suspended in 3.0 ml of THF (dried over molecular sieves 3A), and then was added 183.0 mg of 1-adamantanamine (1.2 mmoles). The suspension was cooled to 5-10ºC and then 590 μl of 2.0 M solution, of EtMgBr in THF was added. The resulting mixture was allowed to stir for 10 minutes, and then refluxed for 1-2 hours under N2. The mixture was cooled to 0°C and then quenched with saturated solution of NH4CI (about 10 ml.). The organic layer was separated and the aqueous layer extracted with three volumes CH2Cl2.
The organic layers were combined, washed 2 times with H2O, twice with saturated sodium chloride, and dried over MgSO4, filtered and evaporated to dryness in vacuum. Crystallization from EtOAc
afforded 75.0 mg of product. Recrystallization from MeOH and drying at 110ºC for 2 hours/0.1 mm gave product, mpt. 305-306ºC. Molecular weight (by FAB) showed M+=451: Calculated =451.
Anal. Calcd. for C29H42N2O2:
C.77.28; H.9.40; N,6.21.
Found: C.76.84; H.9.73; N.5.93. EXAMPLE 7
Synthesis of 17β(N-2-adamantyl-carbamoyl)-4-aza-5α-androst-1-en-3-one
Following the above-described general procedure of Example 6 but utilizing 2-adamantamine (prepared by aqueous neutralization of the hydrochloride and EtOAc extraction and isolation) in place of 1-adamantamine, and carrying out the reflux for 7 hours rather than 1-2 hours, the title compound is prepared, mpt. 284-285ºC.
EXAMPLE 8 Synthesis of 17β(N-1-adamantylcarbamoyl)-4-aza-5α- androstane-3-one .
100.0 mg of the adamantyl derivative produced in Example 6 was dissolved in 5.0 ml of dry THF. 300 mg of 5% Pd/C was added and the mixture was hydrogenated for 6.0 hrs. at R.T. at 40 psi.
The mixture was filtered through celite, the cake washed with THF (3 times) and solvent evaporated under vacuum to yield 97.0 mg. of crude above-titled product. NMR showed absence of olefins. The crude material was placed on 15.0 g silica gel column, and eluated with 1:1(CH2Cl2: acetone).
Collected fractions afforded a single spot material by TLC weighing 77.98 mg. NMR was in excellent agreement with the proposed structure. Recrystallized from EtOAc to yield 65.59 mg of the above-titled product, mp. 323-324°C.
Anal. Calcd. for C29H44O2N2 1/4 H2O:
C.76.18; H.9.81; N,6.13.
Found: C75.91; H,9.97; N.6.06.
EXAMPLE 9
Synthesis of 17β(N-1-adamantylcarbamoyl)-4-methyl-4- aza-5α-androst-1-en-3-one
120 mg of the thiopyridyl ester of Example 3 was suspended in 20 ml of dry THF, to the suspension was added 175.0 mg of 1-adamantanamine under N2. The reaction was carried out at R.T. for 16 hours under N2. The reaction was monitored by silica gel TLC, using 1:1 acetone: hexane. The product was separated on TLC 20 cm × 20 cm, 1000 μm silica gel plate, eluted with 1:1 (acetone/hexane).
The product was crystallized from ethyl acetate, to give 50.0 mg of pure material m. pt. 202-205ºC.
Molecular Weight (FAB) showed 465; Calc: 465.
Recrystallization afforded 19.14 mg of the
above-titled product, m.pt. 202-202.5ºC.
Anal. Calcd for C30H44N2O2●H2O:
C.74.64; H.9.60; N.5.80.
Found: C74.32; H,9.47; N.5.89 EXAMPLE 10
Hydrolysis of Methyl-3-oxo-4-aza-5α-androstane-17β-carboxylate
The 17ß-androstane 'carboxylate starting material of Example 1 was hydrolyzed with 7% KOH in isopropanol or aqueous methanol, followed by an acidic work-up to give the corresponding 17ß carboxylic acid which was utilized in Example 11.
EXAMPLE 11
N-(1-adamantyl)-3-oxo-4-aza-5α-androstane-17β- carboxamide
A solution of 5.0 g of the product of Example
10, 3.35 g of dicyclohexylcarbodiimide and 3.18 g of 1-hydroxybenztriazole in 500 ml of dichloromethane was stirred at room temperature overnight. The solid was separated by filtration and the filtrate was treated with 1-adamantamine. This solution stood at room temperature for 64 hours, then filtered, and the solution was washed successively with 10% hydrochloric acid and saturated aqueous sodium chloride. After drying with MgSO4, it was filtered and concentrated. The crude product was eluted through 240 g of silica gel with 3:7 (acetone-dichloromethane) to give 5.5 g of the above-titled product, m.p. 323-324°C. EXAMPLE 12
Synthesis of Benztriazol-1-yl-3-oxo-4-methyl- 4-aza-5α-androstan-17β-carboxylate ;
A suspension of 83.7 g of methyl-3-oxo- 4-methyl-4-aza-5α-androstane-17ß-carboxylate. (See Rasmusson, et al. J. Med. Chem 21, 2298-2315, 1986) was hydrolyzed with 7% KOH in aqueous methanol, followed by an acidic work up to give the corresponding 17ß-carboxylic acid.
The acid was readily converted into benzotriazyl-1-yl-3-oxo-4 methyl-4-aza-5α-androstane 17ß carboxylate as described in Example 13. The
activated ester (the benzotriazoyl derivative) was purified on TLC (4 plates, 20 cm x 20 cm × 20 cm × 1000μm silica gel) eluted with 4:96 (MeOH-CHCl3). The isolated product was washed with ether to give the active ester m.pt. 198-200°C with decomposition. EXAMPLE 13
Synthesis of 17β (N-1-adamantylcarbamoyl)-4-methyl- 4-aza-5α-andrpstan-3-one
100.0 mg of the 4-methyl-4-aza-benzotriazole derivative prepared as described in Example 12, was dissolved in 20.0 ml CH2Cl2. To the clear solution was added 127 mg of 1-adamantamine. The reaction mixture was stirred overnight at R.T./N2.
Crystallization from EtOAc after filtering the solution through Teflon Acrodisc CR afforded
26.32 mg, m.pt. 210-217°C. The product was further purified on 1.0 g silica gel column (EM silica gel) with 1:1 (acetone-hexane) as eluant to give after recrystallization (ethyl acetate) 21.75 mg of white needles of the above-titled product, m.pt. 203-205°C.
Anal. Calcd. for C30H46N2O2●1.5 H2O:
C.73.58; H.9.68; N.5.62;
Found: C.73.15; H.9.30; N.5.67.
EXAMPLE 14 Diastereomeric Synthesis of 17β(N-exo-2-norbornanyl-carbamoyl)-4-aza-5α-androst-1-en-3-one)
100.0 mg of the corresponding 4-H thiopyridyl ester of Example 3, prepared by the procedure of
Example 3, but utilizing the 4-H methyl ester product of Example 1, (See Rasmusson et al. J. Med. Chem.
Vol. 29, pp. 2298-2315 (1986), was dissolved in 3.0 ml of dry THF under N2. To the clear solution was added 477 μl of (±) racemic exo-2-aminonorbornane. Allowed the reaction to proceed for 16 hours at
R.T./N2. The reaction mixture was evaporated to dryness in vacuum. The residue was dissolved in chloroform. The organic layer was washed with 2.5 N HCl acid (3 times); 3 times with water; 3 times with saturated NaCl solution, dried over MgSO4, filtered and evaporated to dryness in vacuum to afford 56.3 mg of a racemic diastereomeric mixture.
The crude product was chromatographed on TLC (2 plates, 20 cm × 20 cm × 500 μm silica gel) eluted with 70:30 (CHCl3:acetone) to yield 43.4 mg.of the above-titled product. Recrystallization from EtOAc yielded 30 mg product, m.pt 245-245.9°C. NMR (CDCl3) confirmed the above structure.
FAB mass spectrum calcd. for C26H38O2N2: m/e 411; Found: 411.
Anal. Calcd. for C26H38O2N2.H2O:
C72.82; H.9.40; N.6.58.
Found: C.73.21; H,9.20; N.6.25.
EXAMPLE.15
Synthesis of 17β(N-1-adamantylmethylcarbamoyl)-
4-aza-5α-androst-1-en-3-one
200.0 mg of the 4-H thiopyridyl aza steroid, used in Example 14, was suspended in 2.0 ml of dry THF.
To the suspension was added 400 μl of 1-aminomethylene adamantane via syringe at R.T./N2.
After several minutes, a yellow clear solution resulted and after 1/2 hr., precipitation occurred. The reaction was allowed to proceed overnight/N2.
Diluted with CH2Cl2, washed with 10% NaOH, two times, then with H2O two times, followed by 10% HCl (two times), H2O (two times), and finally two times with satd. NaCl solution.
The organic layer was dried over MgS04, filtered, concentrated in vacuo to obtain the
product, as shown by NMR, recrystallized from EtOAc, to yield 149.0 mg product, m.pt 255-257°C with decomposition.
FAB Mass Spectrum, Calcd: m/e 464 + 1 = 465:
Found 465. EXAMPLE 16
Synthesis of 17β(N-2-adamantylcarbamoyl)- 4-aza-5α-androstan-3-one
A mixture of 1.09 grams 17ß-(N-2-adamantylcarbamoyl)-4-aza-5α-androst-1-en-3-one (See Example 10 for preparation), 150 ml of ethanol, and 1.0 g. of 307.
Pd/C was hydrogenated overnight with shaking under 45 psig. hydrogen pressure. The suspension was filtered to remove catalyst, and evaporated to dryness to yield a grey residue. This was chromatographed by elution on a 200 ml silica gel column with 40:60 acetone/ methylene chloride eluant to yield 1.0 g of solid, mp. 294-296°C.
Anal. Calcd. for C29H44N2O2●0.2H2O
Calcd. C, 76.33; H, 9.80; N, 6.14
Found C, 76.23; H, 9.86; N, 5.92
Mass Spec. Analysis by electron impact showed
MW of 452.
EXAMPLE 17
Synthesis of 17β-(N-2-adamantylcarbamoyl)- 4-aza-4-methyl-5α-androst-1-en-3-one
A suspension of 500 mg of 17ß-(N-2-adamantylcarbamoyl)-4-aza-5α-androst-1-en-3-one, as prepared in Example 16, 10 ml sieve-dried DMF, 140 mg NaH, were heated and stirred at 70°C under a nitrogen atmosphere for 18 hours. Cooled to room temperature and then added 0.4 ml methyl iodide dropwise with stirring which was continued at 50°C for 3 hours. The reaction mixture was then treated by cooling to room temperature, followed by the addition of 15 ml water. The mixture was extracted with 3 × 20 ml of CH2Cl2. The organic layers were combined, washed with brine, dried and evaporated to yield a white crystalline residue. Recrystallization from ethyl acetate/CH2Cl2 yielded a pure white solid, mp 246-248°C.
Analysis calculated for C30H44N2O2●0.3H2O
Calcd. C, 76.65; H, 9.56; N, 5.95
Found C, 76.50; H, 9.75; N, 5.84
Mass spectroscopy showed a molecular weight of 464.
EXAMPLE 18
Synthesis of 17β-(N-2-adamantylcarbamoyl)- 3-oxo-4-methyl-4-aza-5α-androstane
17ß-(N-2-adamantylcarbamoyl)-4-methyl-4-aza- androsten-1-en-3-one, (200 mg) as prepared in
Example 17, were placed into 25 ml absolute ethanol with 200 mg 30% Pd/C hydrogenation catalyst. The suspension was rocked overnight under 40 psig hydrogen pressure.
The suspension was filtered, and the filtrate
evaporated to dryness. The residue was
recrystallized from hot ethyl acetate to give a white crystalline solid, mp. 113-115°C. Calcd. for
C32H5ON2O3●0.5 EtOAc
Calcd: C, 75.25, H, 9.86, N, 5.48
Found C, 75.07; H, 9.52; N, 5.28
Mass spectroscopy depicted a molecular weight of 466 for the non-solvated molecule. EXAMPLE 19
Synthesis of 17β-(N-methyl-N-2-adamantyl)
carbamoyl-4-methyl-4-aza-androst-1-en-3-one
17ß-(N-2-adamantyl)carbamoyl-4-aza-androst-1-en-3-one (5.0 g) and 1.5 g sodium hydride in 100 ml dry DMF were stirred under dry nitrogen for 3 hours at 40°C. The reaction was cooled to room temperature and about 4 ml of methyl iodide was added dropwise and allowed to stir at room temperature for one hour. The reaction was cooled in an ice bath and a large excess of about 250 ml, water was added. The aqueous mixture was extracted with CH2Cl2 (3 × 100 ml), the organic extracts combined, washed with H2O, brine, and then evaporated to dryness to yield crude product. The crude product was eluted on an HPLC column (Si gel) with 10/1 acetone/CH2Cl2 to yield 2 peaks having retention times of 3 CV(B) and 3.8 CV(A). Peak (A) was analyzed as per the 4-methylaza titled product of Example 15. The second product (B) was analyzed as the 4-methylaza-17ß-(N-methyl-N-2-adamantyl/carbamoyl analog, i.e. the titled compound, mp. 163-165.
Calcd. for C31H46N2O2
Calcd. C, 77.77; H, 9.68; N, 5.85
Found C, 77.29; H, 9,79; N, 5.77
Mass spectrometry showed a molecular weight of 478. EXAMPLE 20
Synthesis of 17β-(N-methyl-N-2-adamantylcarbamoyl) 4-aza-4-methyl-androstan-3-one
The crude reaction mixture from Example 19
(4.6 g) was dissolved in 200 ml ethanol and together with 1.0 g 30% Pd/C was hydrogenated under 40-45 Psig a hydrogen atmosphere at room temperature overnight. The mixture was filtered, residue washed with ethanol. The ethanol solution was evaporated to dryness to yield a crude mixture. Recrystallized from CH2Cl2/ diethyl ether/hexane to yield 800 mg of the pure monomethyl androstane compound of Example 16, mp
113-115°C. Second and third crops were combined with mother liquor and treated by HPLC as in Example 17 to yield the dimethylated title compound, mp 180-182°C. Anal. Calcd. for C31H48N2O2
Calcd. C, 77.45; H, 10.06; N, 5.83
Found C, 77.26; H, 9.87; N, 5.82
Mass spectrometry showed a molecular weight of 480.
EXAMPLE 21
N-t-Butyl Androst-3,5-diene-17β-carboxamide-3-Carboxylic Acid
(a) N-t-butyl androst-3,5-diene-3-bromo-17β- carboxamide
To a solution of oxalic acid (0.0011 mol, 0.1 g) and oxalyl bromide (0.0211 mol, 3 ml) in 15 ml of sieve dried toluene was added over a one hour period 1 g (0.003 mol) of androst-4-ene-3-one 17ß-carboxylic acid. The reaction was stirred at room temperature for 2 hours and then it was
concentrated in vacuo. The excess oxalyl bromide was removed by azetoroping with toluene. The resulting brown oil was redissolved in toluene, cooled to 0°C and then 10 ml t-butylamine (7.0 g) in 30 ml of toluene was added dropwise over 15 minutes. Once the addition was complete, the reaction was stirred at 0°C for 15 minutes and then it was kept at -20°C for 19 hours. The reacton mixture was allowed to warm to room temperature and then stirred at 25°C for one hour. The volatiles were removed in vacuo. The residue was partitioned between chloroform/water, the layers were shaken together and separated and then the aqueous phase was back-extracted twice with chloroform. The combined organic extracts were washed with water (2x) and then dried with anhydrous magnesium sulfate. The crude product was purified by flash chromatography on silica, eluting with 20% ethyl acetate in hexane, to give 1.06 g of the title compound, a white solid.
(b) N-t-Butyl Androst-3,5-diene-17β-carboxamide-3-carboxylic acid
To a solution of N-t-Butyl Androst-3,5-diene-3-bromo-17ß-carboxamide (0.5 g, 0.00115 mol) in 5 ml of tetrahydrofuran, cooled to -78°C (dry
ice/acetone bath) under argon, was added dropwise 1.5 ml (0.00375 mol) of a 2.5 M solution of n-butyl lithium in hexane. The reaction mixture was stirred at this temperature for one hour and then carbon dioxide was bubbled into the reaction for 45 minutes, via a concentrated sulfuric acid tower. The reaction mixture was allowed to warm to room temperature and then it was diluted with water, aqueous HCl solution and chloroform. The layers were shaken together and separated, with the aqueous phase being back- extracted with chloroform (2x). The combined organic extracts were washed with water (2X), and brine (1 x) and then dried with anhydrous magnesium sulfate. The solvents were removed under reduced pressure give 0.6 g of a crude solid. This material was slurried with hexane and a white solid was isolated (0.43 g). The title compound was recrystallized from acetonitrile, m.p. 247°-250°. CHAPTER 2
EXAMPLE 1
Methyl 3-pχp-4-aza-5a-andrpst-1-ene-17g-carbpχylate
A suspension of 83.7 g of methyl 3-oxo- aza-5a-androstane-17-carboxylate* and 126.5 g of benzeneseleninic anhydride in 2.09 1 of chlorobenzene was heated at reflux for 2 hours. The reflux condenser was switched to a distillation head and the mixture was distilled slowly to remove water that had formed in the reaction (2 hours). The solution was evaporated to leave 198 g of wet residue. The residue as a solution in dichloromethane was washed with saturated aqueous NaHCO3 solution and saturated NaCl solution, then dried and evaporated to leave 172.4 g. This material was chromatographed on 2.56 kg of silica gel eluting first with dichloromethane (5 liters) and then with 4:1 dichloromethane-acetone. The desired product was eluted with 8 liters of the above-mixed solvent and evaporated to dryness in vacuo to yield 53.4 g solid. It was washed with diethyl ether and dried to leave 49.5 g of the above-titled product, m.p. 278-280°C.
*Rasmusson Johnston and Arth. U.S. Patent 4,377,584, March 22, 1983.
EXAMPLE 2
S-(2-Pyridyl)-3-oxo-4-aza-5α-androst-1-ene-17β-thio-carboxylate
A suspension of 25.0 g of the above product from Example 1 was saponified with 12.5 g of KOH in 150.0 ml of 5:1 CH3OH-H2O under reflux conditions for 4 hours/N2. The mixture was cooled to 25°C and acidified to pH <2. Water (175 ml) was added gradually with stirring to leave a crystalline precipitate which was collected and washed with water.
After drying, the product amounted to 25 g., m.pt 313-315°C with decomposition.
The crude dry acid (23.0 g) was suspended in 210 ml of toluene, and to the suspension was added triphenylphosphine (56.0 g) and 2,2'-dipyridyl
disulfide (48.3g), and the mixture was stirred at 24°C overnight/N2. The reaction mixture was placed on a column of silica gel (1.3 kg) and was eluted with 1:1 (acetone/CH2Cl2). The desired thioester eluted slowly, and after rinsing with ether, yielded
36.8 g of the above-titled product, m.p. 232-235°C. EXAMPLE 3
22-Methyl-4-aza-21-nor-5α-chol-1-ene-3 , 20-dione
Figure imgf000200_0001
To a solution of 7.2 g of S-(2-pyridyl)-3-oxo-4-aza-5α-androst-1-ene-17ß-thiocarboxylate in 288 ml of tetrahydrofuran was added at -78°C 33.6 ml of 1.3M S-butylmagnesium chloride. After 30 minutes at -78°C the solution came to room temperature and was treated with saturated aqueous NaCl solution. The product was extracted into dichloromethane and was washed with saturated aqueous NaCl solution and 10% aqueous NaOH solution, then dried and
concentrated. The residue was eluted through 430 g of silica gel with 9:1 dichloromethane-acetone to give 4.5 g of the product, m.p. 246-249°C.
When the procedure is repeated using the following reagents, the indicated product is obtained Starting
Material Reagent Product
S-(2-pyridyl)3- 2-pyrrolyl mag17ß-(2-pyrrolyl-oxo-4-aza-5α- nesium chloride carbonyl)-4-aza-androst-1-ene- 5α-androst-1-ene- 17ß-thiocarbox3-one
ylate m.p. 294-296°C
S-(2-pyridyl)3- sec-butyl mag4,22-dimethyl-4-oxo-4-methyl-5α- nesium chloride aza-21-nor-5α-androst-1-ene- chol-1-ene-3,20- 17ß-thiocarboxdione
ylate m.p. 134-136°C
S-(2-pyridyl)3- 2-pyrrolyl mag4-methyl-17ß-(2-oxo-4-methyl-4- nesium chloride pyrrolylcarbonaza-5α-androst- yl)-4-aza-5α- 1-ene-17ß-thio- androst-1-ene-3- carboxylate one
m.p. 234-238°C
S-(2-pyridyl)3- isobutyl mag23-methyl-4-aza-oxo-4-aza-5α- nesium chloride 21-nor-5α-androst-ene-17ß- -cholane-3,20-thiocarboxylate dione
m.p. 220-222°C
EXAMPLE 4
22-Methyl-4-aza-21-nor-5α-chol-1-ene-3 , 20-dione
Figure imgf000202_0001
A solution of 21 g of 22-methyl-4-aza-21-nor- 5α-cholane-3,20-dione and 29.49 g of
benzeneseleninic anhydride in 552 ml of chlorobenzene was refluxed with water separation for 4 hours. The mixture was concentrated and the residue was
redissolved in dichloromethane. After washing with 10% aqueous sodium hydroxide, then 10% hydrochloric acid and saturated aqueous sodium chloride the
solution was dried and concentrated to 45 g of yellow residue. This was chromatographed on 1.5 kg of silica gel packed in dichloromethane and eluted with ethyl acetate to give 10.6 g of the product, m.p.
248-251°C.
When the procedure is repeated using 23-methyl-4-aza-21-nor-5α-cholane-3,20-dione as starting material the product obtained is 23-methyl-4-aza-21-nor-5α-chol-1-ene-3,20-dione, m.p.
283-286°C. EXAMPLE 5
17β-(phenylcarbonyl)-4-aza-5α-androst-1-ene-3-one
To a stirred suspension of 43 g of S-(2-pyridyl)-3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-thiocarboxylate in 500 ml of anhydrous tetrahydrofuran (THF) was added at -78°C a THF solution of 157 ml of 2N phenylmagnesium chloride over 60
minutes. After stirring at -78°C for 60 minutes, the mixture was brought to -30°C and was quenched by addition of 107. HCl while maintaining the temperature below -20°C. After warming to 0°C, the mixture was diluted with 2000 ml of water and extracted with 4000 ml of dichloromethane in portions. The organic layer was washed sequentially with water, IN sodium
hydroxide, water and saturated sodium chloride solution. Drying with MgSO4 and concentration afforded 37.5 g of crude product. Recrystallization from dichloromethane/ ethyl acetate gave the title phenyl ketone (30.4 g, 77% yield).
m.p. 290-291°C.
Calc Found
N 3.61 3.56
C 77.48 77.16
H 8.26 8.19
EXAMPLE 6
17-beta-4-fluorophenycarbonyl-4-aza-5-alpha-androst-l-ene-3-one
The procedure of Example 5 was repeated except using p-fluorophenylmagnesium bromide as the Grignard reagent and the title compound was
obtained, m.p. 315-315.5°C. EXAMPLE 7
17β-(cyclohexylcarbonyl)-4-aza-5α-androst-1-ene-3-one
To a suspension of 34.8 g of the thiopyridyl ester of Example 2 in 700 ml of anhydrous THF was added at -65 degrees C 130 ml of a 2 M ether solution of cyclohexyl magnesium chloride over a period of 20 minutes. After stirring at -70 degrees C for 60 minutes the solution was warmed and stirred at -10 degrees C for 60 minutes. The mixture was diluted with 500 ml of dichloromethane and then dropwise with dichloromethane, the phases were separated and the organic layer was treated sequentially with water, 1 N sodium hydroxide, water and saturated sodium chloride solution. The organic solution was
decolorized with charcoal, filtered and concentrated to a residue which was crystallized from ethyl acetate to give 28.2 of the title compound, m.p.
271.5-277 degrees C.
EXAMPLE 8
The title compound of Example 7 was also prepared by the following procedure.
To a mixture of 150 g of methyl
3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-carboxylate in 2800 ml of anhydrous THF was added with stirring at less than 0 degrees C internal temperature 678 ml of a 2 N ether solution of cyclohexyl magnesium chloride. The solution was then refluxed for 6 hours. The cooled (less than 10 degrees C) reaction mixture was acidified with 10% HCl solution and was extracted with dichloromethane. The organic layer was washed sequentially with water, saturated NaHCO3 solution and saturated NaCl solution. Drying (MgSO4) and evaporation left 163 g of crude cyclohexyl ketone. Recrystallization from dichloromethane/ ethylacetate gave 131 g of the pure material.
m.p. 269-270 degrees C.
% Calc. Found
N 3.61 3.61
C 77.37 77.37
H 9.74 10.13
EXAMPLE 9
17-beta-(cyclopentylcarbonyl)-4-aza-5-alpha-androst- 1-ene-3-one ;
When the procedure of Example 7 or 8 was repeated using cyclopentylmagnesium chloride, the title compound was obtained: m.p. 272-273 degrees C
Calc Found
N 3.66 3.78
C 75.25 74.89
H 9.60 9.54
EXAMPLE 10
17-beta-(cyclobutylcarbonyl)-4-aza-5-alpha-androst-1- ene-3-one
When the procedure of Example 7 or 8 was repeated using cyclobutylmagnesium chloride, the title compound was obtained: m.p. 288-289 degrees C.
%Calc Found
N 3.94 3.87
C 77.71 78.06
H 9.36 9.61 EXAMPLE 11
Synthesis of 17-β-(4-Phenylbenzoyl)-4-aza-5a-androst- 1-en-3-one
To a suspension of 258.0 mg of dry activated magnesium chips in 5.0 ml of dry THF was added 932.0 mg of 4-bromobiphenyl in 5.0 ml of dry THF under N2. The reaction was run in an ultrasonic bath at a temperature range of 24-30°C. To the well-agitated mixture was added dropwise 30 ml of 1,2-dibromoethane/N2. The reaction was allowed to proceed for 1-1 1/2 hours at 28°C/N2. The concentration of the Grignard reagent was 4.0 mmoles in 10.0 ml of dry THF.
The steroid from Example 2 (205.0 mg, 0.5mmol of thiopyridyl ester) was suspended in 2.0 ml of dry THF, cooled to -80°C and the above Grignard 3.80 ml was added via syringe to the steroidal suspension over 5-10 minutes/N2. The reaction was allowed to proceed for 1 hour at -80°C/N2 and then at -10°C for an additional hour/N2. The solution was diluted with 10.0 ml of methylene chloride and quenched with saturated aqueous solution of NH4CI to pH=4. The organic layers were separated, washed 3 times with water, 3 times with saturated sodium chloride, dried over MgSO4, filtered, and evaporated under vacuum to afford 156.2 mg of crude product. Crystallization from EtOAc gave the above-titled product in 98.58 mg, m.pt. 290°C-290.5°C.
Anald. Calcd. for C31H35NO2:
C82.08; H.7.78; N.3.09;
Found: C.81.84; H.8.01; N.3.06.
FAB: Calc. for C31H35NO2: 453; Found: 453.
EXAMPLE 12
17-β-(3-Phenylbenzoyl)-4-aza-5a-androst-1-en-3-one
To a suspension of 258.0 mg of dry activated magnesium chips in 8.0 ml of dry THF was added 932.0 mg of 3-bromobiphenyl in 2.0 ml of dry THF under N2. The reaction was run in an ultrasonic bath at a temperature range of 24-30°C. To the well-agitated mixture was added dropwise 30 microliters of
l,2-dibromoethane/N2. The concentration of the
Grignard reagent was 4 mmoles in 10.0 ml of dry THF.
The steroid from Example 2, 205.0 mg (0.5 mmoles) was suspended in 2.0 ml of dry THF, cooled to -80°C and the above prepared Grignard, 3.80 ml, was added via syringe to the steroidal suspension over 5-10 minutes/N2. The reaction was allowed to proceed for 1 hour at -80°C/N2 and then at -10°C for an additional hour/N2. The solution was diluted with 10.0 ml of methylene chloride and quenched with a saturated aqueous solution of NH4CI to pH=4. The organic layers were separated, washed 3 times with water, 3 times with saturated sodium chloride, dried over MgSO4, filtered, and evaporated under vacuum. Crystallization from ethyl acetate afforded 122.84 mg of product. The material was purified on 20.0 g of silica gel column using 70:30 (CHCl3-acetone) as eluant, to give a single spot material 117.0 mg of the above-titled compound, m.pt. 184-185°C.
Anald. Calcd. for C31H35NO2:
C82.08; H.7.78; N.3.09;
Found: C82.28; H.8.04; N,2.98.
FAB: Calcd. for C31H35NO2: 453; Found: 453.
EXAMPLE 13
Synthesis of 17-β-(4-Methylthiobenzoyl)-4-aza-5-α-androst-1-en-3-one
To a suspension of 250.0 mg of dry activated magnesium chips in 8.0 ml of dry THF was added 812.0 mg of p-bromophenyl methyl sulfide in 3.0 ml of dry THF under N2. The reaction was run in an ultrasonic bath at a temperature range of 24-30°C. To the well-agitated mixture was added dropwise 40 μl of 1,2-dibromoethane/N2. The reaction was allowed to proceed for 1 to 1 1/2 hours at 28°C/N2. The
concentration of the Grignard reagent was 4.0 mmoles in 10 ml of dry THF. The steroid from Example 2, i.e. the pyridylthio ester, 205 mg, was suspended in 2.0 ml of dry THF, cooled to -80°C and the above prepared Grignard was added via syringe to the steroidal suspension in 5-10 minutes/N2. The reaction was allowed to proceed for 1 hour at -80°C/N2 and then at -10°C for an additional hour/N2. The solution was diluted with 10.0 ml of methylene chloride, and quenched with saturated aqueous solution of NH4CI to pH=4. The organic layers were separated, washed 3 times with water; 3 times with saturated sodium chloride, dried over MgSO4, filtered, and evaporated under vacuum to afford 105.0 mg of crude product.
The crude product was chromatographed on TLC (one plate, 20 cm x 20 cm × 20 cm × 1000 μm silica gel) eluted with 80:20 (CH2Cl2-acetone) to afford 66.0 mg of single spot material. Crystallization from EtOAc afforded 45.0 mg of the above-titled compound, m.pt. 286-287ºC.
FAB for C26H33NO2S (Calcd.) 424; Found 424.
EXAMPLE 14
Synthesis of 17-β-(4-methylsulfinylbenzoyl) and - (4-methylsulfonylbenzoyl)-4-aza-5α-androst-1-en-3-one A. Qxidation
19.91 mg of the methylthio product from Example 13 was dissolved in 2.5 ml of CH2Cl2, cooled to 0-(-2)°C and was treated with a solution 9.6 mg of m-chloroperbenzoic acid in 1.0 ml of CH2Cl2 over a period of 4 minutes. After stirring for 1 hour at 0-(-2)°C, the reaction was diluted with 10 ml. CH2Cl2. The layers were washed subsequently with 2.5% NaHCO3, H2O and saturated NaCl solutions. The organic layer was dried over MgSO4 overnight, filtered and evaporated in vacuo to yield 17 mg product. Crystallization from EtOAc gave 11.8 mg of the above-titled compound, a solid, mp. 313-313.5°C (with dec.).
Anal. Calcd. for C26H33NO3S · 1/4H2O:
C.70.31; H.7.60; N.3.15;
Found: C70.47; H,7.70; N,3.00.
FAB for C26H33NO3S (Calcd. 440); Found 440.
Sulfone
Fifteen percent (15%) of the corresponding sulfone, 17ß-(4-methylsulfonyl benzoyl) derivative, was isolated by chromatography from the reaction as a byproduct. Recrystallized from EtOAc to yield a solid, mp. 279-279.5°C. Molecular weight by FAB showed 456; calculated 456.
Anal, for C26H33NO4S · 0.25 H2O
Calc: C.67.87; H,7.28; N,3.04.
Found: C67.96; H.6.72; N.2.95.
EXAMPLE 15
Synthesis of 17-β-(4-acetoxymethylthiobenzoyl)-4-aza-5α-androst-1-en-3-one
Trifluoroacetic anhydride (165 μl) was dissolved in 780 μl of acetic anhydride and kept for 5 hours at room temperature (RT). To 300 μl of the above solution of mixed anhydrides was added 34.15 mg pure sulfoxide from Example 14 with stirring. A few minutes later 54.0 μl of 2,6-1utidine was added and the reaction'Was
allowed to stir at RT/N2 for 17 hours.
The liquid anhydrides were removed under reduced pressure and the remaining residue extracted (4 times with CHCl3). The CHCl3 extracts were washed subsequently with dilute HCl; 5% NaHCO3 solution, 3 times; 3 times with H2O; and finally with saturated NaCl solution, and then dried over MgSO4 filtered and evaporated the solution to dryness in vacuo to yield 42.1 mg of crude product.
The crude product from Step A was purified by chromatography on silica gel using 95:5 (CHCl3- acetone) as eluant and then crystallizing the
obtained solid from EtOAc to yield 17.8 mg of the above-titled compound as crystals, m.pt. 235-236°C (dec).
Anal. Calcd. for C28H35O4NS · 1/4 H2O:
C.68.57; H.7.40; N.2.86;
Found: C.69.02; H,7.39; N.2.73.
FAB for C28H28O4NS calcd.: 482; Found 482.
The NMR (proton) was in agreement with
the assigned product structure.
EXAMPLE 16
Synthesis of 17β(4-mercaptobenzoyl)-4-aza-5α-andrpgt-1-en-3 one
40.0 mg of the acetoxy-methyl-thio
derivative from Example 15 was suspended in 3.0 ml of isopropanol. The reaction mixture was flushed several times with N2, and with vacuum, and the system kept under nitrogen atmosphere. To the above mixture was added 40.0 mg of K2CO3 in 2.00 ml of water (free of oxygen) via syringe, and the
temperature of the reaction mixture was allowed to rise to 80ºC under gentle reflux under slight vacuum for 10 minutes, and then under N2 for 1 hour. After 1 hour, the reaction mixture was a clear yellow solution. It was brought to R.T., cooled to 0-5°C and quenched with 2.5 N HCl acid/N2. The reaction mixture was extracted 4 times with CH2Cl2. The organic layer was washed with H2O 4 times; 3 times with saturated salt solution, and finally dried over MgSO4. Filtered and evaporated to dryness in vacuo to yield 36.9 mg of crude product. The crude product was dissolved in 2.0 ml of CHCl3, filtered through Teflon (Acrodisc CR) and purified by preparative HPLC on silica gel and eluted with 60:40
(CH2Cl2-acetone). Crystallization, from EtOAc afforded a single spot material, 20.7 mg of the above-titled compound, m.pt. 285-286ºC.
Anal. Calcd. for C25H31O2NS . 1/2 H2O:
C72.19; H.7.69; N.3.24;
Found: C.71.82; H.7.43; N.3.26.
FAB: Calcd. for C25H31O2NS: 410; Found: 410.
EXAMPLE 17
Synthes is of 17-β-(4-Dimethylaminobenzoyl )-4-aza-5-a- androst-1-en-3-one
To a suspension of 291.0 mg of dry activated magnesium chips in 8.0 ml of dry THF was added 800.0 mg of 4-bromo-N,N-dimethylaniline in 2.0 ml of dry THF under N2. The reaction was run in an ultrasonic bath at a temperature range of 24-30°C. To the well-agitated mixture was added dropwise 30 ml of 1,2-dibromoethane/N2. The reaction was allowed to proceed for 1 to 1 1/2 hours at 28°C/N2. The
concentration of the Grignard reagent was 4.0 mmoles in 10.0 ml of dry THF.
The steroid from Example 2 (205 mg of pyridyl thioester) was suspended in 2.0 ml of dry
THF, cooled to -80°C and the above Grignard 3.8 ml (3 equivalents) was added via syringe to the steroidal suspension over 5-10 minutes/N2. The reaction was allowed to proceed for 1 hour at -80°C/N2 and then at -10°C for an additional hour/N2. The solution was diluted with 10.0 ml of methylene chloride and quenched with a saturated aqueous solution of NH4CI to pH=4. The organic layers were separated, washed 3 times with water 3 times with saturated sodium chloride, dried over MgSO4, filtered, and evaporated under vacuum to afford 151.3 mg of crude product.
Crystallization from ethyl acetate gave 124.5 mg of the above-titled compound, m.pt. 268.5-269°C.
FAB: Calcd. C27H36N2O2: 421; Found: 421.
The NMR (proton in CDCl3) confirmed the assigned structure. EXAMPLE 18
General Procedure for Preparing Protected Silyl
Derivatives
1.0 mole of phenol or its derivatives, or 1 mole of alcohol is treated with 1.5 liters of dry methylene chloride. To the clear solution is added dry 3.0 moles of imidazole/N2. The clear solution is cooled to 0°C/N2, and 2.0 moles of t-butyl dimethyl chlorosilane in 300.0 ml of dry methylene chloride is added dropwise at 0°C/N2. Towards the end of the addition, precipitation occurs. The ice bath is removed, and the reaction is allowed to proceed overnight at R.T./N2. Filter, wash the cake with cold CH2Cl2 solution, and the solvent is evaporated in vacuo to afford crude product. The crude product was readily purified by filtering through a silica gel column. (1 gr. of crude product per 100 g of silica gel, using CH2Cl2 as eluant) This method gives about 99% of pure silyl derivatives of phenols and alcohols.
Synthesis of 17-β-(4-Hydroxybenzoyl)-4-aza-5-α-androst-1-ene-3-one
A. Grignard Reaction
To a suspension of 1.22 g of dry activated magnesium chips in 20.0 ml of dry THF was added 5.6 g of 1-bromo-4-(tertiary-butyl dimethyl silyloxy)benzene (prepared from p-bromophenol by the General Procedure detailed above) in 10.0 ml of THF under N2. The reaction was run in an ultrasonic bath at a temperature range of 24-30°C. To the well-agitated mixture was added dropwise 150 μl-200 μl of
1,2-dibromoethane/N2. The reaction was allowed to proceed for 1-1 1/2 hours at 28°C/N2. The concentration of the Grignard reagent formed was 19.5 mmoles in 30.0 ml of dry THF.
The steroid from Example 2 (1.02 g, 2.49 mmoles) was suspended in 20.0 ml of dry THF, cooled to -80°C and the above-prepared Grignard (11.5 ml) was added via syringe to the steroidal suspension in 5-10 minutes/N2. The reaction was allowed to proceed for 1 hour at -80°C/N2, and then at -10°C for an additional hour/N2. The reaction solution was diluted with 10.0 ml of methylene chloride and quenched with a saturated aqueous solution of NH4CI to pH=4. Organic layers were separated, washed 3 times with H2O, 3 times with saturated sodium
chloride, dried over MgSO4, filtered, and evaporated under a vacuum to a yellow color solid.
Crystallization from ethyl acetate afforded 607 mg of product m.p. 248-249°C.
Anal. Calcd. for C31H45O3NSi:
C73.32; H.8.93; N.2.75
Found: C.73.27; H.8.99; N.2.75.
FAB: Found 508; Calc. 508.
B. Desilylation
Dissolved 1.3g of product from above step A in 20.0 ml of dry THF. Cooled to -5°C and added 437 μl of glacial acetic acid/N2. To the cold solution at -5°C was added via syringe 3.0 ml tetra-n-butyl-ammonium fluoride dropwise under N2 atmosphere.
Allowed the reaction to proceed under stirring for 1 1/2-2 hours at 0° to -5°C/N2. The reaction mixture was poured into a 2-1ayer mixture of ethyl
acetate/sodium bicarbonate saturated solution at 0°C. The water layer was separated and further extracted with EtOAc 3 times and with CH2Cl2 (3 times).
The organic layers were combined, washed 3 times with H2O, 1 time with saturated sodium chloride solution, and dried over MgSO4, filtered and evaporated to dryness under vacuum. The crude product was crystallized from ethyl acetate to afford 977.9 mg, and further recrystallized from methanol to afford 842.3 mg of the above-titled product, m.pt. 296-297°C.
Anal. Calcd. for C25H31NO3.1/3 H2O:
C75.15; H,7.98; N.3.51.
Found: C.75.13; H.7.76; N.3.54.
(Mass Spec.) FAB: Found 394; Calcd. 394. EXAMPLE 20
17-β-(3,5-dimethyl-4-hydroxybenzoyl)-4-aza-5α-androst-1-ene-3-one
A. Preparation of Grignard Reagent
To a suspension of 260.0 mg of dry activated magnesium chips in 6.0 ml of dry THF was added 628.0 mg of 1-bromo-3,5-dimethyl-4-tertiary-butyl-dimethyl-silyloxybenzene (prepared from 4-bromo-2,6- dimethylphenol by the General Procedure described above) in 4.0 ml of THF/N2. The reaction was
conducted in an ultrasonic bath at a temperature range of 24°-30°C. To the well-agitated mixture was added dropwise 40 μl of 1,2-dibromoethane/N2. The reaction was allowed to proceed for 2 hours/N2.
The concentration of the Grignard reagent thus formed was 2 mmoles in 10.0 ml of dry THF.
The steroid from Example 2 (205.0 mg (0.5 mmoles) was suspended in 3.0 ml of dry THF, cooled to -80ºC, and 7.5 ml (1.50 millieq.) of the
above-prepared Grignard was introduced via syringe to the steroidal suspension over a period of 5-10
minutes/N2. The reaction was allowed to proceed for 1 hour at -80°C/N2 and then at -10ºC for additional hour/N2.
The reaction was quenched with 1N HCl, and then diluted with chloroform. The organic layers were combined, washed 3 times with H2O, 3 times with saturated sodium chloride and dried over MgSO4, filtered and concentrated in vacuo. The crude
residue was washed with ether to afford 121.7 mg of product.
The crude product was dissolved in 70:30
(CHCl3-acetone), filtered through Teflon (Acrodisc CR) and purified by preparative HPLC (Waters Prep-pak) on silica gel and eluted with 70:30 (CHCl3-acetone).
The major component was recrystallized from ethyl acetate to give 52.0 mg of product m.pt
245-245.5ºC.
Anal. Calcd. for C33H49O3NSi:
C73.96; H.9.23; N,2.61
Found: C.74.06; H.9.33: N,2.64
(Mass Spec . ) FAB : Found : 536 ; Calc : 536 B. Deblocking the Silyl Derivative
Dissolved 54.0 mg of the above product from A in dry THF (1.3 ml). The clear solution was cooled to O°C, and 29 μl of glacial HOAc was added via syringe/N2. To the above solution was added dropwise 172 μl of tetra-n-butylammonium fluoride at 0ºC dropwise via syringe/N2. Allowed the reaction to proceed at 0°C/N2 for 1 1/2 hours. The reaction mixture was poured into ice/saturated NaHCO3 solution and EtOAc. Stirred for several minutes. Allow the layers to separate, and the H2O Oayer was
extracted 3 times with EtOAc and 3 times with CHCl3.
Combined the organic layers and washed 3 times with H2O, then 3 times with saturated NaCl, and then dried over MgSO4, filtered and evaporated to dryness in vacuum to afford.52.2 mg.
The product was crystallized from EtOAc to give 22.5 mg of the above-titled product m.pt
305-306ºC.
calc for C27H35O3N●H2O:
C, 73.77; H, 8.49; N, 3.10.
Found: C, 73.62; H, 7.90; N, 3.44.
(Mass Spec.) FAB: Calc: 422; Found: 422 EXAMPLE 21
Synthesis of 17-β-(4-Methoxybenzoyl)-4-aza-5-α-androst-1-ene-3-one
A. Grignard Reaction
To a suspension of 258.0 mg of dry activated Mg chips in 8.0 ml of THF/N2 was added 748.0 mg p-bromoanisole in 2.0 ml of dry THF. The reaction was run in an ultrasonic bath at a temperature range of 24-30°C/N2. To the well-agitated mixture was added dropwise 30.0 μl of 1,2-dibromoethane as a catalyst. The reaction was allowed to progress for 1-2 hours at 28°C. The formed Grignard reagent had a concentration of 4 mmoles in 10.0 μl of dry THF.
The steroid from Example 2 (205.0 mg (0.50 mml) was suspended in 2.0 ml of THF, cooled to -78°C and the above-prepared Grignard reagent (3.75 ml; 14 milliequivalents) was added via syringe to the
steroidal suspension over 5-10 minutes/N2 and then at -10°C for an additional hour/N2. The resulting reaction mixture was a clear solution, which was cooled to 0-5°C, diluted with chloroform and quenched with 1N HCl acid. The organic layers were separated, washed with H2O 2 times, followed with saturated NaCl solution, dried over MgS04, filtered and evaporated in vacuo. The crude product was washed with ether, and crystallized from EtOAc to give 110 mg of
product m.pt 305-306°C.
Further purification was carried out by chromatographic isolation on a TLC. plate, (20 cm x 20 cm x 1000 μm), using as eluant, 70:30 (CHCl3:
acetone). Recrystallization from EtOAc yielded 78.56 mg of the above-titled product, m.pt 305-306°C (dec).
(Mass Spec) FAB: Calcd., 408; Found 408.
EXAMPLE 22
Synthesis of 17-β-(3-hydroxybenzoyl)-4-aza-5α- andrpst-1-ene-3 one A. preparation of Grignard Reagent
To a suspension of 230.0 mg of dry activated Mg chips in 2.0 ml of dry THF was added 722.4 mg of 1-bromo-3-tertiary-butyl dimethyl-silyloxybenzene (prepared from 3-bromophenol by the General Procedure described above) in 8.0 ml of dry THF/N2. The reaction was run in an ultrasonic bath at a temperature range of 24-30ºC/N2. To the well-agitated mixture was added dropwise 20.0 μl of 1,2- dibromoethane/N2. Allowed the reaction to progress for 2 1/2 hours at 28°C/N2. The formed Grignard reagent had a concentration of 2.52 mmoles in 10.0 ml of dry THF.
The steroid from Example 2 (205.0 mg (0.5 mmoles) was suspended in 2.0 ml of THF, cooled to -78ºC and the above-prepared Grignard reagent (6.0 ml, (1.5 milliequivalents) was added via syringe to the steroidal suspension over 5-10 minutes/N2, and then stirred for an additional hour at -10ºC/N2. The clear reaction mixture was quenched at 0 to -5ºC with 1N HCl acid for 10.0 minutes and diluted with CHCl3. The combined organic layers were washed 3 times with H2O, 3 times with saturated NaCl, and then dried over MgSO4, filtered and concentrated in vacuo to afford crude product. The product was purified on silica gel column and was eluted with 70:30 (CHCl3- acetone). The desired product amounted to 58.0 mg, as the silyl derivative, 17ß-(3-tertiary-butyl-dimethylsilyloxybenzoyl)-4-methyl-4-aza-5α-androst-
1-en-3-one.
B. Deblocking
57.6 mg of the above silyl derivative was dissolved in 3.0 ml of dry THF. The solution was cooled to 0°C, and 20 μl of glacial acetic acid was introduced via syringe. To the clear solution was added 130.0 μl of (n-butyl)4NF via syringe, and allowed the reaction to proceed for 1 hour/N2 at 0°C. The reaction mixture was poured into
EtOAc/NaHCO3 sat. solution @ 0ºC. The water layer was separated, extracted 3 times with EtOAc and then 3 times with chloroform. The organic layers were combined and washed 3 times with H2O, 3 times with saturated NaCl solution; dried over MgSO4, filtered and evaporated in vacuo to give 57.11 mg of crude product. The crude product was chromatographed by TLC (one plate, 20 cm × 20 cm × 250 μm silica gel), eluted with 70:30 (CHCl3-acetone) to afford 44.5 mg of the above-titled product. Recrystallization from EtOAc gave 29.30 mg m.pt 279-280ºC.
Anal. Calcl. for C25H31NO3: 8H2O:
C73.60; H.8.06; N.3.43.
Found: C.73.26; H.8.22; N.3.28.
(Mass Spec.) FAB: Calcd: 394; Found 394. EXAMPLE 23
Synthesis of 17-β-(4-hydroxymethyl-benzoyl)-4-aza-5α- androst-1-en-3-one
A. Preparation of Grignard solution
To a suspension of 100.0 mg (4 mmoles) of dry activated Mg chips in 5.0 ml of dry THF/N2, was added 753.0 mg (2.5 mmoles) of 1-bromo-4- tertiary-butyl dimethyl silyloxy methyl benzene
(prepared from 4-bromobenzyl alcohol by the General Procedure described above). The reaction was conducted in an ultrasonic bath at a temperature range of 24-30ºC/N2- To the well-agitated mixture was added 20 μl of 1,2-dibromoethane/N2. Allowed the reaction to progress for 2 hours at 28ºC/N2. The concentration of formed Grignard was 2.5 mmoles in 5.0 ml of dry THF.
B. Grignard Reaction
The steroid from Example 2 (205.0 mg (0.5 mmoles) was suspended in 2.0 ml of THF, cooled to
-78ºC, and the above-prepared Grignard (3.0 ml , 3.75 milliequivalents ) was introduced via syringe into the steroidal suspension over 5-10 minutes/N2. Allowed the reaction to progress for 1 hour at -80ºC/N2 , and then for an additional hour at -10ºC/N2. The clear reaction solution was quenched with saturated NH4CI at 0° to -5ºC, and then diluted with CH2Cl2. The organic layers were separated and washed 3 times with water, 3 times with saturated NaCl, dried over MgSO4, filtered and evaporated in vacuo to dryness. Crude product was crystallized from EtOAc to give 137.8 mg of silyl product.
(Mass Spec.) FAB: Calcd for C30H41O3NSi: 521.75 Found: 522.0.
C. Deblocking of Silyl Derivative
The product from Step B above (23.67 mg) was dissolved in 0.5 ml of THF and 0.5 ml of MeOH and cooled to 0°C/N2. To the cold solution was added 10 μl of concentrated sulfuric acid (98%). The reaction was stirred for 45 minutes at 0ºC/N2. To the cold solution at 0ºC was slowly added a saturated solution of NaHCO3 and chloroform. Extracted 3 times with CHCl3. The organic layers were washed 3 times with water, 3 times with saturated NaCl, solution dried over MgSO4, filtered and evaporated to dryness in vacuo, to afford 10.18 mg. After chromatography on a TLC plate (elution with 1:1 CHCI2: acetone) The crude product was crystallized from EtOAc to give 6.0 mg of the above-titled product, m.pt 318-320ºC.
Anal. Calcd. for C26H33O3N.1/3H2O:
C.75.41: H.7.94; N.3.38.
Found: C.75.61; H.7.84; N.3.12.
(Mass Spec.) FAB: Calc: 408; Found: 408
EXAMPLE 24
Synthesis of 17-β-(4-Carboxybenzoyl)-4-aza-5α- androst-1-en-3-one
A. Oxidation
90.2 mg of the product from Example 23 was dissolved in 2.63 ml of glacial acetic acid and to the clear solution was added 69.0 mg of CrO3
(previously dried over P2O5 at R.T. for 2 days in vacuo). After stirring overnight, the reaction mixture was diluted with water and allowed to age overnight in the refrigerator. The reaction mixture was filtered and the mother liquor and washes were extracted overnight using a liquid-1iquid extractor, (H2O-EtOAc) under reflux conditions. The organic layer was dried over MgSO4, filtered and evaporated in vacuo. The residue was dissolved in hot MeOH, filtered and evaporated in vacuo to afford a product weighing 32.0 mg.
FA8: Calc for C26H31O4N: 422.0;
Found: 422.
B. Purification
The above free acid was purified by dissolving the above product in 1N sodium hydroxide solution. The clear solution was extracted 3 times with EtOAc. The aqueous basic solution was cooled and acidified with 1N HCl acid dropwise to pH=4 with stirring. The reaction mixture was allowed to age for 1 hour at 0ºC. It was filtered and the residue was washed with cold water. Dried overnight to 100°C in vacuum <0.2 mm pressure.
Yield of the above-titled free acid was 9.85 mg.
FAε: Calc for C25H31O4N: 422; Found 422.
NMR analysis indicated the product to be an acid. C. Sodium Salt of Above Acid
4.9 mg of the above product acid ε was dissolved in 2.0 ml of hot methanol. To the clear solution, was added 11.6 μl of 1N NaOH(aq). To solution after methanol evaporation in vacuo, was added water to reach pH 7.21. The aqueous solution was freeze dried to give 6.3 mg of the sodium salt of the above-titled product. EXAMPLE 25
Synthesis of 17-β-(4-hydroxyethylbenzoyl)-4-aza-5α-androst-1-en-3-one
A. Grignard Reagent
To a suspension of 252 mg of dry activated
Mg chips in 10.0 ml of dry. THF was added 1.26 g (4 mmoles) of 1-bromo-4 tertiary-butyl dimethyl silyloxy ethyl benzene (prepared from 2-(p-bromophenyl) ethanol by the General Procedure described above). The reaction mixture was vigorously stirred using an ultrasonic vibrator/N2. To the well-agitated mixture was added 40 μl of 1,2-dibromoethane to catalyze the above reaction. Allowed the reaction to progress for 3 1/2-4 hours/N2. The concentration of formed
Grignard reagent was 4 mmoles in 10 ml of THF.
B. Grignard Reaction
205.0 mg (0.5 mmoles) of the aza-steroid of Example 2 was suspended in 2.0 ml of dry THF/N2, cooled to -80°C, and the above-prepared Grignard
(3.75 ml, 1.5 milliequivalents) via syringe was introduced into the steroidal suspension over 5-10 minutes/N2. The reaction was run at -80ºC for 1 hour/N2 and then for an additional hour at -10ºC.
The reaction was quenched with a saturated solution of NH4CI at 0-5°C and diluted with 10.0 ml of
CH2Cl2. The organic layers were washed with water (3 times), saturated NaCl solution (3 times), dried with MgSO4, filtered and evaporated in vacuo to dryness. The crude product was crystallized from EtOAc
overnight to give 152.0 mg of product m.pt. 233-234ºC.
Anal. Calcd. for C33H49O3NSi:1/4 H2O:
C73.55; H.9.18, N,2.59.
Found: C,73.45; H.8.94; N,3.21
FAB: Calc. 536; Found: 536 C. Desilylation
70.8 mg of product from Step B, was dissolved in 1.45 ml of methanol and 1.45 ml of THF. The solution was cooled to 0-5ºC and 29 μl of cone H2SO4 was added via syringe under N2. The reaction was allowed to proceed for 45 minutes/N2. The
reaction was carefully quenched at 0ºC with a
saturated solution of NaHCO3, and extracted 3 times with CH2Cl2. The organic layers were separated, washed with water (3 times), then with saturated NaCl solution, dried over MgSU4, filtered and evaporated in vacuo to give 43.0 mg of crude product. The crude product was placed on a column of silica gel and was eluted with 1:1 acetone-CH2Cl2. The isolated product was crystallized from anhydrous methanol to afford 20.0 mg of the above-titled product m.pt 292-293°C with dec.
Anal. Calcd. for C27H35O3N.l/4 H2:
C.75.31; H.8.25; N.3.25.
Found: C,75.49; H.8.29; N.3.45.
FAB: Calcd 422; Found 422. EXAMPLE 26
Synthesis of 17-β-(4-carboxymethylbenzoyl)-4-aza-5α- androst-1-en-3-one
A. Oxidation
13.0 mg of the product from Example 25 was dissolved in 1 ml of glacial acetic acid. To the clear solution was added 10.0 mg of CrO3 (previously dried over P2O5 in vacuum at R.T.). Allowed the reaction to progress overnight at R.T., and then at 0°C for 48 hours. The addition of 7.0 ml of water caused the product to crystallize overnight in a refrigerator. The crude product was isolated, washed with cold water and dried in a vacuum at 110ºC below 1 mm pressure.
The dried crude product was dissolved in IN sodium hydroxide and the basic solution was extracted 3 times with methylene chloride (The organic layers were separated, and the aqueous basic solution was cooled and acidified with 1.5 N hydrochloric acid. The precipitate was filtered, washed with water dried at 110ºC under vacuum at 0.1 mm pressure.
Yield of above-titled product=7.0 mg. FAB Calc C27H33O4N: 436; Found 436.
EXAMPLE 27
Synthesis of 17-β-(3,4-dihydroxybenzoyl)-4-aza-5α- androst-1-en-3-one
A. Grignard
To a suspension of 258.5 mg of dry activated magnesium chips in 10.0 ml of dry THF, was added 482 rag. of 4-bromo-1,2-methylenedioxybenzene/N2. (The starting material is commercially available from Aldrich Chemical) The reaction was conducted in an ultrasonic water bath at a temperature range of
24°-30°C. To the well-agitated mixture was added 40 μl of 1,2-dibromoethane as a catalyst/N2, and the reaction was allowed to progress for 1 1/2-2 hours at 28°C/N2. The concentration of the formed Grignard reagent was 3.75 mmoles in 10 ml of dry THF.
The steroid from Example 2 (410 mg, lmmole) was suspended in 4.0 ml of dry THF/N2 and cooled to -80°C and 8.0 ml of the above-prepared Grignard (3.04 milliequivalents) was added via syringe to the steroidal suspension/N2 over a period of 5-10
minutes. The reaction was allowed to proceed for 1 hour at -80ºC, and then at -10ºC for an additional hour/N2. The reaction mixture was diluted with
CH2Cl2, and then quenched with 1N HCl at -5°C.
The organic layers were collected and washed with water 3 times, saturated NaCl solution 3 times, dried over MgSθ4» filtered and evaporated in vacuo to dryness. Purification of the crude product was carried out on 50.0 g of silica gel using as eluant 1:1(CH2Cl2-acetone) to give 347.0 mg.
FAB showed 422; Calcd. 422.
62.4 mg of the above product was
crystallized from EtOAc to afford 11.39 mg of product m.pt.324-325ºC.
Anal. Calcd. for C26H31O4N .3/4 H2O:
C71.78; H.7.53; N.3.22.
Found: C,71.90; H.7.54; N.3.25.
FAB for C26H31O4N showed 422; Calcd: 422.
B. Cleavage of Methylene Dioxylan Group
70.0 mg of the product from Step A was dissolved in dry 25.0 ml of 1,2-dichloroethane at
R.T./N2. The solution was allowed to cool to -10ºC, and 1.03 ml of BBr3 (1.0 M solution in
dichloromethane) was added dropwise under N2
atmosphere. The reaction was allowed to proceed at R.T. for 3 1/2-4 hours/N2. After 4 hours/N2, the reaction was cooled to (-10ºC) and quenched with 10.0 ml of methanol for 10 minutes at 0ºC, and then gradually the temperature was allowed to rise to R.T./N2. The reaction mixture was evaporated in vacuo to dryness. The residue was extracted 3 times with EtOAc. The organic layers were washed with water 3 times, 2 times with saturated NaHCO3
solution, 3 times with water and finally with a saturated solution of NaCl. The organic layers were dried over magnesium sulfate, filtered and
concentrated in vacuo. The crude material was chromatographed on 2 silica gel plates, (20 cm × 20 cm × 20 cm × 250 μm) eluted with 1:1 (acetone - methylene chloride). Recrystallization from EtOAc afforded 5.0 mg of the above-titled product m.p.
222-222.5ºC.
Anal. Calcd. for C25H31O4N . 1/2 H2O:
C.71.78; H,7.66; N.3.35.
Found: C.71.71; H.7.71; N.3.33.
FAε: Calcd. for C25H31O4N: 410; Found 410.
EXAMPLE 28
Synthesis of 17-β-(2 methoxybenzoyl)-4-aza-5α- androst-1-ene-3-one A. Grignard
To a suspension of 258.0 mg of dry activated magnesium chips in 8.0 ml of dry THF was added 771.0 mg of o-bromoanisole in 2.0 ml of dry THF/N2. The reaction was conducted in an ultrasonic water bath at a temperature range of 24-30ºC. To the well-agitated mixture was added 30 μl of 1,2-dibromoethane/N2, and the reaction was allowed to progress for 2 hours at 28ºC/N2. The concentration of the formed Grignard reagent was 4 mmoles in 10.0 ml of dry THF.
The steroid from Example 2 (205 mg, 0.5 mmoles) was suspended in 2.0 ml of dry THF/N2, cooled to -79ºC, and 4.0 ml of the above-prepared Grignard (1.6 milli-equivalents) was added via syringe to the steroidal suspension/N2 over a period of 5-10
minutes. The reaction mixture was allowed to proceed for 1 hour at -80°C, and then at 0-2°C for an
additional hour/N2. The reaction mixture was diluted with CH2Cl2 and then quenched with 1N HCl solution at 0°C.
The organic layers were combined, washed 3 times with water, 3 times with saturated NaCl
solution; and dried over MgSθ4. Filtered and
evaporated in vacuum to dryness. The crude material was crystallized from EtOAc to give 124.5 mg of product m.pt 228-230ºC. Purification on silica gel column using 70:30 (CHCl3-acetone) gave a single spot material in a yield of 83.0 mg m.pt. 241-241.5.
Anal. Calcd. for C26H33O3N:
C76.91; H,8.19; N,3.45
Found: C,76.36; H.8.26; N.3.35.
FAB calcd. for C26H33O3N: 406; Found: 406.
B. Cleavage of Methoxy Group
12.7 mg (0.03 mmoles) of the product from Step A was dissolved in 5.0 ml of dry methylene chloride/N2. To clear solution at -79ºC/N, was added 50 μl of 1 mmole/ml of BBr3 in CH2CI2 via syringe dropwise. Allowed the reaction to proceed
at R.T. overnight/N2 with rapid stirring. Next day, a clear yellow solution was obtained. The reaction mixture was cooled to 0-2ºC and quenched with water, to hydrolyze excess of BBr3. The organic phase was washed 3 times with dilute sodium hydroxide, 3 times with water, 3 times with dilute HCl, 3 times with water, 3 times with saturated NaCl solution, and dried the organic layer over MgSO4. Filtered, concentrated in a vacuum to dryness. The crude product crystallized from EtOAc to afford 7.0 mg of a pure single spot material being 17-ß-(2-hydroxymethyl-benzoyl)-4-aza-5-α-androst-1-en-3-one.
FAB for C25H31NO2; Calcd: 394; Found: 394.
EXAMPLE 29
17β(α-hydroxybenzyl)-4-aza-5α-androst-1-ene-3-one
570 milligrams of 17ß-benzoyl-4-aza-5α- androst-1-ene-3-one (prepared from the thiopyridyl ester of Example 2 and commercially available phenyl magnesium bromide, analogously via the procedure in Example 5, to produce the 17-benzoyl derivative, mp. 295-296°C crystallized from EtOAc) was suspended in 80 ml of anhydrous isopropanol. To the suspension was added 500.0 mg of NaBH4 in 5 portions. When all the hydride was added, 20.0 ml of dry THF was
carefully added, so that the reaction mixture became a clear solution. Allowed the reaction to proceed at R.T./N2 overnight. The reaction was quenched
carefully with 1N HCl, and allowed to stir under N2 for an additional hour at R.T. It was then diluted with water, and extracted 3 times with CHCl3. The organic layers were combined, washed 3 times with H2O; 3 times with saturated NaCl solution, and dried over MgSO4. Filtered and evaporated to a white solid weighing 495.0 mg.
The crude material was crystallized from
EtOAc to afford 349.5 mg of material. Further purification on a silica gel column, using as eluant, 70:30 (CHCl3-acetone) gave a single spot material, 221 mg, of the above-titled compound, m.pt 296-297°C.
Anal. Calcd. for C25H33NO2:
C79.17; H.8.78; N.3.70.
Found: C.79.24; H.8.85; N.3.48.
FAB Calcd. for C25H33NO2: 380; Found: 380.
EXAMPLE 30
17β-hydroxymethyl-4aza-5α-androst-1-ene-3-one
500.0 mg of S-2-pyridyl-3-oxo-4-aza-5α-androst-1-ene-3 one (Example 2) was dissolved in 40.0 ml of dry THF at R.T./N2. The solution was cooled to -78°C/N2 and 5.5 ml of 1 M dibutyl aluminium hydride in THF was slowly added via syringe to the solution, with rapid stirring. Allowed the reaction to proceed at -76 to -78°C for half ah hour under N2. The temperature was gradually brought to R.T. and the reaction mixture kept for 2-1/2 hours/N2. The reaction was then quenched at 0º to 5°C with 2N HCl acid, and then diluted with CHCl3. The organic layers were separated, washed with H2O 3 times, then with saturated NaCl solution, and finally dried over MgSO2. Filtered, and the organic phase was
evaporated under vacuum to give 216.0 mg of crude product.
The crude product was chromatographed on 20.0 g of E.M. silica gel column, using 70:30(CHCl3-acetone) as eluant.
Yield of single spot material was 126.3 mg of the above-titled compound, m.pt. 271-271.5ºC.
Calcd. for C19H29O2N: FAB 304; Found 304.
NMR in CDCl3 confirmed the above structure. EXAMPLE 31
17β-Formyl-4-aza-5α-androst-1-ene-3-one
Into a 100.0 ml dry flask was placed 1.3 ml of oxalyl chloride (2 M in CH2Cl2) with 50.0 ml of dry CH2CI2/N2. The above solution was cooled to -78°C and 338 μl of DMSO was added dropwise via syringe/N2. The mixture was stirred at -78ºC/N2 for 30 minutes, and a solution of above-prepared alcohol from Example 15, i.e. 17ß hydroxymethyl-4- aza-5α-androst-1-ene-3-one (256.9 mg in 15.0 ml of dry CH2Cl2/N2 was added via syringe. The reaction was allowed to progress for one hour at -78ºC/N2. After an hour at -78ºC, was added 1 ml of dry
triethylamine at a rapid rate. Reaction was raised slowly to R.T./N2 with stirring, the resulting yellow solution was then poured into 50.0 ml of cold water . The organic layers were washed with a saturated solution of NaHCO3, and then with a saturated
solution of NaCl. Dried over MgSO4, evaporated the solvent under vacuum to give 172.4 mg of crude product. The crude product was chromatographed on 60.0 g silica gel column using 70.30 (CHCl3-acetone), to give a single spot material. Crystallization from EtOAc afforded the above-titled compound, 37.7 mg, m.pt. 258-259ºC.
EXAMPLE 32
Synthesis of diastereoisomeric 17β(α-hydroxybenzyl)-
4-aza-5α-androst-1-ene-3-ones
26.3 of above-prepared formyl derivative
(from Example 31) was dissolved in 7.0 ml of dry THF/N2. The solution was cooled to -78°C/N2, and 131 μl of phenyl magnesium bromide (Aldrich reagent) 0.393 milliequivalents) in dry THF was added dropwise via syringe/N2. Allowed the reaction to proceed for 1 hour/N2 at -78°C and then at R.T. for addition hour/N2.
The reaction was quenched at 0-5°C with 2.5N HCl, and then diluted with CHCl3. Organic layers were separated, washed 3 times with water; 3 times with saturated NaCl solution, dried over MgSO4.
Filtered and evaporated in vacuum to dryness to afford 28.6 mg of crude product. Analysis of the NMR spectra and peak heights from HPLC indicated this product to be a 1:1 mixture of diastereoisomers.
The crude product was filtered through a 1 μm Teflon filter and purified by HPLC on a Whitman Portisil 10 column using 70:30(CHCl3-acetone). The FAB mass spectrum indicated the same M++1 for both isomers, being 380 mass units. The faster eluting isomer, m.pt. 289-289.5°C, was crystallized from EtOAc and showed a single spot material on TLC.
Anal. Calcd. for C25H33NO2●1/4 H2O;
C78.39; H,8.81; N.3.65.
Found: C78.11; H.8.65; N.3.58. The slower eluting isomer, m.pt. 300-301°C showed a single spot material on TLC. The faster isomer showed by NMR(CDCl3): CH3 at C-18 was
deshielded (0.89δ) as compared to the slower isomer CH3 at C-18 at (0.696). The benzilic proton for the faster isomer was also deshielded (4.5δ) versus (4.95δ). The olefinic proton at C-1 showed
deshielding effects for the faster isomer at (6.81δ) to (6.62δ). From the above data, the two isomers showed distinctly different physical properties.
CHAPTER 3
EXAMPLE 1
Preparation of 4-(2-(11-carboxyundecanoylamino)- phenoxy)butyric acid step A: Ethyl 4-(2-nitrophenoxy)butyrate(3)
To a stirred solution of 2-nitrophenol (1.4 g, 10 mM) and ethyl 4-bromobutyrate (2.1 g, 1.57 mL, 11 mM) in 35 mL of dry acetone is added 2 g (14.5 mM) of anhydrous, ground potassium carbonate. The resultant colored mixture is then heated under a nitrogen atmosphere at gentle reflux until the color due to the phenol anion has dissipated and a yellow mixture remains. Concentration of the cooled and filtered mixture yields an oil which on flash
chromatography (silica gel, ethyl acetate/hexane or methylene chloride as eluant) yields 2.4 g (96% yield) of the title compound (3) as an oily liquid. When substituted ortho-nitrophenols are used in place of 2-nitrophenol in the above example, the
corresponding substituted 2-nitrophenoxybutyrate is obtained. Likewise, when ethyl 4-bromobutyrate is replaced by other halo esters. the corresponding 2-nitrophenoxyalkanoate is obtained. Step B: Ethyl 4-(2-aminoρhenoxy)butyrate (4)
A solution of 3 (1.27 g, 5.0 mM) in 15 mL ethyl acetate containing 200 mg of 5% palladium on carbon is reacted in a hydrogen atmosphere (40 psig.) at room temperature until hydrogen uptake ceases.
The mixture is then filtered and concentrated in vacuo to yield 1.0+ g of (4) as an oil/low melting solid.
Step C: 12-(Isopropylthio)dodecanoic acid (6)
A mixture of 12-bromododecanoic acid (5)
(0.558 g, 2.0 mM) and sodium isopropylthiolate (1.1 g, 11.2 mM) in 1,2-dimethoxyethane (50 mL) was
deaerated (N2), heated to 85°C (bath temperature), and kept at this temperature for 72 hours. The cooled mixture was filtered, the collected solid dissolved in water and filtered. The stirred
solution was acidified with dilute hydrochloric acid, aged, filtered, the solid washed well with water and dried. There was obtained product & (0.54 g) as a white solid.
When other halo-acids are used in place of 12-bromododecanoic acid in the above example, the corresponding (isopropylthio)-acid is obtained.
Likewise, when other mercaptan salts are used in place of sodium isopropylthiolate in the above example, the corresponding (alkylthio)alkanoic acids are obtained.
Representative of, but not limited to, the acids obtained by this procedure are:
8-(Isopropylthio)octanoic acid 10-(Isopropylthio)decanoic acid
10-(Ethylthio)decanoic acid
11-(t-Butylthio)undecanoic acid
14-(n-Propylthio)tetradecanoic acid 9-(Methylthio)nonanoic acid
Step D: Ethyl 4-(2-(12-(Isopropylthio)dodecanoyl- amino)-phenoxy)-butyrate (7)
To a solution of (4) (0.25 g, 1.14 mM) and (6) (0.274 g, 1.0 mM) in dry methylene chloride (10 mL) at room temperature was added 4-dimethylamino- pyridine (0.122 g, 1.0 mM) followed within one minute by a solution of N,N'-dicyclohexylcarbodiimide (0.22 g, 1.06 mM) in methylene chloride (1 mL), 3X1 mL rinses with methylene chloride. After 2 days, the filtered mixture was concentrated in vacuo and the residue flash chromatographed on silica gel using 15-20% ethyl acetate in hexane as eluant to give product 2 (0.22 g) as an oil that solidified readily in a short time.
Step E 4-(2-(12-(Isopropylthio)dodecanoylamino)
phenoxy)-bυtyric acid (8)
A stirred solution of ester (7) (0.124 g,
0.258 mM) in methanol (10 mL) was treated at room temperature under a nitrogen atmosphere with 2.5N sodium hydroxide solution (0.6 mL). Methanol (2X2 mL) was used to clear the mixture, and the reaction allowed to continue until TLC analysis showed no ester remained. The filtered mixture was concen trated in vacuo and the residue obtained stirred with water (30 mL). After aging, the mixture was filtered (The cake is the sodium salt of the product (100 mg), and the stirred filtrate acidified with dilute hydro- chloric acid, aged, filtered, washed with water and dried to give product 8 (0.02 g) as a white solid. M.P. 82-84ºC, with softening from 66ºC.
Treatment of 8 with NaIO4 as in Step Ja will produce the corresponding sulfoxide, and treatment of 8 with m-chloroperbenzoic acid with Step Jb will produce the corresponding sulfone.
Step F: 4-(2-(12-(Isopropylthio)dodecanoylamino)
phenoxy)-butyramide (9)
To a stirred solution of (7) (20 mg, 0.041 mM) in methanol (10 mL) is. added methanol saturated with ammonia (5 mL) and the stoppered mixture allowed to stir at ambient temperatures until TLC analysis shows little or no (D) remains. Concentration of the reaction mixture followed by preparative thin layer chromatography (silica gel; 3% methanol/methylene chloride as eluant) yields product 9 (11 mg) as a waxy solid. Step G: Ethyl 4-(2-Amino-phenylthio)butyrate
( 11 )
To a stirred deaerated (N2) solution of 2-aminothiophenol (10) (1.25 g., 10mM) and ethyl 4-bromobutyrate (2.14g., 11mM) in 40mL. of dry
1,2-dimethoxyethane is added 8.3g. of solid ground anhydrous potassium carbonate, the resultant mixture deaerated 3X under nitrogen and allowed to stir at room temperature until TLC analysis indicates the reaction is complete. The filtered mixture is then concentrated and the residue flash chromatographed on silica gel (85g.) using 15% ethyl acetate/hexane as eluant to give 1.8g. of (11) as a pale tan oil.
Step H: Ethyl 4-(2-(10-(Isopropylthio)decanoylamino)- phenylthio)butyrate (12)
When (11) and 10-(Isopropylthio)decanoic are reacted together analogously as per the conditions in Step (D) above, the title compound 12. is obtained.
Step I: 4-(2-(10-(Isopropylthio)decanoylamino)
phenylthio)-butyric acid (13)
When (12) is hydrolyzed as per the
conditions of Step (E) the title compound 12 is obtained. Step J: 4-(2-(11-(ethylsulfinyl)undecanoylamino)
phenoxy)-butyric acid
When the subject esters or acids are treated with sodium metaperiodate (Step Ja) in a suitable solvent (e.g. acetone/water) the corresponding
sulfoxides are obtained. Treatment with
meta-chloroperbenzoic acid (Step Jb) yields the corresponding sulfones. For example, when ethyl
4-(2-(11-(ethylthio)undecanoylamino)phenoxy)-butyrate 14 (0.045 g, 0.1 mM) in acetone (10 mL) is reacted with sodium metaperiodate (0.072 g, 0.33 mM) in water (2 mL) at room temperature the corresponding sulfoxide 15 is obtained. Hydrolysis as per Step (E) yields product 16 as an off-white solid.
Additionally, treatment of 14 with m-chloroperbenzoic acid will produce the sulfone 17, which yields the acid 18 upon hydrolysis using the hydrolysis
conditions of Step E.
The method of preparing the novel compounds of the present invention, already described above in general terms, may be further illustrated by the following examples which should not be construed as being limitations on the scope or spirit of the instant invention. EXAMPLE 2
Synthesis of 4-(2-(11-Carboxyundecyloxy)phenoxy)-butyric acid (7)
Figure imgf000241_0001
A. Ethvl 4-(2-Benzyloxyphenoxy)-butyrate (3)
To a stirred solution of 2-benzyloxyphenol (1) (4.0 g, 20 nM) and ethyl 4-bromobutyrate (2.) (5.6 g, 28.7 mM) in dried acetone (100 mL) was added anhydrous ground potassium carbonate (6.0 g, 44 mM) and the resultant mixture heated at reflux under nitrogen until TLC analysis showed the absence of the starting phenol. Flash chromatography (silica gel, 15% ethyl acetate/hexane as eluant) of the filtered and concentrated mixture yielded 3.0 g of product (2) as a clear oil.
When the ethyl 4-bromobutyrate is replaced by halo-esters in the above example, the corresponding ether-ester is obtained. Likewise, when the above phenol is replaced by other substituted 2-benzyloxyphenols, the corresponding 2-substituted ethers are obtained . Substitution of a 2-benzyloxy- or a 2-benzylthio-thiophenol for the 2-benzyloxyphenol yields the corresponding thioether-ester. B. Ethyl 4-(2-Hydroxyphenoxy)-butyrate ( 4)
A mixture of (2) (1.57 g, 5.0 mM), ethanol (50 mL), glacial acetic acid (7 drops) and 10% palladium on carbon (0.7 g) was reacted in a hydrogen atmosphere (40 p.s.i.) at room temperature until hydrogen uptake ceased. Concentration of the filtered mixture yielded the product (4) as an oil.
C. Ethyl 4-(2-11-(Carbomethoxy)
undecyloxyphenoxy)butyrate (6)
When (4) (0.224 g, 1.0 mM) and methyl 12-bromododecanoate (2) (0.32 g, 1.1 mM) were reacted with potassium carbonate in acetone as per Example (A), there was obtained product & (0.3 g) as a
colorless oil. When methyl 12-bromododecanoate is replaced by other halo esters in the above example, the
corresponding diester is obtained.
D. 4-(2-(11-Carboxyundecyloxy)phenoxy)butyric acid (7)
To a stirred solution of (6) (0.102 g, 0.23 mM) in methanol (4 mL) and water (3 drops) was added 2.5 N sodium hydroxide solution (0.55 mL, 1.37 mM) dropwise, and the resultant mixture cleared with additional methanol (2 mL) . When TLC analysis (2% methanol in methylene chloride (10 mL) containing glacial acetic acid (4 drops) indicated no mono- or diester remained, the methanol was removed in vacuo, the residue stirred with water (10 mL), and the solution filtered and acidified with 2N hydrochloric acid. Filtration of the resultant precipitate followed by washing with water and drying yielded product 2 (88 mg) as a white solid; M.P. collapses at 95°C, all melted at 105°C (uncorr.; A. O. Spencer Hot Stage).
Calculated for C22H34O6:
C. 66.98; H. 8.69.
Found: C. 67.32; H. 8.45. Compounds (1)-(2) all had NMR and Mass Spectral data consistant with their assigned molecular formulas.
4-(2-(11-Carboxyundecyloxy)
phenylsulfinyl)butyric acid(7B)
When the subject thioethers, e.g., Compound 7A in Flow Sheet C, as the ester or acid, are treated with sodium metaperoidate in a suitable solvent
(e.g., acetone/water) the corresponding sulfoxides are obtained. Likewise, reaction of the subject thioethers with m-chloroperbenzoic acid yields the corresponding sulfones. For example, when 4-(2- (11-carboxyundecyloxy)phenylthio butyric acid 7A
(0.41 g, 1.0 mM) in acetone (25 mM) is reacted with sodium metaperiodate (0.72 g, 3.3 mM) in
water at room temperature, the title sulfoxide
7B is obtained. When the same starting material in methylene chloride is reacted with excess
m-chlorobenzoic acid, the corresponding sulfone is obtained.
Compounds (3)-(16) all had NMR and Mass Spectral data consistent with their assigned molecular structures.
EXAMPLE 3
Preparation of 4-(2-(11-carboxyundecanoylamino)-phenoxy)butyric acid
Step A: Ethyl 4-(2-nitrophenoxy)butyrate (3)
To a stirred solution of 2-nitrophenol
(1) (1.4 g, 10 mM) and ethyl 4-bromobutyrate (2.1 g, 1.57 mL, 11 mM) in 35 mL of dry acetone is added 2 g (14.5 mM) of anhydrous, ground potassium carbonate. The resultant colored mixture is then heated under a nitrogen atmosphere at gentle reflux until the color due to the phenol anion has dissipated and a yellow mixture remains. Concentration of the cooled and filtered mixture yields an oil which on flash
chromatography (silica gel, ethyl acetate/hexane- or methylene chloride as eluant) yields 2.4 g (96% yield) of the title compound (2) as an oily liquid.
Step B: Ethyl 4-(2-aminophenoxy)butyrate (4)
A solution of (3) (1.27 g, 5.0 mM) in 15 mL ethyl acetate containing 200 mg of 5% palladium on carbon is reacted in a hydrogen atmosphere (40 psig.) at room temperature until hydrogen uptake ceases. The mixture is then filtered and concentrated in vacuo to yield 1.0+ g of (4) as an oil/low melting solid.
Step C: Dodecanedioic acid, mono methyl ester (6)
Diethyl dodecanedioate (5) (34.4 g, 0.12 M) is reacted with barium hydroxide octahydrate (19.2 g, 0.06 M) in methanol (240 mL) as per the analogous procedure of Org. Syn, Coll, Vol, III, p. 635 to yield 24.8 g of (6) as a white solid. Step D: Dodecanedioic acid, mono methyl
ester mono acid chloride (7)
A mixture of mono acid (6) (10.0 g, 0.041 M) and thionyl chloride (12.1 mL, 0.166 M) is refluxed for 5 hours, the excess thionyl chloride removed in vacuo. and the residual acid chloride repeatedly dissolved in dry benzene and concentrated until no thionyl chloride remains to yield 10.8 g of the title compound (2) as a waxy solid. Step E: Ethyl 4-(2-(11-carbomethoxyundecanoylamino)- phenoxy)butyrate (8)
To a stirred, ice-cold solution of 0.89 g (4.0 mM) amine (4) and dried triethylamine (1.2 mL) in dry ether (40 mL) is added dropwise over ca. 4 minutes a solution of acid chloride (2) (1.04 g, 4.6 mM) in 20 mL of dry ether. The resultant mixture is allowed to stir cold for 20 minutes, and then at room temperature overnight. After filtering off the triethylamine hydrochloride, the ether filtrate is concentrated in vacuo and the residue chromatographed on an 82 g silica gel column using 20% ethyl acetate/ hexane as eluant to give 1.49 g (85%) of (2) as a waxy solid.
The ether/triethylamine in the above reaction may be replaced by methylene chloride/pyridine with similar results. The same compound may also be prepared via direct coupling of acid (6) with the same amine using common coupling reagents, such as dicyclohexylcarbodiimide/N,N-dimethylamino¬pyridine, and the like.
Step F: 4-(2-(11-Carboxyundecanoylamino)
phenoxy)-butyric acid (9)
To a stirred solution of (2) (1.0 g, 2.22 mM) in methanol (100 mL) is added 1 mL of water followed by dropwise addition of 2.5 N sodium hydroxide solution (4.0 mL). The walls of the reaction flask are rinsed down with 10 mL of methanol and the mixture is stirred under a nitrogen atmosphere until TLC analysis shows no ester (mono- or di-) remaining. The methanol is removed in vacuo, the residue taken up in 100 mL of water, stirred for solution, filtered (20 mL water rinses), and the stirred filtrate acidified dropwise with 2 N hydrochloric acid. Filtration of the resultant precipitate followed by copious water washing and drying gave 0.87 g (96%) of (9) as a chalk-like white solid. The compound was one component by TLC (silica gel, the eluant was 10 mL of 2% methanol in methylene chloride containing 4 drops of glacial acetic acid), mp 128.5-130°C uncorr.
Microanalysis: Calc.: C, 64,84; H, 8.16; N, 3.44.
Found: C, 64,90; H, 8.34; N, 3.33.
Step G: Ethyl 4-(2-Amino-3-methylphenylthio)
butyrate (11)
To a stirred deaerated (N2) solution of 2-aminothiophenol (Ifl) (1.25 g., 10 mM) and ethyl 4-bromobutyrate (2.14 g., 11 mM) in 40 mL. of dry 1,2-dimethoxyethane is added 8.3 g. of solid ground anhydrous potassium carbonate, the resultant mixture deaerated 3X under nitrogen and allowed to stir at room temperature until TLC analysis indicates the reaction is complete. The filtered mixture is then concentrated and the residue flash chromatographed on silica gel (85 g.) using 15% ethyl acetate/hexane as eluant to give 1.8g. of (11) as a pale tan oil.
Step H: 4-(2-(11-Carboxyundecanoylamino)
phenylthio)butyric acid (13)
When amine (H) is acylated with acid chloride (2) as per procedure Step (E), and the resultant diester (ethyl 4-(2-(11-carbomethoxy undecanoylamino)phenylthio)butyrate 12 is hydrolyzed in Step I as per procedure (F), the title compound, 12 m.p. 113.5-115°C is obtained.
The following representative compounds in this series were additionally made by the procedures outlined above:
14) 4-(2-(9-Carboxynonanoylamino)phenoxy)butyric
acid, m.p. 121.5-124.5ºC.
15) 4-(2-(10-Carboxydecanoylamino)phenoxy)butyric
acid, m.p. 110-111.5ºC.
16) 4-(2-(12-Carboxydodecanoylamino)phenoxy)butyric acid, m.p. 116-119°C.
17) 4-(2-(13-Carboxytridecanoylamino)phenoxy)butyric acid, m.p. 128-129.5ºC. 18) 4-(2-(15-Carboxypentadecanoylamino)phenoxy)butyric acid, m.p. 121-125ºC.
19) 5-(2-(11-Carboxyundecanoylamino)phenoxy)valeric acid, m.p. 112-113.5ºC.
20) 4-(2-(11-Carboxyundecanoylamino)-3-methylphenoxy) butyric acid, m.p. 134.5-136.5ºC.
21) 4-(2-(11-Carboxyundecanoylamino)-4-methylphenoxy) butyric acid, m.p. 99.5-100.5°C.
22) 4-(2-(11-Carboxyundecanoylamino)-5-methyIphenoxy) butryic acid, m.p. 109.5-113ºC. Step J: Benzyl 2-Nitrophenyl Ether (23)
When 2-nitrophenol (1 )is reacted with benzylbromide under the conditions of Step A
the title ether (23 ) is obtained as a golden oil.
Step K: Benzyl 2-Aminophenyl Ether (24)
A solution of benzyl 2-nitrophenyl ether (23) (1.15g., 5.0 mM) in ethanol (25 mL) saturated with anhydrous ammonia is stirred under a hydrogen atmosphere (40 p.s.i.) with Raney Nickel (2 g.) until TLC analysis indicates the absence of starting nitro compound. The filtered mixture is freed of excess ammonia by bubbling in anhydrous nitrogen. Removal of ethanol via vacuum distillation at room temperature yields 1.0 g. of title compound (24) as a deep colored crust, which was used as-is in the next reaction. This compound may also be obtained via careful reduction in ethanol or ethyl acetate using palladium on carbon as catalyst, but can be accompanied by slight over-reduction if not monitored.
Step L: N-Trifluoroacetyl 2-Benzyloxyaniline (25)
To a stirred, near solution of amine (24)
(5.0 mM) in dry diethyl ether (30 mL) is added anhydrous sodium carbonate (6.0g., 57 mM) and
the resultant mixture cooled in an ice-water bath. Trifluoroacetic anhydride (1.5 mL, 10.6 mM) is added dropwise to this cold mixture over 2 minutes , the color changing to a yellowish red. After 2 hours the cooling-bath is removed and the mixture allowed to stir at ambient temperatures overnight. After filtering, the filtrate is concentrated in vacuo and then pumped to yield 1.3 g. of the title compound (25) as a pale tan (with some reddish-brown color around the edges) crust.
Step M: N-Methyl-2-Benzyloxyaniline (27)
A well-stirred solution of (22) (0.295 g., 1.0 mM), methyl iodide (0.25 mL, 4.0 mM) and anhydrous acetone (5.0 ml) is set in an oil-bath previously heated to 59ºC, and kept for 2 minutes. Powdered anhydrous potassium hydroxide (0.225g., 4.0 mM) is added all at once, and the bath temperature allowed to rise to 65°C. Clumping-up of some of the KOH is observed. After 15 additional minutes, the reaction mixture is removed from the bath, allowed to cool, and the volatiles removed. Methanol (7 mL) is added with stirring to the residue of N-Methyl-N-trifluoroacetyl-2-benzyloxyaniline (26) obtained, followed by water (1 mL), and methanol (2 mL) (to wash down the sides). After stirring overnight at ambient temperatures, the methanol is removed in vacuo, the residue distributed between ether and water, separated, the organic layer washed with additional water, saturated sodium chloride solution, and dried over sodium sulfate. Concentration of the filtered ether solution gives the title compound (27)
(0.212 g.) as an oil. NMR, MS, and TLC indicate little, if any, dimethyl compound. Step N: N-(11-(Carbomethoxy)undecanoyl)- N-Methyl-2-Benzyloxyaniline (28)
To a stirred ice-cold solution of (27) (0.21 g., 1.0 mM) in dried methylene chloride
(10 mL) containing anhydrous pyridine (0.3 mL) is added (2) (0.27 g., 1.03 mM), dissolved in 5 methylene chloride (5 mL), dropwise over 1 minute (some methylene chloride used as a rinse). After stirring cold for 30 minutes, the mixture is allowed to stir at ambient temperature for completion of the reaction. The reaction mixture is washed IX with 1N HCL, dried (Na2SO4) and filtered. Flash chromatography (silica gel, 207. ethyl acetate/hexane as eluant) of the residue obtained gives the title compound (22) (0.33 g) as a colorless oil.
Step O: N-(11-(Carbomethoxy)undecanoyl)- N-Methyl-2-Hydroxy aniline (29)
A solution of (22) (0.11 g., 0.25 mM) in methanol (11 mL) containing 10% palladium on carbon
(30 mg.) is shaken in a 40 p.s.i. hydrogen atmosphere until no (V) remained (TLC analysis). The filtered solution was then concentrated in vacuo to give the title compound (22.). used immediately in step P.
Step P: Ethyl 4-(2-N-(11-Carbomethoxyundecanoyl)- N-(methyl)-amino)phenoxybutyrate (30)
To a stirred solution of (22.) (0.087 g.,
0.25 mM) and ethyl 4-bromobutyrate (0.115 mL, 0.80 mM) in anhydrous acetone (10 mL) is added anhydrous ground potassium carbonate (0.45 g., 3.2 mM) and the resultant mixture heated under gentle reflux undera nitrogen atmosphere for 24 hours. The mixture is cooled, filtered, and concentrated, and the residue flash chromatographed (silica gel; 20% ethyl acetate/ hexane eluant) to give 80 mg. of the title compound (30) as a colorless oil.
Step O: 4-(2-N-(11-Carboxyundecanoyl)-N- (methyl)-amino)-phenoxybutyric Acid (31)
When (22) (0.055 g., 0.118 mM) is hydrolyzed as per its N-desmethyl analog (Step F, supra), and the resultant oil obtained after acidification is extracted with methylene chloride, there is obtained the title compound (31), (51 mg.), as a colorless oil.
Step R: Ethyl 4-(2-(11-Bromoundecanoylamino)
phenoxy)-butyrate (32)
To a solution of (4) (2.60 g., 11 mM) and 11-bromoundecanoic acid (2.65 g., 10 mM) in anhydrous methylene chloride (90 mL) is added
4-(dimethylamino)pyridine (1.22 g., 10 mM) followed by N.N'-dicyclohexylcarbodiimide (2.3 g., 11 mM)
(4X5 mL of methylenechloride rinses). Precipitation of dicyclohexylurea (DCU) begins within 4 minutes.
when TLC analysis indicates the reaction is complete, the mixture is filtered, the filtrate concentrated in vacuo and the residue extracted with ether. The combined ether extracts are washed IX with 1N hydrochloric acid, IX saturated sodium chloride solution, dried (Na2SO4) and concentrated to a residue which is stirred, filtered, and concentrated alternately with ether and methylene chloride until all DCU is removed. Concentration of the final solution yields the title product (32) (2.35 g.) as an oil that goes readily to a waxy solid.
Attempted purification of an earlier run via column chromatography (silica gel;20% ethyl acetate/ hexane as eluant) gave an impure product of greatly diminished yield.
Step S: Diethyl 10-(N-((2-(3-Carboethoxy)propyloxy)- phenyl)carboxamido)decylphosphonate (33)
A stirred mixture of (22) (0.235 g., 0.5 mM) and triethyl phosphite (TEP) (0.3 mL) is heated at 180°C (bath temperature) under a nitrogen atmosphere for 8 hours, cooled, excess TEP removed in vacuo, and the residue flash chromatographed (Silica gel; ethyl acetate as eluant) to yield product 33 (0.13 g.) as a clear colorless oil.
Step T:
Cleavage of the phosphonate ester (33) using bromotrimethylsilane (procedure of J.C.S. Chem.
Comm. p.739 (1979) yields 10-(N-((2-(3-(Carboethoxy)-propyloxy)phenyl)carboxamido)decylphosphonic acid (34).
Step U :
Further hydrolysis of (34) using the procedure of Example (F) above yields the corresponding di-acid, 10-(N-((2-(3-Carboxy)propyloxy)phenyl) carboxamido)-decylphosphonic acid (35). Step V: 10-(N-((2-(3-Carboethoxy)propyloxy)phenyl)- carboxamido)decaneispthiouronium bromide (36) A stirred solution of (32) (0.047 g., 0.1 mM) in ethanol (2 mL) is reacted with thiourea (0.010 g., 0.13 mM) under the same conditions as (in Step W.).
Concentration of the reaction mixture yields the title compound (36) (contaminated with a small amount of thiourea) which slowly solidifies in crystalline circles on standing. Stirring with dried chloroform followed by filtration and concentration yields the product as a thick wax.
Step W: Sodium 10-(N-((2-(3-Carboethoxy)propyloxy)- phenyl)carboxamido)decanethiosulfate (37)
To a stirred solution of (32) (0.047 g., 0.1 mM) in ethanol (2.0 mL) is added water (10 drops, slowly) followed by sodium thiosulfate (0.035 g., 0.14 mM), and the reaction mixture heated in an oil-bath (bath temperature ca. 90ºC) under a nitrogen atmosphere until TLC analysis indicated no starting bromo compound. The cooled mixture was then concentrated to remove the ethanol and water yielding a white crust. Extraction of this crust with chloroform, followed by filtration from inorganics, yielded product (37) (49 mg.) as a glaze which goes with time to a waxy solid. This product has appreciable water solubility. Oxidation of (36) or (37) as per the
analogous procedures in J.S. Showell et al., J. Org. Chem 27 (1962) 2853 or C. Ziegler et al J. Org. Chem. (1951) 621) yields the corresponding sulfonic acid (22).
Step X: Ethyl 4-(2-Nitropyrid-3-yloxy)butyrate (40)
This compound was prepared from ethyl
4-bromobutyrate 2 and 2-nitro-3-pyridinol (39) via the procedure of Step (A), supra. Following flash chromatography (silica gel; 1.5% methanol/methylene chloride eluant) a dilute sodium bicarbonate wash of an ether solution of the product was necessary to remove traces of starting phenol. The product (40) was obtained in 76% yield as a pale yelow oil.
Step Y: Ethyl 4-(2-Aminopyrid-3-yloxy)butyrate (41) This compound was prepared via reduction of
(40) as per the procedure of step (B), above. The amine (41) was obtained as a waxy solid.
Step Z: Ethyl 4-(2-(11-Carbomethoxyundecanoylamino) pyrid-3-yloxy)butyrate (42)
When (41) and (7) are reacted as per the procedure of step (E), above, the title compound (42) is obtained. Hydrolysis will yield the corresponding di-acid (4-(2-(11- Carboxyundecanoylamino)pyrid-3-yloxy)butyric acid (43). Step AA: N-(11-Carbomethoxyundecanoyl)-2- hydroxyaniline (44)
To a stirred near solution of 2-aminophenol
(0.24 g, 2.2 mM) in anhydrous methylene chloride (25 mL) was added dry pyridine (0.66 mL) and the mixture cooled in an ice-water bath. A solution of (2) (0.525 g, 2.0 mM) in methylene chloride (2 mL) was added over 1 minute (2X1.5 mL methylene chloride rinses), and the mixture allowed to stir cold. After 30 minutes the bath was removed. After stirring overnight at ambient temperatures, the mixture was filtered, the solvents removed in vacuo. and the residue pumped to remove all traces of pyridine. The product, (44) was used as is in subsequent steps.
Step BB: 4-(2-(11-Carbomethoxyundecanoylamino)
phenoxy)-butyronitrile (45)
When (44) and 4-bromobutyronitrile are reacted under the conditions of step (A), above,
(45) is obtained as a waxy solid. Conversely,
reacting (44) with ethyl 4-bromobutyrate as in
step (A) yields (2).
Step CC: 4-(2-(11-Carbomethoxyundecanoylamino)
phenpxy)-butyramide (46)
To a stirred solution of (45) (11 mg, 0.027 mM) in methylene chloride (3 mL) is added activated manganese dioxide (100 mg) and the resultant suspension allowed to stir stoppered at room temperature. After a few days some additional methylene chloride and manganese dioxide (100 mg) are added and the reaction allowed to continue. This is repeated one additional time. When TLC analysis shows no nitrile remains the mixture is filtered, the catalyst washed well with fresh methylene chloride, and the filtrate concentrated to yield the title product, (42) as a waxy solid.
The above new isolated, purified compounds had NMR and Mass spectra consistent with their assigned chemical structures. All melting points were taken on an A.O. Spencer hot stage and are uncorrected.
CHAPTER 4
EXAMPLE 1 17β-Benzoyl-Androst-3,5-diene-3-Carboxylic Acid
The title compound is made by reacting 17ß-carbomethoxy-androst-3,5-diene-3-protected carboxylic acid in e.g., THF, with phenyl magnesium bromide under standard Grignard conditions. Standard workup procedure yields the title compound, m.p.222-225ºC.
REFERENCE EXAMPLE 1
Synthesis of 4-(4-isobutylbenzyloxy)-2.3-dimethyl-benzaldehyde
Figure imgf000257_0001
A mixture of 4-hydroxy-2,3-dimethyl- benzaldehyde (220 mg), 4-isobutylbenzyl bromide (341 mg), potassium carbonate (1.38 g) and ethyl methyl ketone (10 ml) was refluxed for 6 hrs. After cooling, the reaction mixture was diluted with ethyl acetate, the solution was washed with dil
hydrochloric acid, water, successively, dried and evaporated. The residue was purified by column chromatography on silica gel (hexane:EtOAc = 10:1) to give the title compound (383 mg) having the following physical data:
TLC: Rf 0.48 (hexane:EtOAc=5:1); NMR: δ7.64 (1H, d), 7.32 (1H, d), 7.16 (1H, d), 5.12 (2H, s), 2.60 (3H, s), 2.48 (2H, d), 2.24 (3H, s), 1.94-1.80 (1H, m), 0.90 (6H, d).
REFERENCE EXAMPLE 2
Synthesis of 4-(4-isobutylbenzyloxy)-2.3-dimethyl-benzoic acid
Figure imgf000258_0001
A solution of the aldehyde prepared in reference example 1 (380 mg) in acetone (5 ml) was cooled with ice. To the solution, Jones' reagent (2.67 N; 2 ml) was dropped and allowed to stand. The solution was stirred for 1.5 hrs at room temperature. The reaction was stopped by addition of isopropyl alcohol. The crystals deposited were washed with hexane, dried and purified by column chromatography on silica gel (hexane-EtOAc) to give the title compound (328 mg) having the following physical data: TLC: Rf 0.36 (hexane:EtOAc=2:1); NMR: 67.80 (1H, d), 7.33 (1H, d), 7.15 (1H.d), 6.90 (1H,d), 5.09 (2H, s), 2.58 (3H, s), 2.48 (2H, d), 2.26 (3H, s), 0.91 (6H, d).
REFERENCE EXAMPLE 3
Synthesis of 4-[2-[4-(4-isobutylbenzyloxy)-2,3-dimethylbenzoylaminolphenoxy]butanoic acid ethyl ester
Figure imgf000259_0001
Oxalyl chloride (2 ml) was dropped to a solution of the carboxylic acid prepared in reference example 2 (325 mg) in methylene chloride (2 ml). The solution was stirred for 1 hr and evaporated. To an ice-cooled mixture of ethyl 4-(2-aminophenoxy)-butanoate (232 mg), pyridine (1 ml) and methylene chloride (15 ml), the above solution was dropped. The mixture was stirred for 30 mins at the same temperature and for 1 hr at room temperature. The reaction solution was washed with water, dried and evaporated. The residue was purified by column chromatography on silica gel (hexane:EtOAc = 5:1) to give the title compound (383 mg) having the following physical data:
TLC: Rf 0.5 (hexane:EtOAc=3:1); NMR: δ 8.58-8.48 (1H, m), 8.05 (1H, s), 7.34 (H, d), 7.16 (1H, d), 7.08- 6.96 (2H, m), 6.90-6.80 (2H, m), 5.07 (2H, s)
4.14-3.96 (4H, m), 2.49 (2H, d), 2.44 (3H, s), 1.18 (3H, t), 0.91 (6H, d).
REFERENCE EXAMPLE 4
Synthesis of 4-[2-[4-(4-isobutylbenzyloxy)-2,3-dimethylbenzoylaminolphenoxylbutanoic acid
Figure imgf000260_0001
1N aq. Solution of lithium hydroxide (3 ml) was added to a solution of the ester prepared in Reference Example 3 (380 mg) in dimethoxyethane (8 ml). The mixture was stirred for 30 mins at 50ºC. After reaction, the solution was neutralized with dil. hydrochloric acid and was extracted with ethyl acetate. The extract was dried and evaporated. The residue obtained was recrystallized from hexane to give the title compound (317 mg) having the following physical data:
TLC: Rf 0.26 (hexane:EtOAc = 1:1): mp: 143°C.
REFERENCE EXAMPLE 5
By the similar procedure as reference examples 1, 2, 3 and 4, the following compound was made, 4-[2-[4-[1-(4-isobutylphenyl-)ethoxy)-2,3-dimethylbenzoylamino]phenoxy]butanoic acid, having the structural formula:
Figure imgf000261_0001
where R2 is
Figure imgf000261_0002
in which the Rf value is 0.37 (hexane :EtOAc = 1:1), and the mass spectrum exhibited m/z values of 503, 345. REFERENCE EXAMPLE 6
(-)-4-[2-(4-[1-(4-isobutylphenyl)ethoxy]-2,3-dimethylbenzoylamino phenoxy]butanoic acid
The compound prepared above in reference
example 5, (403 mg) and cinchonidine (2.36 g) were dissolved into acetone (70 ml) with heating. The solution was allowed to stand to give white
crystals. The crystals were gathered by filtration and purified by recrystallization from acetone four times. The white crystals obtained were dissolved into chloroform. The solution was wahsed with dil. hydrochloric acid. The oily layer was washed with water, dried and evaporated to give the title
compound having the following physical data:
Appearance: white crystal;
Optical angle of rotation: [a]D-39.6º (c=1, CHCI3)
REFERENCE EXAMPLE 7
Sodium salt of (-)-4-[2-(4-[1-(4-isobutylphenyl)-ethoxyl-2.3-dimethylbenzoylamino)phenoxy]butanoic acid
The compound prepared in Reference Example 6 was dissolved into methanol. The equivalent molar of an aq. Sodium hydroxide solution was added and
evaporated to give the title compound having the following data:
IR: v 3050, 1750, 1580, 1560, 1510, 1445, 1260, 1090,
1020, 740 cm-1. FORMULATION EXAMPLE
The following components are admixed in conventional method and punched out to obtain 100 tablets each containing 50 mg of active ingredient
4-[2-[4-[1-(4-isobutylphenyl)ethoxy)- 5 g
2,3-dimethylbenzoylamino)phenoxy]
butanoic acid
Cellulose calcium gluconate 0.2 g
(disintegrating agent)
Magnesium stearate 0.1 g
(lubricating agent)
Microcrystaline cellulose 4.7 g

Claims

WHAT IS CLAIMED IS:
1. A method of treating benign prostatic hyperplasia in patients who are in need of such treatment comprising the step of administering to such patients therapeutically effective amounts of a 5α-reductase inhibitor selected from 17β-substituted non azasteroids, 17β-acyl-3-carboxyandrost- 3,5-dienes, benzoylaminophenoxy butanoic acid
derivatives, cinnamoylamides, fused benz(thio)amides, aromatic 1,2-diethers or thioethers, aromatic
orthoacylaminophenoxy alkanoic acids, orthothioalkylacylaminophenoxyalkanoic acids, or
pharmaceutically acceptable ester or salts thereof in combination with an aromatase inhibitor.
2. The method of Claim 1 wherein said 5α-reductase inhibitor is
(a) a 17ß-substituted 4-aza steroid of the formula:
Figure imgf000264_0001
wherein:
the dotted line represents a double bond when present; R1 and R3 are independently hydrogen, methyl or ethyl; R2 is a hydrocarbon radical, selected from
substituted or unsubstituted straight or branched chain alkyl, cycloalkyl, or aralkyl of from 1-12 carbons or monocyclic aryl optionally containing 1 or more lower alkyl substituents of from 1-2 carbon atoms and/or 1 or more halogen substituents;
R' is hydrogen or methyl;
R" is hydrogen or ß-methyl;
R'" is hydrogen, α-methyl or ß-methyl, and
pharmaceutically acceptable salts or esters thereof;
(b) a 4-aza steroid of the formula:
Figure imgf000265_0001
wherein the dotted line represents a double bond
when present and ,
R is selected from hydrogen, methyl and ethyl; and R2 is (a) a monovalent radical selected from
straight or branched chain alkyl, or cycloalkyl, of from 1-12 carbons, which can be substituted by. one or more of C1-C2 alkyl or halo;
(b) an aralkyl radical selected from benzyl or phenethyl; (c) a polycyclic aromatic radical which can be substituted with one or more of: -OH, protected -OH, -OC1-C4 alkyl, C1-C4 alkyl, halo or nitro;
(d) a monocyclic aromatic radical which can be substituted with one or more of:
(1) -OH, -OC1-C4 alkyl, C1-C4 alkyl,
-(CH2)mOH, -(CH2)n, COOH, including protected hydroxy, where m is 1-4, n is 1-3, providing C1-C4 alkyl is only present when one of the above
oxygen-containing radicals is present;
(2) -SH, -SC1-C4 alkyl, -SOC1-C4 alkyl,
-SO2C1-C4 alkyl, -SO2N(C1-C4-alkyl)2,
C1-C4 alkyl -(CH2)mSH, -S-(CH2)n-O- COCH3, where m is 1-4 n is 1-3,
providing C1-C4 alkyl is only present when one of the above sulfur containing radicals is present;
(3) N(R3)2, which can be protected, where R3 is independently H or C1-C4 alkyl, where the monoaryl ring can also be further substituted with C1-C4 alkyl; and
(e) heterocyclic radical selected from 2- or 4-pyridyl, 2-pyrrolyl, 2-furyl or thiophenyl; R' , R'', R''' are each selected from hydrogen and methyl, and pharmaceutically acceptable salts thereof;
(c) a 17-substituted non-aza steroid of the formula:
Figure imgf000267_0001
in which:
the A ring has up to 2 double bonds;
the B, C, and D rings have optimal double bonds where indicated by the broken lines, provided that the A, 5, and C rings do not have adjacent double bonds and the D ring does not have a C16-C17 double bond when R3 represents two substituents or a divalent substituent;
Z is (CH2)n and n is 0 or 2, provided that Z is (CH)n when adjacent to a double bond;
X is H, Cl, F, Br, I, CF3, or C1-6 alkyl;
Y is H, CF3, F, Cl, or CH3, provided that Y is H when there is no C5-C6 double bond;
R1 is H or C1-8 alkyl; R2 is absent or present as H or CH3, provided R2 is absent when the carbon to which it is attached is unsaturated; and
R3 is
(1) α-hydrogen, or α-hydroxyl, or α-acetoxy and/or
(a)
Figure imgf000268_0001
where W is a bond or C1-12 alkylidene, and
(i) hydrogen,
(ii) hydroxyl,
(iϋ) C1-8alkyl,
(iv) hydroxylic C1-8 alkyl,
(v) C1-8 alkoxy,
(vi) NR5R6, where R5 and R6 are each independently selected from hydrogen, C1-8 alkyl, C3-6 cycloalkyl, phenyl; or R^ and R^ taken together with the nitrogen to which they are attached
represent a 5-6 membered saturated ring,
(vii) OR7, where R7 is hydrogen, alkali metal, C1-8 alkyl, benzyl, or (b) -Alk-OR8, where Alk is C1-12
alkylidene, and R8 is
(i) phenyl C1-6 alkylcarbonyl,
(ii) C5-10 cycloalkylcarbonyl, (iii) benzoyl, (iv) C1-8 alkoxycarbonyl,
(v) aminocarbonyl, or C1-8 alkyl
substituted aminocarbonyl,
(vi) hydrogen, or
(vii) C1-8 alkyl,
(2) =CH-W-CO-R4 or =CH-W-OR8, where W is a bond of C1-12 alkylidene and R4 and R8 have the same meaning as above and R8 also is hydrogen or C1-20 alkylcarbonyl,
Figure imgf000269_0001
where the dashed bond replaces the 17-α-hydrogen,
(4) α-hydrogen and NHCOR9 where R9 is C1-12 alkyl
or NR5R6 where R5 and R6 have the same meaning as above,
(5) α-hydrogen and cyano,
(6) α-hydrogen and tetrazolyl, or
(7) keto;
or a pharmaceutically acceptable salt thereof; except compounds in which:
(i) the B ring has a C5-C6 double bond, R1 is CH3, and R3 is keto,
methoxycarbonyl, or acetyl; or
(ii) the A-nor ring has a C3-C4 double bond and R3 is acetoxy or acetyl;
(iii) R1 is CH3 and R3 is acetoxy or acetyl; or (iv) the A-nor ring has a C3-C4 double bond and R1 is methyl; or
(v) the B ring has a C3-C4 double bond and R3 is ß-hydroxy;
(d) a 17ß- acyl 3-carboxy-androst-3,5-diene of the formula:
Figure imgf000270_0001
wherein R1 is (a) C1-C6 linear or branched alkyl;
C1-C12 cycloalkyl, which can be substituted with C1-C4 alkoxy or C1-C4 linear/branched alkyl;
C1-C12 ary!, or C1-C13 aralkyl which can be substituted with one or more of: -OH, -OC1-C4 alkyl,
C1-C4 alkyl, -(CH2)mOH, -(CH2)n COOH, including protected -OH, where m is 1-4, n is 1-3;
(b) C1-C6 linear or branched alkyl;
C3-C12 cycloalkyl, which can be substituted with C1-C4 alkoxy or C1-C4 linear/branched alkyl;
C1-C12 aryl, or C1-C13 aralkyl which can be substituted with one or more of: -OH, -OC1-C4 alkyl, C1-C4 alkyl, -(CH2)mOH, -(CH2)n COOH, including protected -OH, where m is 1-4, n is 1-3, and R2 is selected from COOH, SO3H, PO(OH)2, PH(O)OH;
(e) a benzoylaminophenoxy butanoic acid derivative of the formula:
Figure imgf000271_0001
wherein R' is hydrogen or alkyl of from 1 to 4 carbon atom(s); A is oxygen atom, sulfur atom or sulfinyl (SO) group; both R1's are methyl or chlorine, or the two R1's and the carbon atoms of the benzene ring to which the two R1's are linked together are
cyclopentane, cyclohexane or a benzene ring; and
R2 represents a group of formula:
Figure imgf000272_0001
wherein B is oxygen, sulfur or a group of formula:
NR11 wherein R11 is hydrogen or alkyl of from 1 to 4 carbon atom(s),
R3, R4, R5, R6, R7, and R8 are, independently, hydrogen, alkyl of from 1 to 4 carbon atom(s), halogen, trifluoromethyl or cyclobutylmethyl,
m is 0 or 1,
n is an integer of from 1 to 5, and
R9 is a hydrogen, alkyl of from 1 to 5 carbon atom(s) or a group of formula:
Figure imgf000273_0001
or
Figure imgf000273_0002
wherein R12, R13, R14, and R15 are, independently, hydrogen, alkyl of from 1 to 4 carbon atom(s), halogen, trifluoromethyl or cyclobutylmethyl, and 1 is an integer of from 1 to 4, and
s a group of formula:
Figure imgf000273_0003
or
Figure imgf000273_0004
wherein R12, R13, R14, and R15 are,
independently, hydrogen, alkyl of from 1 to 4 carbon atom(s), halogen, trifluoromethyl or cyclobutylmethyl, and 1' is an integer of from 1 to 4; or non-toxic salts thereof;
(f) a cinnamoylamide of the formula:
Figure imgf000274_0001
wherein R2 and R3 each independently represents a hydrogen or methyl group with the proviso that
(i) when R2 represents a methyl group, R3
represents hydrogen and (R^)n represents a member selected from the group consisting of 3-group, 4-pentyl group, 4-neopentyl group, 4-(2-ethylbutyl) group and
4-(2-methylpentyl) group, or
(ii) when R2 represents hydrogen, R3 represents a methyl group and (R1)n represents a 3-pentyl group, or non-toxic salts thereof; (g) a fused benz(thio)amide of the formula:
Figure imgf000275_0001
wherein A represents a single bond or a group of methylene, ethylene, trimethylene, tetramethylene, vinylene, propenylene, butenylene, butadienylene or ethynylene group optionally being substituted by one, two or three of straight or branched alkyl group(s) of from 1 to 10 carbon atom(s) and/or phenyl group(s);
B represents a heterocyclic ring of from 4 to 8 members containing one, two or three hetero atom(s) selected from the group consisting of oxygen, nitrogen and sulphυr atom(s), wherein the said ring may
optionally be substituted by group(s) selected from oxo, thioxo and/or hydroxy group(s) including a ring of formula:
T represents an oxygen atom or a sulphur atom;epresents a group of general formula:
Figure imgf000276_0001
Figure imgf000276_0002
or
Figure imgf000276_0003
(iv) a straight or branched alkyl, alkenyl or
alkynyl group of from 1 to 20 carbon
atom(s), wherein R5 and R6 independently represent a hydrogen atom or a halogen atom or a straight or branched alkyl, alkenyl or alkynyl group of from 1 to 20 carbon atom(s) being unreplaced or replaced by one, two, three, four or five optional carbon atom(s), by oxygen atom(s), sulphur atom(s), halogen atom(s), nitrogen atom(s), benzene ring(s), thiophene ring(s), naphthalene ring(s), carbocyclic ring(s) of from 4 to 7 carbon atom(s), carbonyl group(s), carbonyloxy group(s), hydroxy group(s), carboxy group(s), azido group(s) and/or nitro group(s); R2 represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s);
R3 represents a hydrogen atom, a halogen atom, a hydroxy group, a nitro group, a group of general formula: --COOR7, wherein R7 represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s), or a straight or branched alkyl, alkoxy or alkylthio group of from 1 to 6 carbon atom(s);
R4 represents a group of general formula:
-U-(CH2)n-COOR8
Figure imgf000277_0001
--(CH2)p-COOR8, or
Figure imgf000277_0002
wherein U represents an oxygen atom or a sulphur atom, R8 represents a hydrogen atom or a straight or branched alkyl group of from 1 to 6 carbon atom(s), n and m represent an integer of from 1 to 10, respectively, p and q represent zero or an integer of from 1 to 10, respectively, or
non-toxic salts thereof; (h) an ortho-acylaminophenoxy alkanoic acid of the structure:
Figure imgf000278_0001
wherein
A is an 1,2-disubstituted aromatic ring selected from
(a) benzene;
(b) 5-6 membered heteroaromatic ring, containing 1-2 N atoms, 1 S or O atom, or combination thereof;
D and E are independently -COOH, -CONH2, -CONHRb, SO2OH, -SO2NH2, -CO2Rb, -SSO2ONa, SO3OH, P(O)(OH)2;
X is O, S, SO or SO2;;
R is H,
C1-C4 alkyl,
phenyl or substituted phenyl,
halo,
haloalkyl,
hydroxy,
carboxy,
cyano,
C1-C4 alkoxy,
C1-C4 alkylthio, C1-C4 alkylsulfinyl,
C1-C4 alkylsulfonyl,
amino,
nitro,
C1-C4 mono or di-alkylamino;
R1 and R" are independently
H,
halo,
C1-C4 alkyl or C1-C4 alkoxy,
amino, or oxo, where CH-R' or CH-R''
in the formula become -C=O;
Ra is H, C1-C4 alkyl;
Rb is C1-C12 alkyl, phenyl, or phenyl C1-C4 alkyl; y is 1-6; z is 6-20; and wherein and
Figure imgf000279_0001
can independently represent substituted
Figure imgf000279_0002
or
unsubstituted alkyl or alkenyl radicals
containing at least one alkene bond;
and pharmaceutically acceptable salts and esters thereof; (i) an ortho-thioalkylacylaminophenoxy alkanoic acid of the structure:
Figure imgf000280_0001
wherein
A is a 1,2-disubstituted aromatic ring;
D is OH, NH2, NHRC, ORC
X is O, S, SO, or SO2;
R is H,
C1-C4 alkyl,
phenyl or substituted phenyl,
halo,
haloalkyl,
hydroxy,
carboxy,
cyano,
C1-C4 alkoxy,
C1-C4 alkylthio,
C1-C4 alkylsulfinyl,
C1-C4 alkylsulfonyl, nitro,
amino,
C1-C4 mono or di-alkylamino; R' and R" are independently
H,
halo,
C1-C4 alkyl or C1-C4 alkoxy,
amino, or oxo, where CH-R1 or CH-R''
in the formula become -C=O;
Ra is H, C1-C4 alkyl;
Rb, Rc are independently, C1-C12 alkyl, phenyl, phenyl-C1-C4 alkyl; n is 0-2; y is 1-6; z is 6-20; and wherein and can independently represent substituted or
Figure imgf000281_0001
unsubstituted alkyl or alkenyl radicals containing at least one alkene bond;
and pharmaceutically acceptable salts and esters thereof; (j) an aromatic diether or thioether compound of the structure:
Figure imgf000282_0001
wherein
A is a 1,2-disubstituted aromatic ring;
D is OH, NH2, NHRC, ORC:
X is O, S, SO, or SO2;
R is H,
C1-C4 alkyl,
phenyl or substituted phenyl,
halo,
haloalkyl,
hydroxy,
carboxy,
cyano,
C1-C4 alkoxy,
C1-C4 alkylthio,
C1-C4 alkylsulfinyl,
C1-C4 alkylsulfonyl,
nitro,
amino, C1-C4 mono or di-alkylamino;
R' and R" are independently
H,
halo,
C1-C4 alkyl or C1-C4 alkoxy,
amino, or oxo, where CH-R' or CH-R''
in the formula become -C=O;
Ra is H, C1-C4 alkyl;
Rb, Rc are independently, C1-C12 alkyl, phenyl, phenyl-C1-C4 alkyl; n is 0-2; y is 1-6; z is 6-20; and wherein
Figure imgf000283_0001
and
Figure imgf000283_0002
can independently represent substituted or unsubstituted alkyl or alkenyl radicals
containing at least one alkene bond;
and pharmaceutically acceptable salts and esters thereof.
3. The method of Claim 1 wherein said aromatase inhibitor is a steroid substrate analogue or a non-steroid analogue which binds and inactivates aromatase or is a compound that inhibits the
cytochrome P450 component of the aromatase complex. 4. The method of Claim 3 wherein the said aromatase inhibitor is selected from the group
consisting of:
6-C(1H-imidazol-1-yl)phenyl-methyl]-1 methyl-1H- benzotriazole, 6-[(4-chlorophenyl)(1H-1,2,4-triazol- 1-yl)methyl]-1-methyl-1H-benzotriazole; 2,2-[5-(1H- 1,2,4-triazol-1-ylmethyl)-1,3-phenylene]di(2-methyl propiononitrile), 2,2-[5-(imidazol-1-ylmethyl)-1,3- phenylene]-di(2-methylpropiononitrile), 2-[3-(1- hydroxy-1-methylethyl)-5-(1H-1,2,4-triazol-1-ylmethylphenyl]-2-methylpropiononitrile, 2,2-[5-dideuterio (1H-1,2,4-triazol-1-yl)methyl-1,3-phenylene]di(2-trideuteriomethyl-3,3,3-(trideuterio-propiononitrile), 2,2-[5-dideuterio(lg-1,2,4-triazol-1-ylmethyl-1,3-phenylene)di(2-methyl-propiononitrile);
1,1-dimethyl-8-(1H-1,2,4-triazol-1-ylmethyl)-2(lE)-naphtho[2,1-b]furanone, 1,2-dihydro-1,1-dimethyl-2-oxo-8-(1H-1,2,4-triazol-1-ylmethyl)naphtho-[2,1-b] furan-7-carbonitrile, 1,2-dihydro-1,1-dimethyl-2-oxo-8-(1H-1,2,4-triazol-1-ylmethyl)-naphtho[2,1-b]furan-7-carboxamide, 1, 2-dihydro-1,1-dimethyl-2-oxo-8-[di(1H-1,2,4-triazol-1 yl)methyl]naphtho[2,1-b3-furan-7-carbonitrile; 2-(4-chlorobenzyl)-2-fluoro-1,3-di(1,2,4-triazol-1-yl)propane, 2-fluoro-2-(2-fluoro-4-chlorobenzyl)-1,3-di(1,2,4-triazol-1-yl)-propane, 2-fluoro-2-(2-fluoro-4-trifluoromethyl- benzyl)-1,3-di(1,2,4-triazol-1-yl)propane, 3-(4- chlorophenyl)-1-(1,2,4-triazol-1-yl)-2-(1,2,4-triazol- 1-ylmethyl)butan-2-ol, 2-(4-chloro-α-fluorobenzyl)- 1,3-di(1,2,4-triazol-1-yl)propan-2-ol, 2-4(4- chlorobenzyl)-1,3-bis(1,2,4-triazol-1-yl)propane,
4-[2-(4-chlorophenyl)-1,3-di(1,2,4-triazol-1-ylmethyl) ethoxymethyl]-benzonitrile,1-(4-fluorobenzyl)-2-(2- fluoro-4-trifluoromethyl-phenyl)-1,3-di(1,2,4-triazol-1-yl)propan-2-ol, 2-(4-chlorophenyl)-1-(4-fluorophenoxy)-1,3-di(1,2,4-triazol-1-yl)propan-2-ol, 1-(4-cyanobenzyl)-2-(2,4-difluorophenyl)-1,3-di(1,2,4-triazol-1-yl)-propan-2-ol, 2-(4-chlorophenyl)-1-phenyl-1,3-di(1,2,4-triazol-1-yl)-propan-2-ol; 5-bis(4-chlorophenyl)-methylpyrimidine;α,α-bis(4-chlorophenyl)-2-pyrazinemethanol;
N-(2,4-difluorophenyl)-N-benzyl-3-pyridinemethanamine,
N-(2-chlorophenyl-α-(4-fluorophenyl)-3-pyridinemethanamine; 1-(10,11-dihydro-5H-dibenzo
[a,d]cyclohepten-5-yl)-1H-imidazole, 1-(9H-fluoren-9-yl)-1H-imidazole; 3-bis(4-chlorophenyl)-3-methyl-pyridine, α,α-bis(4-chlorophenyl)-3-pyridine-methanol; 5H-5-(4-cyanophenyl)-6,7-dihydro-pyrrolo-[1,2-c]imidazole, 5H-5-(4-cyanophenyl)-6,7,8,9-tetrahydroimidazo[l,5-a]azepine; 5-[(1H-imidazol-1-yl)phenylmethyl]-2-methyl-1B-benzimidazole,
5-(3-chlorophenyl)(1H-imidazol-1-yl)-methyl]-1H-benzimidazole; (Z)-α-(l,2,4-triazol-1-ylmethyl-stilbene-4,4'-dicarbonitrile, (Z)-4'-chloro-α-(1,2,4-triazol-1-ylmethyl)stilbene-4,4'-dicarbonitrile, (Z)-4'-chloro-α-(1,2,4-triazol-1-ylmethyl) stilbene-4-carbonitrile, (Z)-α-(1,2,4-triazol-1- ylmethyl)-4'-(trifluoromethyl)stilbene-4-carbonitrile, (E)-ß-fluoro-α-(1,2,4-triazol-1-ylmethyl)stilbene- 4,4'-dicarbonitrile, (Z)-4'-fluoro-α-(imidazol-1- ylmethyl)-stilbene-4-carbontrile, (Z)-2',4'-dichloro- α-(imidazol-1-ylmethyl)stilbene-4-carbonitrile,
(2D-4'-chloro-α-(imidazol-1-ylmethyl)stilbene-4- carbonitrile, (Z)-α-(imidazol-1-ylmethyl)stilbene 4,4'-dicarbonitrile, (Z)-α-(5-methylimidazol-1-yl- methyl)stilbene-4,4'-dicarbonitrile, (Z)-2-[2- (4-cyanophenyl)-3-(1,2,4-triazol-1-yl)propenyl]- pyridine-5-carbonitrile; (1R*,2R*)-6-fluoro-2-(4- fluorophenyl)-1,2,3,4-tetrahydro-1-(1H-1,2,4-triazol- 1-ylmethyl)naphthalene, (1R*,2R*)-6-fluoro-2-(4- fluorophenyl)-1,2,3,4-tetrahydro-1-(1H-imidazolyl- methyl)-naphthalene, (1R*,2R*)-and (1R*,2S*)-2-(4- fluorophenyl)-1,2,3,4-tetrahydro-1-(1H-1,2,4-triazol- 1-ylmethyl)naphthalene-6-carbonitrile, (IR*,2R*))- and (1R*,2S*)-2-(4-fluorophenyl)-1,2,3,4-thetahydro- 1-(1H-imidazolylmethyl)naphthalene-6-carbonitrile, (1R*,2R*)-and (1R*,2S*)-1,2,3-4-tetrahydro-1-(1H- 1,2,4-triazol-1-ylmethyl)naphthalene-2, 6-dicarbo- nitrile, (1R*,2R*)-and (1R*,2S*)-1,2,3,4-tetrahydro- 1-(1H-imidazol-1-ylmethyl)naphthalene-2, 6-dicarbonitrile, (1R*,2S*)-2-(4-fluorophenyl)-1,2,3,4-tetrahydro-1-(5-methyl-1H-imidazolylmethyl)naphthalene-6-carbonitrile; 8-chloro-5-(4-chlorophenyl)-5H-indeno[1,2-d] pyrimidine; 5-bis (4-chlorophenyl) methylpyrimidine; 10-(2-propynyl)-estr-4-ene-3,17-dione; [(4-chlorophenyl)(H-1,2,4-triazol-1-yl)-methyl]-1-methyl-1B-benzotriazole; 1-methyl-androsta 1,4-dien-3,17-dione; 3-ethyl-3-(4-pyridyl)- piperidine-2,6-dione; 4-hydroxyandrostene-3,17-dione; 4-(5,6,7,8-tetrahydroimidazo[1,5-α]-pyridin-5-yl)benzonitrile; 4-[alpha-(4-cyanophenyl)-1-(1,2,4-triazolyl)methyl]benzonitrile; 6-methylene-androsta-1,4-diene-3,17-dione, 4-amino-adrostan-1,4,6-trien-3,17-dione, 4-aminoandrosta-4,6-diene-3,17-dione; 3-(1H-imidazol-1-ylmethyl)-2-methyl-1H-indole-1-propanoic acid; 5-[3-chlorophenyl)(1H-imidazol-1-yl)methyl]-1H-benzimidazole; 10ß-thiiranylestr-4-ene-3, 17-dione, 10ß-oxiranylestr-4-ene-3,17-dione; 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione; 3-(4-aminophenyl)-3-ethyl-pyrrolidine-2,5-dione; 1-(7-carboxyheptyl)-imidazole; 1,1-dimethyl-8-(1H-1,2,4-tetrazol-1-yl-methyl)-2(1H)-naphtho [2,1-b]furanone (1a); 5-(p-cyanophenyl)-5.6.7.8-tetrahydroimidazo [1,5-α]-pyridine hydrochloride; 1,4,6-androstatriene-3,17-dione; and
bis-(p-cyanophenyl)-imidazo-1-yl-methane hemisuccinate and pharmaceutically acceptable deritives, acid addition salts thereof.
5. The method of Claim 3 wherein said aromatase inhibitor is 4-(5,6,7,8-tetrahydroimidazo [1,5-α]-pyridin-5-yl)benzonitrile hydrochloride (fadrazole).
6. The method of Claim 3 wherein said aromatase inhibitor is 1,4,6-androstatriene-3,17-dione.
7. The method of Claim 1 wherein said 5α- reductase inhibitor is finasteride and said aromatase inhibitor is fadrazole.
8. A pharmaceutical composition for the treatment of benign prostatic hyperplasia comprising therapeutically effects amounts of a 5α-reductase inhibitor selected from 17β-substituted 4-azasteroids, 17β-substituted non azasteroids, 17β-acyl-3-carboxy-androst-3,5-dienes, benzoylamino- phenoxy butanoic acid derivatives, cinnamoylamides, fused benz(thio)amides, aromatic 1,2-diethers or thioethers, aromatic orthoacylaminophenoxy alkanoic acids, ortho-thioalkylacylaminophenoxy-alkanoic acids, or pharmaceutically acceptable ester or salts thereof, and an aromatase inhibitor in a pharmaceutically acceptable carrier therefor.
PCT/US1992/002749 1991-04-17 1992-04-06 Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor WO1992018132A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US68672091A 1991-04-17 1991-04-17
US686,720 1991-04-17
US74638891A 1991-08-16 1991-08-16
US746,388 1991-08-16
US84615592A 1992-03-11 1992-03-11
US846,155 1992-03-11

Publications (1)

Publication Number Publication Date
WO1992018132A1 true WO1992018132A1 (en) 1992-10-29

Family

ID=27418473

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/002749 WO1992018132A1 (en) 1991-04-17 1992-04-06 Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor

Country Status (5)

Country Link
AU (1) AU1893492A (en)
IE (1) IE921239A1 (en)
IL (1) IL101574A0 (en)
PT (1) PT100388A (en)
WO (1) WO1992018132A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536714A (en) * 1992-04-20 1996-07-16 Sankyo Company, Limited Steroid derivatives for the treatment of prostatic hypertrophy their preparation and uses
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5565467A (en) * 1993-09-17 1996-10-15 Glaxo Wellcome Inc. Androstenone derivative
US5698720A (en) * 1992-04-20 1997-12-16 Sankyo Company, Limited Steroid derivatives
WO1998027986A1 (en) * 1996-12-24 1998-07-02 Zymogenetics, Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
WO1999007357A1 (en) * 1997-08-08 1999-02-18 Ono Pharmaceutical Co., Ltd. η-TYPE REGULATORS FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
US5977126A (en) * 1993-09-17 1999-11-02 Glaxo Wellcome Inc. Androstenones
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
WO2001012206A3 (en) * 1999-08-13 2002-08-01 Heinrich Wieland Soy-glycine extracts and aromatase inhibitors for positively influencing collagen
EP1099438A3 (en) * 1999-11-10 2003-03-19 Pfizer Products Inc. Use of APO B secretion/MTP inhibitors
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
US6689799B1 (en) 1999-08-23 2004-02-10 Rephartox 1,4-dihydropyridine-5-carboxylic acid ester derivatives and method for the preparation thereof
WO2002036129A3 (en) * 2000-11-02 2004-02-26 Alfred Schmidt Topical treatment of mastalgia with arometese inhibitors such as androstendione
EP1610778A4 (en) * 2003-01-17 2006-05-31 Threshold Pharmaceuticals Inc TREATMENT OF BENIGN PROSTATIC HYPERTROPHY
US7329750B2 (en) 2003-06-30 2008-02-12 Merck & Co., Inc. 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators
US7482357B2 (en) 2003-06-30 2009-01-27 Merck & Co., Inc. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
US7696217B2 (en) 2003-06-30 2010-04-13 Merck Sharp & Dohme Corp. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2012035553A1 (en) * 2010-09-15 2012-03-22 Ind-Swift Laboratories Limited Process for preparing androstenone derivatives
US8314097B2 (en) 2005-08-25 2012-11-20 Novartis Ag Organic compounds
US20150322001A1 (en) * 2012-11-21 2015-11-12 The University Of Sydney Omega-3 analogues
US10869855B2 (en) 2012-07-26 2020-12-22 The William M. Yarbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005216A1 (en) * 1986-03-06 1987-09-11 Schering Aktiengesellschaft Berlin Und Bergkamen COMBINATION OF AROMATASE INHIBITORS AND 5alpha-REDUCTASE INHIBITORS
WO1991000731A1 (en) * 1989-07-07 1991-01-24 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005216A1 (en) * 1986-03-06 1987-09-11 Schering Aktiengesellschaft Berlin Und Bergkamen COMBINATION OF AROMATASE INHIBITORS AND 5alpha-REDUCTASE INHIBITORS
WO1991000731A1 (en) * 1989-07-07 1991-01-24 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698720A (en) * 1992-04-20 1997-12-16 Sankyo Company, Limited Steroid derivatives
US5717088A (en) * 1992-04-20 1998-02-10 Sankyo Company, Limited Method of making steroid derivatives for the treatment of prostatic hypertrophy
US5760025A (en) * 1992-04-20 1998-06-02 Sankyo Company, Limited Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses
US5536714A (en) * 1992-04-20 1996-07-16 Sankyo Company, Limited Steroid derivatives for the treatment of prostatic hypertrophy their preparation and uses
US5977126A (en) * 1993-09-17 1999-11-02 Glaxo Wellcome Inc. Androstenones
US5565467A (en) * 1993-09-17 1996-10-15 Glaxo Wellcome Inc. Androstenone derivative
US5846976A (en) * 1993-09-17 1998-12-08 Glaxo Wellcome Inc. Androstenone derivative
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
WO1998027986A1 (en) * 1996-12-24 1998-07-02 Zymogenetics, Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
US5929058A (en) * 1996-12-24 1999-07-27 Zymogenetics, Inc. Treatment agents and methods for treating type II diabetes and symptoms of type II diabetes
WO1999007357A1 (en) * 1997-08-08 1999-02-18 Ono Pharmaceutical Co., Ltd. η-TYPE REGULATORS FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
WO2001012206A3 (en) * 1999-08-13 2002-08-01 Heinrich Wieland Soy-glycine extracts and aromatase inhibitors for positively influencing collagen
US8278291B1 (en) 1999-08-13 2012-10-02 Curadis Gmbh Treatment of wrinkles and strias with 4-hydroxyandrostenedione or a derivative thereof
US6689799B1 (en) 1999-08-23 2004-02-10 Rephartox 1,4-dihydropyridine-5-carboxylic acid ester derivatives and method for the preparation thereof
EP1099438A3 (en) * 1999-11-10 2003-03-19 Pfizer Products Inc. Use of APO B secretion/MTP inhibitors
WO2002036129A3 (en) * 2000-11-02 2004-02-26 Alfred Schmidt Topical treatment of mastalgia with arometese inhibitors such as androstendione
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
EP1610778A4 (en) * 2003-01-17 2006-05-31 Threshold Pharmaceuticals Inc TREATMENT OF BENIGN PROSTATIC HYPERTROPHY
JP2006516571A (en) * 2003-01-17 2006-07-06 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド Treatment of benign prostatic hyperplasia
US7329750B2 (en) 2003-06-30 2008-02-12 Merck & Co., Inc. 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators
US7482357B2 (en) 2003-06-30 2009-01-27 Merck & Co., Inc. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
US7696217B2 (en) 2003-06-30 2010-04-13 Merck Sharp & Dohme Corp. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
US8314097B2 (en) 2005-08-25 2012-11-20 Novartis Ag Organic compounds
US8835646B2 (en) 2005-08-25 2014-09-16 Novartis Ag Organic compounds
US9278969B2 (en) 2005-08-25 2016-03-08 Novartis Ag Organic compounds
US8299054B2 (en) 2006-08-24 2012-10-30 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8541444B2 (en) 2007-10-01 2013-09-24 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2012035553A1 (en) * 2010-09-15 2012-03-22 Ind-Swift Laboratories Limited Process for preparing androstenone derivatives
US10869855B2 (en) 2012-07-26 2020-12-22 The William M. Yarbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US20150322001A1 (en) * 2012-11-21 2015-11-12 The University Of Sydney Omega-3 analogues

Also Published As

Publication number Publication date
IE921239A1 (en) 1992-10-21
PT100388A (en) 1993-07-30
IL101574A0 (en) 1992-12-30
AU1893492A (en) 1992-11-17

Similar Documents

Publication Publication Date Title
WO1992018132A1 (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US6046183A (en) Method of synergistic treatment for benign prostatic hyperplasia
US5994362A (en) Method of treatment for prostatic cancer
EP0724592B1 (en) 16-substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors
WO1992016233A1 (en) Pharmaceutical combination for the treatment of prostatic cancer containing a 5 alpha reductase inhibitor and an antiandrogen
IE61020B1 (en) Oxidized analogs of 17 beta-n-monosubstituted carbamoyl-4-aza-5 alpha-androst-1-en-3-ones
JPH04506798A (en) Combination therapy for the prevention and/or treatment of benign prostatic hyperplasia
US5204337A (en) Estrogen nucleus derivatives for use in inhibition of sex steroid activity
KR20160042089A (en) Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
EP0650495B1 (en) Improved antiandrogens
JPH08503473A (en) 17-alpha-acyl steroids that inhibit 5-alpha-reductase
NZ260737A (en) Use of alpha1-adrenergic receptor blockers in the treatment of benign prostatic hyperplasia
PT714390E (en) INDOL DERIVATIVES AS 5-ALPHA-REDUCTASE-1 INHIBITORS
PT100256B (en) METHOD FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
WO1998038988A1 (en) Use of pivagabin to prepare pharmaceutical compositions
HRP950100A2 (en) 16-substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors
HK1014878A (en) Combinations for prophylaxsis and/or treatment of benign prostatic hyperplasia containing a 17 beta-hydroxy steroid dehydrogenase(17bhsd) inhibitor and at least one further active ingredient
AU2004200173A1 (en) Inhibitors of Type 5 and Type 3 17B-Hydroxysteroid Dehydrogenase and Methods for Their Use
IE84077B1 (en) Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA CS FI HU JP KR LK MG MN MW NO PL RO RU SD

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA